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The following abbreviations have been used in the text:
Ab Antibody
Ag Antigen
Ag* Radioactively labelled antigen
B Bound antigen
Bo Bound antigen in the absence of competing antigen
Bs Antigen bound specifically to membrane receptor preparation
BPTH Bovine parathyroid hormone
BSA Bovine serum albumin
cAMP adenosine 3' : 5'-phosphate
cpm Counts per minute
CRF Chronic renal failure
CV Coefficient of variation
DC Direct current
DAGPS Donkey anti-guinea pig serum
DAGS Donkey anti-goat serum
DARS Donkey anti-rabbit serum
DASP Double antibody, solid phase
EDTA ethylenediaminetetraacetic acid
F 'Free' (unbound) antigen
HCT Human calcitonin
HPTH Human parathyroid hormone
NGPS Normal(non-immune) guinea pig serum
NIBSC National Institute of Biological Standards and Control
NRS Normal (non-immune) rabbit serum
NS Not significant
NSB Non-specific bound/binding
NSHPP N -succinimidyl 3 -(4 -hydroxyphenyl) propionate
NSS Normal (non-immune) sheep serum
MCT Medullary carcinoma of the thyroid
PBS Phosphate buffered saline
Ppt Precipitate
PPTH Porcine parathyroid hormone
PTH Parathyroid hormone






Tris Tris (hydroxymethyl) methylamine
TTX (serum) Serum from a totally thyroidectomised patient
WHO World Health Organisation




Development and characterisation of radioimmunoassays for parathyroid
hormone (PTH) and calcitonin were undertaken. These assays were applied
to the study of the maintainence of mineral homeostasis during pregnancy
and in the neonatal period.
The PTH assay developed represents one in which many of the problems
encountered in applying the radioirnmmunoassay technique to the measurement
of the circulating hormone have been overcome. Loss of immunochemical
homogeneity of PTH on radioiodination was offset by the adoption of suitable
procedures for purifying the labelled hormone, and the useful lifetime of
IOC
JI-BPTH in the assay system was extended by the inclusion of a simple
pre-assay gel-filtration step. The analytical significance of various non¬
specific interferences in the assay system has been minimised. In particular
non-specific adsorption of PTH has been reduced to a consistently low level.
The behaviour of plasma samples in the assay system was also rigorously
studied and the assay procedure finally accepted for routine use as a result
of these investigations has proved a reliable analytical method for the study
of circulating immunoreactive PTH.
The radioimmunoassay for calcitonin was also optimised with regard to each
of its components. Assay performance was significantly improved by
IOC
modifying the radioiodination procedure used to produce -human calcitonin;
sodium metabisulphite was shown to produce chemical damage to the
calcitonin molecule and consequently was replaced by cysteamine hydro¬
chloride. Immunisation procedures undertaken in the rabbit resulted in
the production of anti-calcitonin sera, but these compared unfavourably
with an available goat anti-calcitonin serum in the radioimmunoassay system.
The assay developed using the goat antiserum was capable of detecting as
little as 20 ng/1 human calcitonin in plasma.
Specific calcitonin receptors have been demonstrated in preparations derived
from rabbit kidney tissue and a radioreceptor assay for calcitonin established.
Calcitonin-receptor interaction was investigated and the relationship between
the hormone's immunochemical and biological behaviour is discussed.
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Membrane preparations isolated from human renal tissue, by the procedure
used to prepare calcitonin receptors from rabbit kidney, failed to display
calcitonin binding activity.
The radioimmunoassays developed were used to study plasma mineral homeo¬
stasis in a series of 227 pregnancies from a Clinical Trial in which the effect
of maternal vitamin-D supplementation (1000 International Units/day) was
investigated.
Analytical data obtained showed that there was little tendency for pregnant
women to become significantly hyperparathyroid, relative to non-pregnant
controls, even though PTH concentrations increased significantly from the
end of the first trimester to term. There was no evidence to support the
hypothesis that calcitonin is of particular physiological importance to the
mother in pregnancy. Infant plasma calcitonin was raised relative to
maternal concentrations throughout the first week of life, whilst plasma
PTH concentrations were relatively low at delivery but increased as post¬
natal maturation occurred.
Although maternal vitamin-D status was shown to be a significant factor
influencing extracellular calcium concentration in the newborn period, it
appeared to be Less important with regard to both maternal and neonatal plasma
PTH and calcitonin concentration.
The relationship between PTH and calcitonin and vitamin-D in pregnancy and
the newborn period is discussed with particular reference to the pathogenesis





The minerals calcium, magnesium and phosphorus are intimately involved in
many vital physiological functions in mammalian systems. For example, it
is well established that calcium is involved in neural transmission and muscle
contraction, and magnesium is a recognised co-factor in a number of enzyme
systems. Phosphorus, both as inorganic phosphate and as various organic
phosphates, is of considerable importance in the processes of intermediary
metabolism. Functions such as these are of fundamental significance and it
is necessary for the extracellular fluid concentration of Ca2 + , Mg2 + and
3 _
PO4 ions to be maintained within physiologically acceptable limits. The
relative stability of their concentrations in the extracellular fluid observed under
varying physiological conditions testifies to the operation of efficient homeo-
static control mechanisms and it has long been recognised that calcium,
magnesium and phosphate are closely related in terms of this control. However,
the detailed inter-relationships of the mechanisms involved in maintaining this
control are only partially understood.
The fetus is completely dependent on the maternal system for its mineral
requirements, which increase during growth and development. Pregnancy
thus represents a physiological state in which changing mineral demands are
placed upon the mother, requiring her homeostatic control mechanism to
respond appropriately. At birth the fetal system experiences an abrupt change.
The maternal supply of minerals is discontinued and if the fetus is to survive
and thrive it must rapidly achieve a functional autonomy and display independent
control of its own mineral balance.
The investigation of mineral control throughout pregnancy and in the newborn
period thus allows knowledge to be gained concerning the operation of the
homeostatic system during situations of both gradual and relatively acute
change in physiological status.
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The study described in this Thesis was primarily concerned with the involvement
of parathyroid hormone (PTH) and calcitonin in the changing pattern of mineral
homeostasis during pregnancy and the influence that maternal metabolism may
have on feta( mineral homeostasis and hence on mineral metabolism in the
neonate.
Physiological Aspects of the Hormonal Components of the Mineral Homeostatic
Regulatory System
In mammalian systems vitamin D, PTH and calcitonin are recognised as the
three main agents responsible for maintaining mineral homeostasis. It is now
clear that these three elements of the control system act in a closely integrated
manner to achieve mineral balance. Thus, although the present study was
primarily concerned with the involvement of PTH and calcitonin, it is desirable
to consider certain aspects of the physiology of the remaining regulatory
component, vitamin D, before discussing the physiology of PTH and calcitonin.
Vitamin D is available to man as vitamin (ergocalciferol) from the diet or
as vitamin D3 (cholecalciferol), generated in the skin by the irradiation of
endogenous 7-dehydrocholesterol by sunlight. Vitamin D itself has no
demonstrable activity in vivo and requires metabolic conversion to attain
biological activity. This metabolism appears to take place in a parallel
manner for both vitamin D2 and vitamin D3, though most studies have been
concerned with vitamin D3 metabolism. Vitamin D3 undergoes enzymatic
hydroxylation to 25 -hydroxyvitamin D3 in the Liver (Ponchon and DeLuca, 1969).
This product displays biological activity but may itself be converted in the
kidney to a more highly active metabolite 1,25-dihydroxyvitamin D3, by
a specific 1 -hydroxylase (DeLuca, 1973). This second hydroxylation step is
regulated in response to physiological mineral requirements. The 1-hydroxy¬
lase activity is increased by a diet Low in calcium (Omdahl e£al, 1972) and
Low in phosphate (Tanaka and DeLuca, 1973), by hypocalcaemia and hypophos-
phataemia and by administration of PTH (Rasmussen et al, 1972; Fraser
and Kodicek, 1973). The activity of the enzyme is suppressed by administration
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of 1, 25-dihydroxyvitamin Dg, by hypercalcaemia, by calcitonin and by para¬
thyroidectomy (DeLuca, 1973). An alternative renal pathway exists for the
metabolism of 25-hydroxyvitamin Dg; hydroxylation to the relatively inactive
24,25-dihydroxyvitamin D^. In regulatory terms this 24-hydroxylation step
is reciprocally related to the 1 -hydroxylation, tending to be favoured when
the 1 -hydroxylation step is depressed (Tanaka and DeLuca, 1974). 1, 25-di¬
hydroxyvitamin Dg has a rapid turnover and its concentration in plasma is
considerably less than that of 25-hydroxyvitamin Dg; Brumbaugh et al (1974)
reported the concentration of 1,25-dihydroxyvitamin Dg in normal subjects
to be 0.03-0.06 ng/ml, whilst Haddad and Chyu (1971) reported a corresponding
reference range for 25-hydroxyvitamin D of 11-55 ng/ml. Both dihydroxy-
lated vitamin D metabolites may be further hydroxylated to 1,24,25-trihydroxy-
vitamin Dg and although this metabolite displays some biological activity, recent
data produced by Castillo et al (1978) suggest that it is not a further activation
product.
Both 25-hydroxyvitamin Dg and 1, 25-dihydroxyvitamin Dg show biological
activity in vivo and in vitro. They increase the absorption of calcium and
phosphate in the small intestine, stimulate resorption of calcium from bone
(a process shown by Garabedian et al, 1974, to require the presence of PTH
in vivo), and enhance renal tubular reabsorption of phosphate and calcium. The
overall effect of these activities is to increase plasma calcium and phosphate
concentrations. It was suggested by DeLuca (1973) that 1,25-dihydroxyvitamin
Dg should be considered as a steroid hormone. The metabolite satisfies the
generally accepted criteria for such a classification; it is produced in a specific
endocrine organ (the kidney), acts at target tissues (intestine, bone and kidney)
where it exerts specific physiological effects; furthermore, its production is
strictly regulated in response to changes in physiological status.
The major form of PTH peptide isolated from the parathyroid glands contains
84 amino acids and has a molecular weight of about 9, 500. The 1 -84 PTH
5
peptides isolated from porcine, bovine and human parathyroid glands show
considerable though incomplete sequence homology in their structures
(Peacock, 1976). It is now clear that synthesis of PTH in the parathyroids
involves the sequential conversion of large peptide structures into smaller
ones until the major 1 -84 form is achieved. Precursor forms of PTH, with
additional amino acid residues adjoined to the N-terminal amino acid of the
1 -84 PTH peptide have been demonstrated. These include proPTH, 90 amino
acids (Potts et a\_, 1973) and pre-proPTH, 115 amino acids (Habener et al, 1974).
The existence of multiple forms of PTH in the circulation was first proposed
by Berson and Yalow (1968) and this was later confirmed experimentally
(Habener et aj_, 1972; Canterbury and Reiss, 1972). It is now clear that PTH
is released from the parathyroid glands into the circulation mainly as the
1-84 peptide, but that other peptide precursors and degradation products are
also released to some extent. The major 84 amino acid form also undergoes
N-terminal degradation following its secretion. Thus, multiple forms of PTH
are present in the circulation, each form displaying a characteristic molecular
size, biological activity and half-life. The principle site of metabolism of PTH
appears to be the kidney (Hruska et al, 1974).
The synthesis and secretion of PTH have been studied both in vitro and in vivo.
The amount of PTH released from parathyroid gland slices in vitro is inversely
related to the concentration of the divalent cations Ca^+ and Mg^~ in
the incubation medium (Sherwood et a_l, 1971). This is reflected in vivo by
a suppression of PTH release by extracellular concentrations of calcium and
magnesium above the normal physiological range and by a correspondingly
increased release when the extracellular concentrations of these two minerals
are decreased (Robinson, 1974). It is apparent that calcium controls the
synthetic and secretory rates of PTH at several sites. It appears to regulate
the rate of entry of amino acids into parathyroid cells and their entry into
proPTH (Chu et aj_, 1973) and may also regulate the conversion of proPTH to
1 -84 PTH as well as the rate at which this peptide is released from the gland.
Magnesium appears not to influence PTH synthesis, but rather to regulate its
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secretion (Sherwood et al, 1972). Release of PTH increases in vitro as
magnesium concentration is reduced until a lower magnesium level is reached
at which point PTH secretion ceases. This behaviour would appear to be due to
the inhibition of a magnesium-dependent adenylate-cyclase, which is responsible
for producing adenosine 3*:5' -phosphate (cAMP) required for PTH secretion
(Dufresne and Gittleman, 1972) and this observation would seem to explain
the decreased PTH production associated with chronic magnesium deficiency
in vivo. There is some evidence that 1, 25-dihydroxyvitamin D3 may have
a direct suppressive effect on release of PTH from the parathyroid glands
(Rasmussen et al, 1974) and Lumb and Stanbury (1974) have discussed further
a direct involvement for vitamin D in the regulation of PTH secretion in human
vitamin D deficiency.
PTH acts upon bone, intestinal and renal cells. Under the influence of PTH
phosphate and calcium from bone are mobilised into the extracellular fluid.
Rasmussen (1974) suggested that this mobilisation involved at least two
mechanisms, an immediate osteocytic osteolysis, followed by osteoclastic
stimulation of bone remodelling. It is clear that PTH action is vitamin D
dependent and is attenuated in states of vitamin D deficiency. PTH enhances
the intestinal absorption of calcium and phosphate, though again this action
appears to be vitamin D dependent (Olson et al, 1972) and may be an indirect
effect, mediated by the PTH stimulated increase in synthesis of 1,25-dihydroxy¬
vitamin D3. PTH also influences the renal tubular reabsorption of minerals.
In the proximal tubule PTH inhibits reabsorption of calcium and phosphate
whilst in the distal tubule increasing reabsorption of calcium and magnesium
but not of phosphate. These actions lead to a net increase in the renal clearance
of phosphate and decrease in the renal clearance of calcium and magnesium
(Haas et al_, 1971). Quantitatively, the action of PTH in the kidney is of such
importance overall as to increase calcium and to decrease phosphate in the
extracellular fluid despite the increased mobilisation of phosphate from bone
and intestine.
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In mammals calcitonin is secreted by parafollicular or 'C' cells found in the
thyroid, parathyroid and thymus glands. This is in contrast to the situation
in birds, amphibia and fish where the calcitonin secreting cells remain in
a discrete structure, the ultimobranchial body. Porcine, bovine, ovine,
salmon and human calcitonin have all been isolated and purified. Their amino -
acid sequences have been determined and synthesised, and all have been found
to contain 32 amino acids. The full sequences appear to be required for the
expression of maximum biological activity (Sieber 1970; Guttmann et al,
1970). Their structures show limited sequence homology, only nine amino
acid residues being common to all five structures. However, many of the
amino acid substitutions are of a conservative nature and common structural
features include a disulphide bridge (1-7) and a carboxy-terminal prolinamide
residue (Potts and Deftos, 1974).
The biosynthesis and secretion of calcitonin is stimulated by increased extra¬
cellular levels of ionised calcium, an effect most marked in hypocalcaemic
subjects given calcium loads (Deftos e^aR 1973). Secretion is inhibited by
low levels of calcium (Foster et al, 1972). Increasing the extracellular
concentration of magnesium may also stimulate calcitonin release, though
such a treatment lowers the raised calcitonin concentrations characteristic
of medullary thyroid carcinoma (Anast et aR 1975). Gastrin, pentagastrin,
glucagon and pancreozymin are also calcitonin secretagogues (Roos et al, 1975).
In a situation analogous to that which exists for PTH it is now clear that other
forms of calcitonin may be present in the circulation in addition to the 1-32
peptide (Singer and Habener, 1974; Deftos e^aR 1974; Sizemoreet^aR 1975).
These forms may result from the release of precursor peptides and degradation
products from the gland or arise in the circulation as a result of the subsequent
enzymatic breakdown and metabolism of peptides released.
Calcitonin has been shown to act upon bone, intestinal and renal cells, the
primary biological action of calcitonin being to lower extracellular calcium
and phosphate levels by inhibiting bone resorption induced by PTH and vitamin D
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(Foster et al, 1972). Calcitonin also acts to increase the renal excretion of
calcium, phosphorus and magnesium (Foster et a]., 1972; Rasmussen et al_,
1974) and to inhibit the intestinal absorption of calcium and phosphate. This
inhibitory action is vitamin D dependent (Olson et aR 1972; Tanzer and Navia,
1973). The net biological effect of calcitonin action is thus to decrease extra¬
cellular calcium and phosphate concentrations. However, it should be stressed
that most studies related to the physiology of calcitonin have been conducted in
species other than man. The relationship of these observations to normal
mineral homeostasis in man remains unclear.
II. Measurement of PTH and Calcitonin
The measurement of physiological and pathological modulations that occur in
the circulating levels of peptide and protein hormones requires the use of an
analytical system endowed with great sensitivity, since hormone concentrations
under study are often very low. A high degree of specificit y is also
needed since the hormone of interest must be determined in a complex mixture
of proteins and other substances. These requirements have provided the
stimulus for the development of the general method of radioimmunoassay over
the past two decades.
The technique of radioimmunoassay arose from the original observation of
Berson and Yalow (1959a and 1959b) that low concentrations of circulating
antibody to the antigen insulin could be detected by their ability to bind
131
1-labelled insulin. It became apparent that this binding of a radioiodinated
hormone to a specific antibody directed against that hormone could be used
to advantage in a system designed to measure the amount of antigen present
in an unknown sample - the radioimmunoassay (Yalow and Berson, 1960).
The system is based on the physicochemical competition which exists between
an antigen (Ag) and a radioactively labelled antigen (Ag*) for binding sites on
a specific antibody (Ab) raised to that antigen (Figure 1 -1). If the number of
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Figure 1 -1
Competition between Labelled Antigen (Ag*) and Unlabelled Antigen (Ag) for
Binding Sites on Specific Antibody (Ab) Raised to the Antigen
Ag*Ab + Ag







binding sites available is limited the degree of inhibition of binding of the
labelled antigen (Ag*) to the antibody will depend on the amount of competing
antigen (Ag) present in the system. The unknown concentration of an antigen
in a sample may thus be determined by comparing the degree of inhibition of
binding of labelled antigen for the unknown sample with that observed for a set
of standards of known antigen content. For this basic principle to be applied
to the measurement of the circulating concentration of a particular hormone
the following criteria must be satisfied:
i. A labelled hormone preparation must be available. It
must have adequate specific activity and retain immuno-
reactivity towards the antiserum.
ii. A specific antiserum must exist capable of cross-reacting
with the antigen.
iii. A standard preparation of antigen must be available.
iv. The immunochemical technique must be applicable to
the biological fluid to be studied, in this case serum or
plasma, and a separation system must be employed which
allows an operational distinction to be made at the end of
the assay incubation period between antigen bound to anti¬
serum and free antigen so as to allow the distribution of
labelled antigen between the 'bound' and 'free' fractions
(Figure 1-1) to be determined.
The Radioimmunoassay for PTH
There is considerable clinical interest in the measurement of circulating levels
of PTH and this has resulted in a sustained effort being made by many groups
of workers to apply the radioimmunoassay technique to PTH analysis in man
(e.g. Bersonetal, 1963; Reiss and Canterbury, 1968; Arnaude^cH, 1971).
However, the degree of difficulty encountered is reflected in both the
wide variation in performance of various assays established for human PTH
(HPTH) and the conflicting nature of the results reported.
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The only HPTH available is that isolated from adenomata removed at surgery
and the development of the radioimmunoassay for PTH has been severely
hampered by the general scarcity of purified HPTH for immunoassay studies.
Early assays for HPTH, for example that of Berson et al (1963), made use of
a heterologous system based on the bovine PTH (BPTH) molecule. Through
necessity subsequent workers have tended to adopt this general approach.
Heterologous assay systems for the measurement of HPTH depend upon the
well established structural similarity of BPTH (or porcine PTH, PPTH) and
HPTH which is paralleled immunochemically. This allows antibodies to be
raised to BPTH (or PPTH) in experimental animals which show strong cross -
reaction with HPTH. Thus, assay systems may be established using as their
components antisera raised against BPTH (or PPTH) and labelled BPTH for the
measurement of HPTH in serum.
There are a number of major technical problems to be faced and overcome
when attempting to apply the radioimmunoassay technique to the analysis of
the low circulating levels of HPTH found in serum. These include:
i. Instability of PTH; the PTH molecule is very unstable
(Barrett and Neuman, 1978) and precautions must be
taken to prevent its degradation at all stages during the
analytical procedure.
ii. Loss of integrity of PTH on radioiodination (Buckle, 1974);
PTH does not readily undergo iodination, tending to lose -
its structural integrity and hence its immunochemical
identity. Furthermore, gpqqq js particularly
unstable. The immunoradiometric assay method has
been applied to PTH in an attempt to resolve some of
these problems associated with radiolabelled PTH
(Addison et al, 1971).
iii. Adsorption to glassware; PTH shows a very strong
tendency to become adsorbed to glassware and other
materials during handling (Barrett and Neuman, 1978).
iv. Non-specific interference; the immunochemical reaction
between antigen and antiserum is subject to considerable
non-specific interference when applied to serum (Franchimont
and Heynen, 1976).
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In the original work Berson et aj_(1963) made use of a purified BPTH working
standard and a number of workers subsequently followed this lead. However,
others have used alternative working standards, such as plasma from patients
with hyperparathyroidism (Reiss and Canterbury, 1968; Arnaudetal, 1971)
or partially purified preparations of HPTH (Potts et_ aC 1971). With the
introduction of an International Reference Preparation for BPTH (BPTH 71/324,
described in Section 2.1) and the current availability of a proposed International
Reference Preparation for HPTH (HPTH 75/549, also described in Section 2.1),
some degree of uniformity of standard usage has more recently been achieved.
The existence of multiple forms of PTH in the circulation leads to heterogeneous
immunochemical behaviour towards antisera directed against PTH. This
phenomenon is of considerable practical significance in immunoassay studies
as has been discussed by Arnaud et aj_(1974). Any antiserum to PTH contains
a population of antibodies directed against differing antigenic determinants on
the molecule and these determinants may or may not be present on the various
species of PTH peptide in the circulation. Thus, the immunoreactivity observed
for a sample of peripheral serum will be dependent on the nature of the anti-PTH
serum used in the analytical procedure.
The successful synthesis of PTH fragments containing partial amino acid
sequences from the complete 1 -84 molecule has led to a number of experimental
approaches intended to increase PTH immunoassay specificity. These have
included the technique of saturating existing antisera with fragments to block
certain binding sites, thereby effectively increasing immunochemical specificity
(Segre e£ a]_, 1972). There has also been development of sequence-specific
assay systems using synthetic fragments to raise antisera specific to certain
amino acid sequences (Fisher et al_, 1974; Barling et al^, 1975). Recently,
attempts have been made to use PTH fragments produced naturally by parathyroid
tumours as immunogens for the production of antisera for radioimmunoassay
studies (Dibella et al, 1978).
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When interpreting the results of PTH immunoassay studies it is clearly
important to consider the influence of the immunochemically heterogeneous
nature of PTH in the circulation since no single antiserum has been generally
available or has been used widely. The lack of uniformity in both the
utilisation of a general methodology and in the adoption of common standards
and antisera undoubtedly explains much of the conflicting nature of reported work
in this field. The situation is represented by the findings of an inter-laboratory
comparison of the results of immunoreactive PTH analyses obtained for standard¬
ised sera by 12 laboratories of the European PTH Study Group (ESPG, 1978).
Direct comparison of PTH values was found to be impossible and led to the
general conclusion that "PTH values cannot be interpreted without a description
of the characteristics of the assay used."
The Radioimmunoassay for Calcitonin
in contrast to the situation for HPTH, there has been no obstacle in the shape
of reagent availability to the development of homologous assay systems for the
measurement of human calcitonin. The 32 amino-acid sequence of human
calcitonin has been determined (Nehar et aU 1968) and its synthesis achieved
(Rittel et^£l, 1968). Consequently synthetic human calcitonin is available
for study. Synthetic human calcitonin has been used as an immunogen for the
production of antisera in experimental animals, although some use has been
made of calcitonin purified from C-cell tumours for this purpose (Tashjian
et al, 1970; DeftosetaD 1971a). The synthetic hormone has also been used
for radiolabelling and, again in contrast to the situation for PTH, it has been
found to iodinate readily.
A complication common to the radioimmunoassay of both PTH and calcitonin
is the existence of multiple forms of the peptides in the peripheral circulation.
Immunochemical heterogeneity of calcitonin in the circulation has been
described (Deftos et al, 1974) and its significance in terms of radioimmunoassay
discussed by Snider et al (1977).
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Though there have been few problems in establishing very sensitive radio¬
immunoassay systems for human calcitonin, the determination of basal
concentrations of the peptide in the peripheral circulation of normal subjects
has proved to be both difficult and controversial. Certain studies with
sensitive radioimmunoassay systems failed to demonstrate basal levels of
calcitonin in the circulation of normal subjects (Deftos et al, 1971b), thereby
calling into question the existence of basal concentrations of calcitonin in man.
However, others (Tashijian et aj_, 1970; Silva et al_, 1974) reported low, though
detectable, concentrations in the basal state. Various attempts have been
made since to increase further the effective sensitivity of existing radio¬
immunoassay systems by extracting calcitonin from plasma prior to assay.
This has been attempted either by immunoprecipitation and immunoextraction
(Parthemore et al, 1975) or by extraction using beads of porous glass (Hillyard
et al_, 1977). Both groups reported low basal concentrations of calcitonin in
normal adult plasma and demonstrated that the concentration of immunoreactive
calcitonin was responsive to perturbations of calcium homeostasis.
Thus, one factor limiting our understanding of the role of calcitonin in physio¬
logical calcium homeostasis in man is seen to be assay sensitivity,
although problems of specificity related to the immunochemical heterogeneity
of calcitonin in plasma should not be underestimated.
The Radioreceptor Assay for Calcitonin
The mechanism by which peptide hormones act upon target tissues to evoke
their characteristic functional response is believed to be initiated by interaction
with a highly specialised portion of the plasma membrane, the hormone receptor
site. The interaction of hormones and receptor sites has been studied by
analysis of the binding reaction between radioactively labelled hormone and
particulate fractions of target cells for a large number of hormone systems
(Roth, 1973, Cuatrecasas, 1974). The general experimental approach adopted
involves the incubation in vitro of radiolabeled hormone with a tissue
preparation. After a period of time the hormone bound to the particulate
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fraction is separated from that which remains free by centrifugation. Ryan
and Lee (1976) have suggested that a number of characteristics are commonly
associated with the binding of a hormone at a specific membrane receptor.
These include:
i. Structural specificity for the hormone
ii. Target organ specificity and specificity for the
cellular organelle (plasma membrane)
iii. High affinity and rapid kinetics, usually with
limited capacity and ready saturability
Although demonstration of the appropriate target organ response to binding
provides direct functional evidence of hormone receptor identity, study of
the nature of the specific binding observed using the radioreceptor assay
techniques provides valuable information on the structural requirements for
specific binding of the hormone at the target organ, which is an essential
prerequisite of expression of the biological activity of the hormone.
Receptors for calcitonin were first demonstrated in membrane preparations
1
derived from kidney and bone in the rat by Marx et al (1972a) using -labelled
salmon calcitonin. The binding of hormone to receptors initiated activation
of adenylate cyclase. Competitive binding studies (Marx et al, 1972b) con¬
firmed the specificity of these receptors. Specificity of binding was
demonstrated by the inhibition of binding by salmon calcitonin and the lack of
inhibition of binding by other peptides, and also by the nature of the binding
observed (high affinity, saturable with time). Receptors from both tissue
origins were found to be similar in terms of their binding behaviour in the
radioreceptor assay. Other workers have also demonstrated renal
receptors for calcitonin in the rat (Sraer and Ardaillou, 1974). An inactivation
system for salmon calcitonin has been demonstrated in rat renal tubular
membranes (Marx et al, 1973; Sraer et al, 1974), a finding that is in
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agreement with the established role of the kidney in the degradation of calcitonin
(DeLuise et al_, 1972).
Salmon calcitonin is known to have high biological effectiveness relative to
mammalian calcitonins (Foster e£aj_, 1972) and this appears to be paralleled
by their relative activity in radioassay systems, salmon calcitonin having the
greatest affinity for receptor binding of all the calcitonins examined in both
renal and bone derived preparations (Marx e£ a_l, 1972a). it is thus evident that
in addition to providing physiological information, the radioreceptor assay
technique provides a valuable experimental probe for the study of calcitonin
structure-function relationships as well as an indirect method for determining
the biological effectiveness of preparations of radioiodinated calcitonin.
III. Mineral Homeostasis in Pregnancy and the Neonate
There is a slight decrease in maternal serum total calcium concentration
throughout pregnancy. However, it has been proposed that this may represent
only an apparent fall due to either relative hypoalbuminaemia (Pitkin, 1975)
or to the haemodilution effect caused by an increase in extracellular fluid
volume during pregnancy (Reitz et al, 1977). During pregnancy the
concentration of ionised calcium has been reported to fall (Tan et al, 1972)
but this finding has been contradicted by the findings of Reitz et al (1977)
who demonstrated a slight but consistent increase in this parameter during
pregnancy. Circulating magnesium and phosphorus concentrations also tend
to show slight falls during pregnancy (Reitz et al, 1977) although again this
may be attributable to a general haemodilution effect.
Minerals required for the growth and development of the fetus are supplied
from the maternal system. There is evidence to support the idea that fetal
calcium requirements are met by a placental active transport system (Shami
and Radde, 1971; Legrand et aj_, 1978), although the details of its mechanism
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remain unclear. However, it is well established that fetal calcium concen¬
trations are maintained at levels significantly greater than those of the maternal
system (Delivoria -Papadopoulos et aU 1967). The fetus receives magnesium
from the mother (Macy and Hunscher, 1934) and phosphorus is also thought
to be transported from the maternal to the fetal system against a concentration
gradient (Economou-Mavrou and McCance, 1958). Thus, placental active
transport processes seem likely to be operative for calcium, magnesium and
phosphorus. David and Anast (1974) observed elevated concentrations of
calcium in the cord blood of the human newborn. Over the first 48 hours of
life they observed a fall in calcium concentration and then noted a subsequent
increase in its value over the next 48-hour period. Plasma magnesium and
phosphorus levels were seen to increase steadily after birth. In normal term
infants serum levels of calcium, magnesium and phosphorus tend to stabilise
so that normal infant values are achieved by the post-natal age of 4-5 days.
These transitions in mineral concentration generally occur asymptomatically.
There are considerable ethical problems and experimental difficulties associated
with the investigation of hormonal regulatory systems during the human pregnancy
and in the neonatal period and much of the knowledge gained in this area has
been derived from indirect studies, or inferred from comparable studies on
experimental animals. Demand for calcium is great in pregnancy (Heaney
and Skillman, 1971) and it is thus not unexpected that the maternal hormonal
regulatory system appears to respond to this requirement. Cushard et al
(1972) and Bouillon and DeMoor (1973) demonstrated raised levels of PTH
during the last trimester of pregnancy in humans. Samaan et al (1974)
reported that plasma levels of calcitonin were higher at the end of pregnancy
than at the beginning or in the non-pregnant woman, a finding in agreement
with experimental results obtained in a number of animal species. A suggested
explanation for the raised levels of calcitonin in pregnancy has been provided
by Garel and Barlet (1978) who developed the view first expressed by Lewis
et £^(1971) that calcitonin may serve to protect the maternal skeleton against
excessive demineralisation during pregnancy.
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Secretory granules are demonstrable in the parathyroid glands of the developing
human fetus at about 12 weeks gestation (Altenahr and Wohler, 1971) and at
about this gestational age bone resorptive capabilities can be demonstrated
for human fetal parathyroids explanted to bone (Scothorne, 1964). Thus,
the fetal parathyroids probably have some functional capacity in early fetal
life, although it might be expected that the high fetal concentrations of
calcium would tend to lead to a relative suppression of their activity in utero.
Correspondingly, C-cell morphology is well developed at about 14 weeks
gestation (Chan and Conen, 1971). One might expect fetal calcitonin levels
to be raised in response to elevated fetal calcium concentrations and indeed
high levels have been observed in the sheep (Garel et al, 1974). Furthermore,
Littledike et al (1972) demonstrated stimulation of fetal calcitonin secretion
in the sheep, pig and cow in response to calcium infusion and Reynolds et al
(1975) demonstrated an in utero hypocalcaemic response in a rhesus monkey
fetus. Despite these studies the role of calcitonin during fetal life remains
obscure, although Garel and Bar let (1978) have suggested that calcitonin may
play a role in skeletal development in utero since high levels of calcitonin
would tend to favour mineralisation of the fetal skeleton. It is clear that
towards the end of the first trimester of pregnancy there is evidence to support
the existence of fetal functional capacity for PTH and calcitonin secretion, and
the fetus may thus display some degree of hormonal autonomy during subsequent
stages of development.
There is no evidence to suggest that either PTH or calcitonin cross the
placenta. In the rat absence of maternal-fetal exchange of calcitonin (Garel
et al_, 1969) and PTH (Garel and Dumont, 1972) have been demonstrated and
Northrop et a_l (1977) reported the failure of PTH to cross the primate placenta,
in contrast, there is direct evidence from studies in the rat that the third
regulatory component, vitamin D, does undergo placental transfer (Haddad
et al, 1971). Hillman and Haddad (1974) demonstrated a significant correlation
between maternal 25-hydroxyvitamin D3 levels and those in corresponding cord
bloods, and their experimental findings were entirely consistent with the operation
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of a passive or facilitated diffusion system for the transport of vitamin D
across the placenta.
In the first 48 hours of life serum PTH levels in human neonates may be low
compared to older infants and adults (David and Anast, 1974; Root et al, 1974)
but in normal full term infants PTH concentrations increase in association
with the normal physiological fall in calcium seen after birth (Tsang et al,
1975). During the newborn period hypocalcaemia induced by EDTA infusion
(Tsang et ajU 197ba) or exchange transfusion (Milner and Woodhead, 1975)
results in increased secretion of PTH. Furthermore, PTH responsiveness,
as indicated by an ability to react to citrate-induced hypocalcaemia, appears
to improve after the first 48 hours of life as the infant matures postnatally
(Tsang et al, 1973b; David and Anast, 1974). It is clear that there is
considerable evidence to suggest that the neonatal parathyroids are normally
capable of responding in an appropriate manner to a hypocalcaemic stimulus,
although their capacity to do so may depend on gestational and postnatal age.
Wolfe e£al (1975) reported the calcitonin content of neonatal thyroid tissue
to be much greater than that of adults, an observation that complements reports
of high circulating calcitonin levels in the neonate (Hesch et al_, 1973;
Samaan et al, 1973, 1975). Dirkensen and Anast (1976) reported that
calcitonin levels were highest in premature infants and that calcitonin levels
in neonates were raised for the first 24 hours of life and thereafter decreased.
Since calcitonin secretion in response to stimulation by certain gastro-intestinal
peptides has been demonstrated there has been speculation that calcitonin
might serve as part of a reflex defence mechanism against post-prandial
hypercalcaemia. Such a system might be of particular importance in the
newborn period when the neonate must rapidly adapt to discontinuous feeding
behaviour after an extended period in utero during which nutrients were
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supplied continuously via the placenta. Theoretically, at least, the effective¬
ness of calcitonin should be maximal in the young animal, since actively
growing bone should be most responsive to the hormone inhibitory effect on
bone resorption. It is therefore of interest to note that the phenomenon of
age-related effectiveness of calcitonin has been reported in the rat (Blahosova
etal., 1978).
Neonatal Hypocalcaemia: a Disturbance of Mineral Homeostasis in the
Newborn Period
True congenital hypoparathyroidism is a very rare condition; however, neonatal
hypocalcaemia, defined as a condition in the term infant of serum calcium
< 1.9 mmol/l, is relatively common. The condition may occur with signs
of neuromuscular hyperactivity (muscle twitching, convulsions and irritability).
Clinically two forms of the condition are recognised and they may be differen¬
tiated clinically and on the basis of the time of their symptomatic onset (Brown
etal, 1972).
Early neonatal hypocalcaemia is characterised by hypocalcaemia occuring
within 12 hours - 4 days of birth and occurs in about 1% of term infants,
although its incidence is considerably increased in pre-term infants of less
than 37 weeks gestation (Tsang et al, 1973a), infants with perinatal complications
(Tsang etal, 1974) and infants of diabetic mothers (Tsang et al, 1972). The
condition may be associated with hypophosphatemia and hypomagnes^mia.
Minimum serum levels of calcium are generally reached at 24-48 hours of
life, the condition being transient in nature and characterised by a gradual,
and generally spontaneous, return to normal over the next few days.
Late onset (or delayed) neonatal hypocalcaemia is characterised by symptomatic
onset between 4-28 days. The condition is often associated with hypomagnesemia
and hypophosphatemia. Infants fed high phosphate diets have been shown to
have a significantly greater incidence of this form of hypocalcaemia than
breast-fed infants (Gittleman and Pincus, 1951).
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Craig and Buchanan (1958) suggested that early neonatal hypocalcaemia
should be regarded as an exaggeration of the physiological tendency towards
hypocalcaemia observed in the normal neonate and the association of the
hypocalcaemia with hyperphosphatemia has led to the generally accepted
view that the condition is due to an extreme presentation of transient
postnatal functional hypoparathyroidism. The transience of the condition may
then be explained by the correction of the hypocalcaemia as parathyroid
function improves with postnatal maturation. In accordance with this general
view late onset neonatal hypocalcaemia may be considered to be attributable
to a prolonged expression of the functional hypoparathyroidism exhibited in
the early form and it has been described as a state of transient congenital
idiopathic hypoparathyroidism (Fanconi and Prader, 1967).
Descriptions of this type, however, do little to add to our basic understanding
of the underlying mechanisms responsible for the pathogenesis of the condition.
It is generally considered that the functional hypoparathyroidism is due to
a deficiency of PTH secretion in affected neonates (David and Anast, 1974).
However, an alternative explanation is that the secretory mechanism for PTH
essentially responds normally and that the functional hypoparathyroidism is
due to end-organ unresponsiveness to PTH in affected neonates. Evidence
for a degree of end-organ resistance comes from the work of Connelly et al_
(1962) who demonstrated an increase in renal phosphaturic response to PTH
between days one and three in the newborn period. Subsequently Linarelli
et al (1972) suggested that this difference in response was attributable to
a maturation of the renal cortex adenyl cyclase response to PTH over the
newborn period. Although Tsang £^£^(19733) demonstrated a calcaemic
response to PTH in premature infants, an immaturity of end-organ response
to the hormone might explain the transient nature of the functional hypopara¬
thyroidism observed in affected infants.
Calcitonin may also be involved in the pathogenesis of neonatal hypocalcaemia
and Dirksen and Anast (1976) reported that for groups of both premature
and term infants the incidence of neonatal hypocalcaemia was greatest in
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those infants with the highest Levels of serum immunoreactive calcitonin.
There appears to be an inequality in the sex distribution of neonates with
hypocalcaemia, male infants having a greater predisposition to the condition
than female infants (Roberts et al_, 1973). It is of interest that Heath and
Sizemore (1977) reported that levels of plasma calcitonin tend to be higher
in males than in females. However, no one has yet demonstrated an
association between these two findings relating to sex difference.
Besides PTH and calcitonin, other factors have been suggested which may have
roles to play in the aetiology of the condition, although their proposed involve¬
ment may to varying extents be dependent upon the two hormones already
discussed. It has been established that the high phosphate content and
unfavourably high phosphate/calcium ratio of cows milk and certain artificial
feeds may precipitate hypocaLcaemia in the neonatal period (Pierson and
Crawford, 1972). It appears that the limited excretory capacity of the
neonatal kidney may be exceeded and that the resultant hyperphosphatemia
may result in hypocalcaemia. This hyperphosphatemia per se may contribute
to some forms of neonatal hypocalcaemia. Hypomagnesemia is another
factor which may contribute to hypocalcaemia in the newborn period. Hypo¬
magnesemia tends to lead to hypocalcaemia by depressing release of endogenous
PTH, by partially impairing organ response to PTH (Chase and Slatopolsky,
1974) and possibly by reducing calcium absorption in the intestine. A relative
vitamin D deficiency in the newborn has also been proposed as an aetiological
factor in neonatal hypocalcaemia (Rosen et al, 1974).
It is apparent that our understanding of the pathogenesis of neonatal hypocal¬
caemia is far from complete. Progress towards a more complete understanding
requires an increase in our knowledge of the maternal-fetal interaction of PTH,
calcitonin and vitamin D.
It has long been recognised that maternal and fetal endocrine systems are
capable of interacting and, more specifically, that pathological disturbances
in maternal calcium homeostasis may adversely affect neonatal parathyroid
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function. Maternal hyperparathyroidism has been found in association with
neonatal hypoparathyroidism (Better et al_, 1973) and, conversely, maternal
hypoparathyroidism is associated with neonatal hyperparathyroidism (Aceto
et a\_, 1966; Bronsky et al, 1968).
In an early study Bakwin (1937) suggested that hypoactivity of the parathyroids
of the newborn might be related to maternal parathyroid hyperactivity
during fetal life. Watney and Rudd (1974), using radioimmunoassay methods
to determine PTH, found that umbilical cord plasma levels were usually as high
as those in the maternal plasma at delivery and took this to be an indication
that parathyroid hormone crossed the placental barrier. This finding seemed
compatible with a direct mechanism for the suppression of fetal parathyroid
activity. However, as has been discussed, the body of evidence now available
suggests that PTH does not cross the placenta and an alternative indirect
mechanism has been proposed to account for the apparent interaction of the
two endocrine systems.
The functional state of the maternal parathyroids clearly influences the calcaemia
of the maternal system. It has been proposed that maternal calcaemia in turn
influences fetal calcaemia, via the placental calcium active transport system.
The resultant fetal calcaemia has then been considered to influence the developing
fetal parathyroids. Thus, states of relative fetal hypercalcaemia would tend
to suppress the functional capacity of the fetal parathyroids whilst states
of relative hypocalcaemia would correspondingly tend to increase their
functional capacity. The condition of the fetal parathyroids would be mirrored
by the functional capability of the neonatal parathyroids at birth.
Neonatal hypocalcaemia has been related to maternal vitamin D deficiency
(Watney et al, 1971). Rosen (1974) proposed a direct role for neonatal
vitamin D deficiency, secondary to maternal vitamin D deficiency, as a direct
pathogenetic factor responsible for neonatal hypocalcaemia in pre-term
infants after observing low plasma concentrations of 25-hydroxyvitamin Dg
in both mothers and their infants with neonatal hypocalcaemia. By contrast,
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Purvis et ad (1973) proposed an indirect roLe for maternal vitamin D deficiency
in the pathogenesis of neonatal hypocalcaemia. In this model it was suggested
that maternal vitamin D deficiency in pregnancy might lead to a state of
secondary maternal hyperparathyroidism, and thus to a consequent functional
hypoparathyroidism in the neonate.
In 1973 a prospective clinical trial undertaken in the Simpson Memorial
Maternity Pavilion, Edinburgh, showed that neonatal hypocalcaemia occurred
less frequently in infants born to mothers who received dietary vitamin D
supplementation during their pregnancy than it did in infants born to mothers
who did not (Cockburn et.aU 1979). This finding gave some support to the
idea that mothers in pregnancy tend to become hyperparathyroid secondary
to vitamin D deficiency, and that the secondary maternal hyperparathyroidism
influenced neonatal metabolism. However, as the study did not incorporate
a direct determination of PTH and calcitonin concentrations the involvement
of these hormones in such a proposed mechanism remained unresolved.
IV Objectives of the Present Study
This study was undertaken to clarify the role of PTH and calcitonin in mineral
homeostasis during pregnancy and to ascertain the influence of maternal
mineral and hormonal status on the regulation of fetal and neonatal mineral
metabolism. It has been suggested that the condition of neonatal hypocalcaemia
is due to a state of functional hypoparathyroidism in the newborn period. An
objective of this study was to differentiate between the two mechanisms
proposed to account for the existence of this state, namely deficient PTH
secretion, possibly attributable to a tendency towards maternal hyperpara¬
thyroidism during pregnancy, or end-organ unresponsiveness to the action
of the hormone. By studying the two hormones both in normal pregnancies
and those characterised by disturbances of mineral relationships it was hoped
that information obtained would indicate the extent of their involvement in the
mechanism of mineral homeostasis in the normal pregnancy and in the
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pathogenesis of neonatal hypocalcaemia.
The strategy of investigation adopted was to determine by radioimmunoassay
maternal and neonatal plasma PTH and calcitonin concentrations in a large
series of human pregnancies and to relate these analytical findings to the
plasma calcium, magnesium and phosphorus concentrations observed in the
same pregnancies. This approach of serially following changes in mineral
homeostasis throughout pregnancy in a large group of women has not previously
been adopted. Analyses were performed on a proportion of the specimens
collected during a prospective clinicaL trial commenced in 1977 in the Simpson
Memorial Maternity Pavilion, Edinburgh, in which supplementary vitamin D
was given to a group of mothers from the twelfth week of their pregnancy.
The analytical requirements of the study necessitated the establishment of
sensitive radioimmunoassay methods for both PTH and calcitonin. Since,
in the past, there have been considerable difficulties associated with the use
of these methods the assays were established with careful regard to the need
for optimisation of all aspects of the analytical procedures. Efforts were made
to control assay performance so as to allow information to be drawn with
confidence from the data collected.
The functional role of calcitonin is not well defined and in order to obtain
further information on this subject an investigation of the interaction between
the hormone and one of its target tissues was undertaken. A radioreceptor
assay for calcitonin was developed to investigate requirements for receptor
binding in terms of the structural integrity of the hormone. In addition, an
attempt was made to isolate receptors with calcitonin-binding activity from
human renal tissue and to folLow this activity at various gestational and
postnatal ages so as to investigate the possible development of a functional
role for the hormone.
Four main areas of experimental work were undertaken:
1. Development of a radioimmunoassay for PTH;
2. Development of a radioimmunoassay for calcitonin;
3. Development and use of a radioreceptor assay for calcitonin;
4. Application of the radioimmunoassay procedures to the study
of mineral homeostasis in pregnancy and the neonate.






Chemicals and Organic Solvents
Unless otherwise stated these were obtained from BDH Chemicals Ltd, Poole,
Dorset, and were of 'Analar' grade.
Buffered Solutions
These were prepared at regular intervals using glass-distilled water and stored
at 4° C.
Automatic Pipettes and Syringes
Unless otherwise stated automatic, adjustable Finnpipettes (5-50, 50-250 and
200-1000 yl) with disposable polypropylene tips were used to sample microlitre
quantities of fluids. (These were supplied by Jencons Scientific Ltd, Hemel
Hempstead, Hertfordshire). Multiple additions of constant volume (50, 100
and 200 yl) were made to assays using Hamilton microsyringes (V.A. Howe
and Co, Peterborough Road, London). Multiple additions of larger constant
volume (0.5 - 2.5 ml) were made using a Cornwall syringe (Becton-Dickinson
and Co, New Jersey, USA).
Radioactivity Counters
Two counters were used in this study:
i. Automatic LKB-Wallac 80000 Gamma sample counter (LKB-Wallac):
LKB Instruments Ltd, South Croydon, Surrey.
ii. Scaler-Detector Counter (SD Counter); this instrument comprised
a modified Nal crystal detector and an NE-Scaler Ratemeter SP3
(Nuclear Enterprises Ltd, Reading, Berkshire).
Counting was performed using the LKB-Wallac unless otherwise stated.
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Decontaminant for Radioactive Glassware
Decon 90 concentrate (Decon Laboratories Ltd, Brighton, Sussex).
Centrifuges
Unless otherwise stated all centrifugation procedures were carried out using
a MSE Mistral 6L centrifuge (MSE Instruments, Crawley, Sussex).
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2.1 MATERIALS USED IN THE DEVELOPMENT OF A RADIOIMMUNOASSAY
FOR PTH
BPTH Preparations Used for Iodination
i. A number of BPTH preparations for iodination were obtained from the
National Institute of BioLogical Standards and Control (NIBSC), London:
Preparation Code Number Material Supplied
BPTH 72/52 2 yg BPTH
100 yg mannitol
BPTH 76/517 2 yg BPTH
100 yg mannitoL
BPTH 76/568 freeze-dried residue
of solution of 2 y g
BPTH in acetic acid
ii. A commerically available BPTH preparation for iodination was also studied
(BPTH 869063) (Calbiochem Ltd, Bishops Stortford, Hertfordshire). This was
obtained from Dr. G. BeastalL, RIA Unit, Royal Infirmary, Glasgow, as
a frozen solution of 2 yg BPTH in 0.01 mol/l acetic acid solution (10 y I).
Preparations for iodination were stored at -20° C.
Materials Used in Iodination Methods
Sodium ["*"^l] Iodide (Radiochemical Centre, Amersham, Buckinghamshire).
Radioactive concentration 100 mCi/ml. Carrier free, in NaOH solution,
pH 7-11.
Phosphate buffer, 0.25 mol/l, pH 7.4. Prepared with KH2PO4 (6.64 g/l)






Quso G32 microfine silica (Philadelphia Quartz Co, USA. UK distributor,
Croxton and Garry Ltd, Esher, Surrey).
Amberlite Ion-exchange resin. CG400 (Chloride), Type 1.
Acetone/acetic acid solution. 1% glacial acetic acid in 20% acetone (v/v).
N-succinimidyl 3-(4-hydroxyphenyl) propionate (NSHPP) (Fluka Chemicals,
Glossop, Derbyshire). 40 ug/ml in toluene: ethyl acetate (1:1 v/v). The
solvents were redistilled to render them anhydrous since NSHPP undergoes
hydrolysis in the presence of water.
Benzene. Redistilled before use.
D ime th y Ifo rmamide.
Glycine.
Borate buffer 0.1 mol/l, pH 8.5. Prepared with sodium tetraborate and
adjusted to pH 8.5 with HCl.
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Materials Used in Further Studies of I-BPTH
Gel Filtration Elution Buffer
Sodium acetate-acetic acid buffer 0.01 mol/l, pH 4,2, containing:
i. 0.1 g/l sodium azide
ii. 1000 U/ml Trasylol (Bayer UK Ltd, Haywards Heath, Sussex).
(Trasylol, Aprotinin, is a highly purified form of a naturally
occuring proteinase inhibitor. Its concentration is described
in terms of kallikrein inactivator units (U)).
iii. 5 g/l protein carrier, either:
bovine serum albumin (BSA) Fraction V powder





Sephadex gels (Pharmacia (GB) Ltd, London).
Automatic fraction collector (Anachem Ltd, Luton, Bedfordshire).
GiLson Microcel TDC 80.
Fraction collection tubes (Coming Ltd, Halstead, Essex).
Trichloroacetic acid (TCA).
Electrophoresis equipment (Shandon Southern Instruments Ltd, Runcorn,
Cheshire):
Power supply (Vokam stabilised constant voltage/current power
pack, Type 2541).
Electrophoresis tank with accessories.




Details of anti-PTH sera are shown in Table 2-1. Antisera were stored
at -20° C.
PTH Standards
These were obtained from the International Laboratory for Biological
Standards, NIBSC, London.
Parathyroid Hormone, Bovine, for Immunoassay (71/324)
This represents the WHO 1st International Reference Preparation (the
International Unit for PTH, bovine, for immunoassay is defined as the
activity contained in 0.60 mg of this preparation). Each ampoule contained

















Eachvialcontains freeze-driedr sidueof 0.5mlof1/10dilution ofserumin0.04mol/1 phosphatebuffer,H7.4 (5g/1BSA,l sodium azide)








Sourcefupply 1.NIBSC,London,England. 2.KindlygiftedbyDrC.D.Arnau ,Mayolinic,Rochest rMinnesota,USA.
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1 yg BPTH
200 yg human serum albumin
1 mg lactose (carrier)
Parathyroid Hormone, Human, for Immunoassay (75/549)
This preparation is undergoing International Collaborative Study to establish
whether the material is suitable to serve as the 1st International Reference
preparation for PTH, human, for immunoassay. The preparation consists of
purified HPTH, extracted from parathyroid adenomata. Each ampoule con¬
tained the freeze-dried residue of a solution which contained:
250 ng HPTH (100 ng pure peptide, nominal)
200 yg human serum albumin (heat inactivated)
1 mg lactose (carrier)
A definitive potency cannot be assigned to this preparation until the International
Collaborative Study has been completed.
Materials Used in Assay Separation Procedures
Activated Charcoal (Sigma London Chemicals Ltd, Kingston upon Thames,
Surrey). C5260, untreated powder.
Dextran T70 (Pharmacia, UK, Ltd, London).
Donkey anti-guineapig serum (DAGPS). Guildhay antiserum, obtained from
Dr. B.A. Morris, University of Surrey, Guildford, Surrey.
Normal guineapig serum (NGPS). A stock of this material was prepared by
reconstituting lyophilised guineapig serum (Wellcome Reagents Ltd, London).
Ethylenediaminetetraacetic acid (EDTA), disodium salt.
N -(3 -nitrobenzyloxymethyl)-pyridinium chloride.
Cellulose powder (Whatman, Maidstone, Kent). CC41, pure microgranular
form.
2 -naphthol.
Ammoniacal cupric hydroxide. Cupric hydroxide (prepared by precipitation
from cupric chloride) dissolved in ammonia (specific gravity 0.88).
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Materials Used in Extraction Procedures for Serum
Ballotini glass (English Glass Co Ltd, Leicester), Grade 20.
Spherosil XQA 400 (JJ (Chromatography) Ltd, Kings Lynn, Norfolk).
Ultrafiltration Unit (Amicon Ltd, High Wycombe, Buckinghamshire). High
performance, Thin-channel filtration system (TCF 10).
Diapor microporous filter, DPQ6 (Amicon, Ltd).
Materials Used in Assay Incubation Systems
Assay Glassware
Glassware investigated for use in the assay system was obtained from the
following sources:
Type of Glassware Supplier
i. Borosilicate glass tubes (10 x 75 mm) Corning Ltd, Halstead,
Essex
ii. Neutral glass tubes (9.5 x 75 mm)
iii. Polypropylene tubes (11 x 75 mm)
iv. Polystyrene tubes (11 x 75 mm)
Radley and Co Ltd,
Sawbridgeworth, Hertfordshire
Sarstedt (UK) Ltd, Leicester
Sarstedt (UK) Ltd.
All tubes were disposable and used once only.
Buffer Systems and Diluents
Assay Diluent. 0.02 mol/l barbitone buffer pH 8.4, containing 5 g/l BSA.
This was prepared from a stock, 0.06 mol/l barbitone buffer, pH 8.4,
which contained:
1. 84 g/l barbitone
10. 30 g/l sodium barbitone
0.60 g/l sodium azide
This assay diluent formed the basis of other diluents used in the assay:
Diluent for -labelled preparations. Assay diluent containing
0.1 g/l Triton X-100 (p-isocytylphenoxypolyethyloxyethanol) (Koch
Light Laboratories, Ltd, Colnbrook, Buckinghamshire) and
1000 U/ml Trasylol.
Wash diluent for separation procedures. Assay diluent with
0.1 g/l Triton X-100 added.
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2.2 MATERIALS USED IN THE DEVELOPMENT OF A RADIOIMMUNOASSAY
FOR CALCITONIN
Except where stated, materials used were common to the PTH radioimmunoassay
and are detailed in Section 2.1.
Human Calcitonin Preparation for Iodination
Human calcitonin (this material was kindly gifted by Dr. G.F. Woods of Organon
Ltd, Newhouse, Lanarkshire, Scotland). SC-30. Pure synthetic peptide,
biological activity 75 MRC Units/mg. This was stored at -20° C.
Alaterials Used in Iodination Methods
i. Direct Iodination using Chloramine-T-. As in Section 2.1, p.30.
ii. Enzymatic Iodination using Lactoperoxidase.
Phosphate buffered saline (PBS). Phosphate buffer 0.05 mol/l, pH 7.5
(1.33 g/l KH2PO4, 5.82 g/l anhydrous Na2HPC>4) containing 9.0 g/l.NaCl.
Lactoperoxidase suspension (Sigma London Chemical Co Ltd). 0.5 g/l in
PBS. Stored at -20° C.
Hydrogen peroxide solution. 300 g/l H2O2 (100 volumes). 50 ul of this
solution was added to 750 ml distilled water just prior to use.
Materials Used in Further Studies of ^^^1-Calcitonin Preparations
Starch (Sigma London Chemical Co Ltd). Potato starch hydrolysed for
electrophoresis.
Glycine-HCl buffer pH 3.0. 0.3 mol/l glycine adjusted to pH 3.0 with
HCl solution.
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Radiochromatogram Scanner (Camlab Ltd, Cambridge). Berthold TL
radiochromatogram scanner.
Anti -Calcitonin Sera
i. Antiserum Used for Radioimmunoassay Studies
The antiserum raised in a goat was designated Goat 1701 (G 1701) and was
produced by Dr. G.W. Sizemore (Mayo Clinic, Rochester, Minnesota, USA)
in collaboration with Dr. C.S. Anast. The goat was immunised with
35-50 yg doses of unconjugated synthetic human calcitonin (Ciba-Geigy
Corporation, Basel, Switzerland) in Freunds Adjuvant, with simultaneous
intramuscular injection of pertussis vaccine. Neat plasma from a single
bleed (11.15. 74) was kindly gifted by Dr. Sizemore.
Initial Dilution for Storage. To avoid the need to repeatedly freeze-thaw
the antiserum supplied, an initial dilution (1/100) was made with assay
diluent. The diluted antiserum was stored in multiple aliquots at -20° C
until required for further dilution.
ii. Materials Used in Procedures for Raising Anti-Calcitonin Sera in
Laboratory Animals
Human calcitonin (Organon). SC-30.
New Zealand White Rabbits (AnimaL Suppliers, London, Ltd, Welwyn,
Hertfordshire).
Mechanical Rotary Emulsifier (Silverson Machines Ltd, Chesham,
Buckinghamshire).
BCG vaccine (Glaxo Laboratories Ltd, Greenford, Middlesex).
Marcol 52 (Esso Petroleum Ltd). Obtained from Dr. B. A, Morris, University
of Surrey.
Arlacel A (Atlas Chemicals Division, ICI America Incorporated). Obtained
from Dr. B.A. Morris, University of Surrey.
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Freunds Adjuvants (Complete and Incomplete) (Difco Laboratories, East
Molesey, Surrey).
Human Calcitonin Standard for Radioimmunoassay (NIBSC, London)
The standard used was Calcitonin, human type, synthetic (70/234). Each
ampoule contained 10 ug synthetic human calcitonin (1 Unit) (a nominal
assignment pending the result of International Collaborative Study).
Materials Used in Assay Incubation Systems
Buffer Systems and Diluents.
As Section 2.1, p.35.
Glassware
Assays were set up in borosilicate glass culture tubes, 10 x 75 mm (Corning
Ltd).
Materials Used in Assay Separation Procedures
Donkey anti-rabbit globulin (PARS) (Wellcome Reagents Ltd). RD17.
Normal rabbit serum (NRS) (Wellcome Reagents Ltd). TC69.
Donkey anti-goat serum (DAGS). Guildhay antisera, obtained from Dr. B. A.
Morris, University of Surrey.
Non-immune sheep serum (NSS). Obtained from Dr. W.M. Hunter, MRC
Radioimmunoassay Team, Edinburgh.
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2.3 MATERIALS USED IN RADIORECEPTOR ASSAY PROCEDURES FOR
CALCITONIN
Materials Used in the Preparation of Rabbit Renal Membrane Preparations
New ZealandWhite Rabbits (Animal Suppliers, London, Ltd).
Fractionation buffer. 0.025 mol/l Tris (hydroxymethyl) methylamine
adjusted to pH 7.5 with HCl. The buffer contained 0.3 mol/l sucrose.
Polytron Homogeniser (Northern Media Supply Ltd, North Cave, North
Humberside).
Reagents for Modified Lowry Method
A Sodium carbonate (20 g/l in distilled water)
B 1:1 (v:v) mixture of:
i. copper sulphate, CUSO4.5H2O (10 g/l in distilled water)
and
ii. potassium sodium tartrate (20 g/l in distilled water)
Mixture prepared immediately prior to use.
C 50:1 (v:v) mixture of A and B
D Folin-Ciocalteau reagent
Protein Standard; BSA (Fraction V powder)
Calcitonin Preparations Iodinated for Use in Receptor Studies
Human calcitonin (Organon). SC-30.
Salmon calcitonin (72/158) (NIBSC, London). This preparation constitutes
the 1st International Reference Preparation of calcitonin, salmon, for bio-
assay. Each ampoule of the preparation contained:
20 ug calcitonin, salmon type, synthetic
2.0 mg mannitol (carrier)
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Materials Used in Radioassay Incubation Systems
i. Diluents
Radioreceptor assay diluent (RRA diluent). 0.025 mol/l Tris buffer
adjusted to pH 7. 5 with HCl solution and containing 5 g/l BSA and 1000 U/ml
Trasylol.
Radioreceptor assay wash diluent (RRA wash diluent). 0.025 mol/l Tris
buffer adjusted to pH 7.5 with HCl solution and containing 5 g/l BSA alone.
ii. Standards and Binding Competitors
Human calcitonin (Qrganon). SC-30.
Salmon calcitonin (72/158).
Salmon calcitonin (Armour) (Armour Pharmaceuticals Co Ltd, Eastbourne,
Sussex). Synthetic salmon calcitonin.
Gastrin (68/439) (NIBSC, London). Gastrin I, human type.
insulin (66/304) (NIBSC, London). 1st International Reference Preparation,
human type.
2.4 OTHER MATERIAL USED IN THE STUDY OF PTH AND CALCITONIN
IN PREGNANCY AND THE NEONATE
Capsules Used in Clinical Trial
All capsules (vitamin D supplemented and placebo) were provided by Glaxo
Laboratories Ltd, Greenford, Middlesex, by courtesy of the Medical
Director, Dr. E. Snell.
SECTION THREE
METHODS
3.1 DEVELOPMENT OF A RADIOIMMUNOASSAY FOR PTH
1 ?s
3.1.1 Radioiodination of BPTH. Purification and Assessment of I-BPTH
Preparations
Iodination Methods
Two methods of radioiodination were studied:
i. Direct iodination, using chloramine-T (Greenwood et al, 1963);
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ii. Indirect iodination, using conjugation to I-NSHPP (Bolton and
Hunter, 1973).
i. Procedure for Direct Iodination, Using chloramine-T
Preparation of BPTH Solution. In order to avoid the need to transfer BPTH
for iodination, the reaction was carried out in the newly opened vial in which
the material was supplied. The BPTH (2.0 yg) was reconstituted in 20 y I
0.01 mol/i acetic acid and the contents of the reaction vial carefully rotated
to ensure that the peptide was completely redissolved. To maintain the pH
of the reaction system in the optimal range 80 yl phosphate buffer 0.25 mol/l
pH 7.4 was added, followed by 20 yl NaOH solution (0.01 mol/l) to ensure
the neutralisation of the acetic acid.
Iodination Step. The following successive additions were made:
15 yl Na ^25j soiution (1.5 mCi)
20 jjl chloramine-T (2.6 g/l in phosphate buffer)
The reactants were mixed using a vortex mixer and the reaction allowed to
proceed for 15 seconds. It was then terminated by the addition of 100 y I
cysteamine hydrochloride (1.8 g/l in phosphate buffer) (or 100 y I sodium
metabisulphite, 1.8 g/l in phosphate buffer; see Section 4.1.1, p.103).
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Initial Purification of Reaction Products by Adsorption onto Quso G32
Microfine Silica. This purification procedure, based on that described by
Yalow and Berson {1966), was carried out immediately after the termination
of the iodination. Samples of the material undergoing purification were
taken at various stages during this procedure, as indicated in Figure 3-1,
to allow the distribution of activity to be followed.
i. To prevent excessive adsorption of BPTH to the glassware
used in the purification procedure, hypoparathyroid serum (1 ml)
was added to the reaction tube as a carrier (this gave a total volume
of 1.25 ml). The contents of the reaction vessel were mixed, using
a glass Pasteur pipette, and transferred to a glass test tube for
centrifugation. A sample (10 yl) of the reactants was taken at this
stage for estimation of specific activity (see p. 50). The activity
adsorbing to the reaction vessel was measured (SD counter). The
vessel was then discarded.
ii. Quso G32 (20 mg) was added to the glass tube and the contents
mixed thoroughly using a vortex mixer. The tube was then centrifuged
(MSE bench centrifuge, five minutes, 1000 g) (Centrifugation I). The
supernatant was carefully removed and its activity counted (SD counter)
before being discarded.
iii. The Quso precipitate was then washed with distilled water (0.5 ml)
and a further 0.5 ml solution of Amberlite ion-exchange resin in distilled
water (100 g/l) was then added to give a total volume of 1.0 ml. The
contents of the tube were mixed for 30 seconds and centrifuged for five
minutes as before (Centrifugation II). The supernatant was counted
(SD counter) and discarded.
iv. A solution of acetone-acetic acid (1.0 ml) was added to the residue
which consisted of a layer of Quso above Amberlite resin at this stage.
After vortex mixing well for one minute the centrifugation was repeated
once again (Centrifugation III). The supernatant was carefully removed
Figure 3-1 Flow Diagram Indicating Sampling Points Used to Follow
Activity Distribution during the Purification Process
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Transfer contents to glass tube
ii. Add Quso G32
-Count empty reaction vessel
(Count 1)
Take 10 y I sample. Count.
Correct (x 125)* to give




iii. Add water and Amberlite resin
-Take 10y I sample. Count.
Correct (x 125)* to give





iv. Add acetone-acetic acid solution
-■Take 10y I sample. Count.






(Quso and Amberlite resin)--
- i. Take 10v I sample. Count.
Correct (x 100)* to give final
product total (Count 5)
ii. Count 10 yl sample
(Count 7)
-Count residue (Count 6)
Notes
Volume corrections (*) were made to relate the activities of samples tc
the total activities present at each stage of purification
2. Counts 1 -6 were obtained on the SD scaler, whilst Count 7 was made
using the LKB-Wallac
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and retained. The acetone-acetic acid eluant (of about 1.0 ml)
constituted the ^^I-BPTH preparation (final product). The Quso
and Amberlite resin residue was counted (SD counter) and
discarded.
Aliquots (100 yl) of the preparation of 12^I-BPTH were prepared in borosilicate
glass tubes and rapidly frozen using a solid CC^/ethanol freezing mixture.
Aliquots were stored at -20° C.
ii. Procedure for indirect Iodination
Preparation of BPTH Solution. BPTH (76/517), 8.0 yg in 10 uI 0.01 mol/1
acetic acid was further diluted in 30 y I 0.1 mol/l borate buffer pH 8.5, to
give a solution of 2. 0 yg in 10 y I.
Iodination of NSHPP. The ester, NSHPP (2.0 yg) present in toluene : ethyl
acetate solvent (5 yl), was pipetted into a small conical glass tube and dried
by evaporating the solvent under vacuum. Reagents were then added to the
dried residue in the following sequence:
20 yl Na solution (2 mCi)
10 y I chloramine-T (5 g/l in phosphate buffer)
After vortex mixing the reaction was allowed to proceed for five seconds
before being terminated by the addition of 10 yl sodium metabisulphite
(12 g/l in phosphate buffer) and 10 yl potassium iodide (200 g/l in phosphate
buffer). The total activity present was counted on the SD counter (Count A).
Extraction of -NSHPP into Benzene. The following reagents were added
to the reaction mixture:
2 yl dimethylformamide
250 yl benzene
The tube was stoppered and the contents mixed gently using a vortex, mixer.
The contents were allowed to settle and the upper benzene layer was carefully
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transferred to a small pear-shaped flask. The aqueous fraction in the
original tube was extracted again with a further 250 y I benzene and the
extract added to the contents of the pear-shaped flask. The radioactivity
remaining in the original tube after extraction was then measured (SD
counter, Count B) before being discarded. The combined extract was then
evaporated fo dryness under vacuum and the contents of the flask further
concentrated at its base by carefully washing the sides of the vessel with
a little more benzene (25-50 pi) and repeating the drying procedure.
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Conjugation of BPTH with I-NSHPP. 10 pi borate solution containing BPTH
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(2.0 pg) was carefully added to the dried residue of I-NSHPP in the bottom
of the pear-shaped flask. The flask was placed in an ice-bath and the
conjugation reaction allowed to proceed for 30 minutes, the contents of the
flask being gently mixed by occasional agitation of the vessel during this
period. At the end of the incubation 0.25 ml of 0.1 mol/l glycine (in borate
buffer) was added and allowed to react with excess iodinated ester for 5 minutes.
Elution buffer containing gelatin (5 g/l) was then added to give a total volume
of 1.0 ml. The radioactivity of this solution was counted (SD counter, Count C).
Purification of Labelled Preparation. Separation of the reaction components
was achieved by gel-filtration on a column (25 x 1 cm) packed with Sephadex G100.
The column was pre-saturated with protein by passing 5-10 ml elution buffer
containing 50 g/l BSA through the column prior to its equilibration with elution
buffer containing 5 g/l gelatin (the low molecular weight labelled products of
the reaction bind to BSA and so this is replaced in the elution buffer with gelatin
as a protein carrier). The iodination reaction mixture was quantitatively
transferred to the equilibrated gel-filtration column and the activity remaining
adsorbed to the flask measured (SD counter, Count D). The material eluted
from the column was collected using an automatic fraction collector, as
30 x 1.0 ml fractions. The elution profile of radioactivity was obtained
(Figure 3-2) and two tubes centrally placed in peak II selected. Their contents
IOC
were pooled and this solution constituted the labelled preparation of JI-BPTH.
Figure 3-2
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Typical Elution Profile Obtained for the Initial Purification of I-BPTH
by Gel-Filtration on Sephadex G100 (Indirect Iodination Procedure)
20
nr
Gel-bed dimensions: 25 x 1cm
Fraction volume: 1.0 ml
Elution carried out with elution buffer (see Section 2.1, p.31) containing
5 g/1 gelatin
Material eluting centrally in Peak II (e.g. fractions 16 and 17) were selected
for further use
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Aliquots (200 y I) of this preparation were dispensed into borosilicate glass
tubes and rapidly frozen using a solid C02/ethanol freezing mixture. Aliquots
were stored at -20° C.
Methods Used in the Quantitative Assessment of Iodination Procedures
To enable quantitative assessments to be made of the iodination procedures
used, estimates were obtained for the specific activity of the labelled
preparations and the percentage yield of the purification processes.
Estimation of Specific Activity of Labelled Preparations. Specific activity
is a measure of unit radioactivity per unit mass (yCi/yg). In order to
estimate specific activity knowledge was required of three parameters:
i. Mass of protein in the reaction system,
ii. Amount of in the reaction system.
1 o c
iii. Percentage incorporation (i.e. the percentage of JI
present that was incorporated into the labelled product).
The following methods were used to quantitate the values of these parameters:
i. Mass of protein in reaction system.
This was known at the start of the reaction since the mass
of protein in the iodination vessel was known accurately
(this assumed that all the protein present was completely
dissolved and available for reaction).
IOC
ii. Amount of JI in the reaction system.
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This was also known since a measured volume of I
was used and the activity of the preparation stated by
the manufacturer. (Since the was always used within
50
14 days of the date of manufacture no correction was
applied to account for decay in activity during the
period since its production).
iii. Percentage incorporation.
An estimate for this figure was obtained by gel-filtration.
This separated unreacted iodine (or iodinated material
of Low moLecuLar weight in the case of the Indirect
Iodination method) from the iodinated protein reaction
products.
Knowledge of the values of parameters (i-iii) enabled an estimate of specific
activity to be made, since:
Activity due to 12^I protein = Total activity x % Incorporation into protein x 1
100
and
Specific activity = Activity due to protein
Mass of protein
Estimation of Percentage Yield of the Purification Processes. Since the
method of estimation was dependent on the nature of the purification process,
which was different for Direct and Indirect iodination methods, this will be
outlined for each case.
Direct Iodination Procedure
Estimate of Specific Activity. Since the mass of protein used in the reaction
(2.0 yg), (i), and the amount of ^2^I (1.5 mCi), (ii), were known, the parameter
to be determined was the percentage incorporation (iii). This determination
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was achieved by measuring the percentage of the total activity which was
adsorbed to the empty reaction vessel (assumed to be protein), and estimating
the percentage activity due to protein in a sample (10 yl) of the reaction
mixture prior to its purification by fractionating the sample on a Sephadex G10
column (1 x 5 cm). (It was assumed that activity losses due to adsorption
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were largely due to iodinated protein since it can be demonstrated that I
does not absorb appreciably to glassware during handling and can be recovered
quantitatively in a single 'salt' peak on gel-filtration following an iodination
procedure carried out in the absence of protein). Using this assumption
and considering the gel-filtration procedure:
Activity due to protein = Activity applied to column - 'salt' peak activity
Knowledge of this quantity led to an estimate of percentage incorporation (iii):
125% Incorporation = % Activity adsorbed to reaction + Activity due to I protein
vessel (from Counts 1 and 2,
Figure 3 -1, p. 45)
Specific activity was then calculated from (i, ii and iii). (The specific activity
so determined refers to the total protein fraction of the reaction product. It
was, nonetheless, of value in that it allowed direct quantitative comparison to
be made of iodination reactions carried out by this procedure).
Estimate of Percentage Yield of the Purification Process. An estimate of the
percentage yield of the purification process was obtained, since:
% yield of purification = Final activity (Count 5) x 100
Total activity (Count 2)
Knowledge of this quantity allowed an estimate of the mass of protein present
in the final labelled preparation, since:
Mass of protein in = Total mass of protein x % Yield of purification x. 1
final preparation (2.0 yg) 100
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This estimate was based on the assumption that all the material in the final
labelled preparation was protein. In practice this was clearly not the case
since gel-filtration studies on Sephadex G100/G10 showed that there was
invariably a minor 'salt' peak present. However, it was found to be more
convenient to let this assumption stand and, if required, to compare fractionation
profiles rather than attempt to compensate for variations in 'salt' peak at this
stage. Strictly the total mass of protein considered in this treatment
required correction for protein loss due to adsorption. However, as the
extent of this loss was likely to be of the same order in each iodination
procedure undertaken, such a correction was not carried out.
Distribution of Activity During the Purification Procedure. Since the purification
procedure was complex it was found useful to follow the distribution of activity
at each stage of the purification procedure, and to use this in addition to the
estimate of percentage yield to compare the purification and recovery of
labelled preparations. The sampling scheme used to follow the distribution
of activity during the purification procedure is indicated in Figure 3-1 (p. 45).
A sample of the labelled preparation (i.e. Final Product) was counted for
60 seconds on the LKB-Wallac (Count 7) to allow a direct comparison
of the total activities of the preparations obtained in successive iodination
procedures.
Quantitation of Indirect Iodination Procedure
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The mass of BPTH (2.0 yg), (i), and the total amount of I (2 mCi), (ii),
were known. Using these values and the counts obtained during the iodination
(Counts A -D, pp. 46,47), estimates of the percentage yield of the iodination
reaction and of the specific activity and mass of protein recovered from the
conjugation reaction were achieved as follows:
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lodination Reaction. The radioactivity incorporated into I-NSHPP
was given by the difference in the total activity taken (Count A) and the
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activity after solvent extraction (Count B). Then,
125
% Yield of iodination reaction = Activity incorporated into I-NSHPPx 100
Total activity
Conjugation Reaction. For the purification process,
Activity applied = Activity in the conjugation reaction - Activity due to adsorbed
to column mixture (Count C) ^5j protein (Count D)
From the elution profile (Figure 3-2, p. 48) it was possible to determine the
percentage of the eluted counts in the protein peaks (I and II), Then,
Activity in protein = % Eluted counts in protein peaks x Activity applied to x 1
peaks the column 100
The total radioactivity in protein could then be found,
Total activity in protein = Activity in protein peaks + Activity due to absorbed
protein
Knowledge of this quantity led to an estimate of specific activity:
Specific activity = Total activity in protein
Mass of protein (2,0 yg)
Furthermore, an estimate of the mass of protein following purification was
possible, since
% Total protein recovered from column = Activity in protein peaks x 100
Total activity in protein
and




Methods Used in the Qualitative Assessment of I-BPTH Preparations
Three characteristics were studied to enable an assessment to be made of
the acceptability of labelled preparations for use in further studies. These
characteristics were:
i. Their binding to dextran-coated charcoal (Buckle and Potts, 1970).
ii. Their binding to specific antiserum.
iii. Their homogeneity on paper chromatoelectrophoresis
(Buckle and Potts, 1970).
i. Binding to Dextran-Coated Charcoal. The labelled preparations were
4
diluted in assay diluent (to give approximately 2.5 x 10 cpm/ml) and incubated
with dextran-coated charcoal at room temperature for 30 minutes. At the
end of this period counts bound to the dextran-coated charcoal were separated
by centrifuging the tubes (20 minutes, 1800 g, 4° C) and tipping them to
remove the supernatant. The counts bound to the dextran-coated charcoal
were measured.
ii. Binding to Specific Antiserum. The labelled preparations, diluted in
4
assay diluent (to give approximately 2.5x10 cpm/ml) were incubated over¬
night at 4° C with anti-PTH serum AS 262 at a final dilution of 1/1000.
Control tubes were also set up to monitor non-specific binding (NSB) to
glassware in which antiserum was replaced with assay diluent. At the end
of the incubation period separation was achieved using a second antibody
precipitation method (Section 3.1.4, p. 59) and the counts bound (specifically
and non-specifically) counted.
iii. Homogeneity on Paper Chromatoelectrophoresis. Strips of cellulose
paper (5 x 25 cm) were allowed to equilibrate for one hour at 4° C with
0.05 mol/l sodium barbitone buffer, pH 8.6. Excess buffer was removed
by pressing the strips lightly between filter papers. The sample solutions
examined consisted of the labelled preparation under test (20 yl) to which
had been added normal serum (10 Pi), to reduce adsorption to the cellulose
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paper, and bromophenol blue (10vl) marker. Portions of these samples (20 y I)
were applied at the origin, close to the cathode, and the chromatoelectrophoretic
system run (DC., 0.5 mA/cm) until the leading edge of the migrating solvent
front moved 5-10 cm towards the anode. The power was then switched off
and the cellulose papers dried using a hot-air drier. The strips were cut
into 1 cm sections on either side of the origin and counted.
To assess routinely the homogeneity of labelled BPTH preparations it was found
useful to examine a sample taken prior to purification (Pre-Quso sample) and
a sample of the purified material eluted from Quso G32 (the Pre-Quso sample
required a tenfold pre-dilution step in barbitone buffer to give it a comparable
activity with the purified material).
Routine Gel-Filtration System for Fractionation of *"^I-BPTH Preparations
A gel-filtration system was required which could be prepared simply and which
gave satisfactory and comparatively rapid fractionation of the components in
the labelled preparation. The following fractionation system was adopted
for routine use;
A 10 cm^ disposable glass pipette was plugged at the bottom with
a small wad of glass-wool and packed with the Sephadex gel under
investigation (the gel was degassed using a water pump prior to
packing). The column was equilibrated with elution buffer
containing 5 g/l BSA as protein carrier. The column was
connected by a short length of plastic tubing to the automatic
fraction collector which allowed fractions to be collected into
disposable borosilicate glass tubes (13 x 100 mm).
This system had the advantage that the fractionation columns were both easily
and economically prepared. It was convenient to prepare a large number of
identical columns at one time. Furthermore, both column and fractionation
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collection tubes were discarded after each fractionation, this being of
importance due to the tendency of PTH to adsorb strongly to glassware.
Selection of Sephadex Gel Type. This aspect of the fractionation system is
discussed in Section 4.1.1, p. lib.
Fractionation Technique. Using a glass Pasteur pipette, samples were applied
quantitatively to the column in a volume of 0.25 ml (0.1 ml labelled preparation
with 0.15 ml elution buffer) and carefully washed onto the column with further
small volumes of elution buffer. The optimal flow rate for separation was
4-6 ml/hour, but separation was acceptable at the faster rate of 10-12 ml/hour,
allowing fractionation to be completed within one hour. Thirty fractions
were collected of volume 0.45 ml. The elution profile was obtained,
each fractionation tube being counted for 10 seconds on the LKB-Wallac.
3.1.2 Anti-PTH Sera
Dilution of Antisera to Working Concentrations
For use in the assay system dilution of antisera to the required working
concentration was made using assay diluent containing Trasylol (1000 U/ml).
Multiple aliquots were made up at these dilutions so as to avoid repeatedly
freeze-thawing the original antisera.
3.1.3 PTH Standards
Two PTH standards were used:
i. BPTH (71/324). Used as a working standard in the immuno¬
assay system.
ii. HPTH (75/549). Used only to allow assay calibration in terms
of human standard.
PTH standards were stored in the dark at -20° C.
Dilution of Standard Preparations to Stock Concentration
Since the ampoules in which the standards were received contained material
sufficient for many assays, it was necessary to dissolve, dilute and re¬
distribute the material in suitable small volumes at a convenient stock
concentration. As PTH in solution displays a strong tendency to become
adsorbed onto glass and plastic surfaces, it was necessary to keep the
solutions reasonably concentrated and to have present a carrier protein to
prevent excessive loss of material. BSA was used for this purpose. The
procedure adopted was carefully to open the ampoule and to dissolve the
contents completely using 200-300 y I of acetic acid solution (0.01 mol/l).
The material was then diluted further using assay diluent to give a stock
solution of concentration 100 ng/ml. Aliquots (200 yl) were then dispensed
into borosilicate glass tubes, which were stoppered and rapidly frozen using
a solid CC^/ethanol freezing mixture. Aliquots were stored in the dark at
-20° C.
Preparation of Standard Solutions for the Standard Curve
Various methods of standard curve preparation were investigated (see Section
4.1.3, p. 131). The standard curve was established immediately prior to
its inclusion in the assay.
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3.1.4 Application of the Radioimmunoassay Technique to the Measurement
of PTH in Serum and Plasma
Methods Used for the Separation of Antibody-Bound from Free PTH
The requirement for a system capable of allowing separation of antigen bound
to antiserum from that unbound (or free) was discussed in Section One, p. 10.
Two methods of achieving this separation were employed:
i. Adsorption onto dextran-coated charcoal;
ii. Immunoprecipitation using a second precipitating antibody
(liquid and solid phase).
i. Separation by Adsorption onto Dextran Charcoal
Preparation of Dextran-Coated Charcoal. Charcoal (5 g) was stirred with
100 ml 0.1 mol/l sodium barbitone, pH 8.6, for 30 minutes at 4° C. Dextran
Dextran T90 (0. 5 g) in 100 ml of the same buffer was added and the suspension
stirred overnight at 4° C. The solution was then allowed to stand for two hours
after which time the supernatant was decanted and replaced volume for volume
with assay diluent. This suspension was stirred for a further hour at 4° C.
Separation Procedure. All operations were carried out on ice. A 2.0 ml
volume was withdrawn from the stirred suspension of dextran-coated charcoal
and added to each assay tube. The tubes were vortex mixed for 15 seconds
and then centrifuged at 4° C (20 minutes, 1800 g). The supernatants were
removed by tipping the tubes, which were allowed to drain onto absorbent
paper. The counts bound to charcoal were measured.
ii. Separation by Immunoprecipitation Using a Second Antibody
Liquid Phase
An antibody molecule, complexed with its antigen, may itself constitute an
antigen for a second antibody. This principle forms the basis for a general
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method of assay separation, immunoprecipitation using a second antibody
(Hunter, 1967).
Application to PTH Radioimmunoassay. All the antisera used for PTH radio¬
immunoassay were raised in guinea pigs. The second antibody system used
consisted of two components:
1. An anti-guinea pig gamma-globulin serum raised in
a donkey (DAGPS).
2. A non-immune guinea pig serum (NGPS).
Complement present in serum samples may inhibit precipitation by a second
antibody. Since the complement system is calcium ion dependent, this effect
was averted by the incorporation of EDTA (0.01 mol/l) in the diluted second
antiserum. Addition of the EDTA directly with the second antibody system
prevented any possible interference of the chelating agent with the primary
antibody-antigen reaction (Hunter and Ganguli, 1971).
Separation Procedure. At the end of the assay incubation period 50 u I of
each component of the second antibody system was added to each assay
tube. After 16-18 hours further incubation at 4° C the tubes were washed
with 2.0 ml assay wash diluent and centrifuged (4° C, 30 minutes, 1800 g).
The supernatants were tipped off by a smooth, rapid inversion of the tubes,
which were allowed to drain onto absorbent paper. The drained tubes were
then counted.
Optimisation of Second Antibody System. Not all anti-gamma-globulin sera
are suitable for use in a second antibody system (Hunter, 1967). It was thus
essential to carry out a preliminary optimisation procedure to test potential
second antibodies and to examine their requirement for non-immune serum
carrier. Each new second antibody was optimised according to the following
procedure:
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Sets of assay tubes (n = 4) were arranged in a 5 x 5 matrix and
*^I-BPTH (100 pi) and guinea pig anti-PTH sera (100 pi) at the
selected working dilution added to each tube. The incubation
volume was made up to 0.3 ml using assay diluent. Incubation
was carried out at 4 °C for 72 hours. At the end of this first
incubation the second antibody (50 pi) and carrier non-immune
serum (50 pi) were added. Each of these had previously been
prepared at five doubling dilutions and these diluted solutions
were added to the matrix in such a way that a grid of the 25 possible
concentration combinations of the second antibody system components
was established. The separation of the assay incubates arranged
in this grid using the procedure described (p. 60) allowed the
second antibody system under investigation to be optimised.
Solid Phase
This separation method is a development of the general second antibody
method. In it the second antibody gamma-globulin is covalently linked to
a solid support.
Preparation of Solid Phase Second Antibody
Conjugation of second antibody gamma-globulin to a solid phase support was
achieved via diazotization of cellulose (Gurvich et al, 1961). Aminocellulose
was first prepared. This was then diazotized to give diazocellulose, which
was coupled to gamma-globulin protein prepared from DAGPS. The methods
used were based on those of O'Riordan and Woodhead (1975).
Preparation of Aminocellulose. Sodium acetate (0. 5 g) and m -nitrobenzyloxy-
methyl pyridinium chloride (1.4 g) were dissolved in 20 ml 90% ethanol
solution (v/v). Cellulose powder (5 g) was added and stored to form a slurry.
This mixture was heated at 70° C until dry and then at 125° C for a further
40 minutes. The nitrocellulose preparation was washed with benzene
(3 x 200 ml) on a glass funnel and sucked dry. After a thorough wash with
water (1 I) the nitrocellulose was suspended in 150 ml, 0.8 mol/l sodium
dithionite. This suspension was mixed at 55° - 60° C for 30 minutes and
the aminocellulose product washed with water then with 30% acetic acid
solution (v/v), and again with water. The aminocellulose was dried in
a dessicator at room temperature and stored at 4° C.
Preparation of Diazocellulose. A fine suspension of aminocellulose was
prepared by dissolving the aminocellulose powder (1 g) in 35 ml ammoniacal
cupric hydroxide. The solution was diluted to a volume of 1.5 I and acidifed
to pH 4.0 with H2SO4 solution (0.2 mol/l). Aminocellulose came out of
solution as a flocculent white precipitate under these conditions. The
supernatant was decanted off and the precipitate washed four times in water.
The aminocellulose was then resuspended in 50 ml HCl (0.4 mol/l) and
2 ml sodium nitrite (0.15 mol/l) added. A test for free oxidant (starch
iodide paper) was positive at this stage of the preparation. The suspension
was mixed on an ice bath for 30 minutes and the solid urea added until the
starch-iodide test was only just positive. At this point the suspension was
washed a further three times in water and once in 0.2 mol/l borate buffer,
pH 8.2. The yellow-green diazocellulose was suspended in a little of this
buffer. (Diazotization could be demonstrated by the formation of a highly
coloured orange product when a sample of the preparation was added to
aqueous 2-naphthol).
Preparation of Gamma-Globulin Fraction from DAGPS. DAGPS (10 ml) was
diluted with 10 ml 0.2 mol/l phosphate buffer, pH 8.0. Protein was then
precipitated by the addition of sodium sulphate (3.6 g). After centrifugation
(1800 g, 10 minutes) the precipitate was redissolved in phosphate buffer
(8.0 ml). The gamma-globulin fraction was then precipitated-out by the
addition of sodium sulphate (2.4 g). Following centrifugation (1800 g, 10
minutes) this precipitate was redissolved in 4.0 ml borate buffer, 0.2 mol/l
pH 8.2.
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Coupling of the Gamma-Globulin to Diazocellulose. Diazocellulose (0.5 g
suspended in 5 ml borate buffer, 0.2 mol/l, pH 8.2) was incubated at 4° C
in the dark for 48 hours with the anti -guinea pig gamma-globulin (approximately
0.5 g suspended in 5 ml of the same buffer). At the end of this incubation
the solid phase cellulose linked gamma-globulin was precipitated by gentle
centrifugation (5 minutes, 500 g) and the supernatant removed. The
preparation was then washed three times with borate buffer and then with:
i. Borate buffer (0.1 mol/l) containing 1 mol/l NaCl;
and
ii. Sodium acetate buffer (0.1 mol/l) containing 1 mol/l NaCl.
Finally, the preparation was washed in borate buffer alone. This material,
resuspended in 150 ml assay diluent, constituted the DASP preparation used
for assay separation.
The Use of DASP as an Assay Separation Agent. At the end of the first assay
incubation period 0.5 ml of the DASP suspension was added to each assay
tube using an automatic delivery syringe (the DASP suspension was mixed
using a magnetic stirrer throughout this procedure). The assay tubes were
then shaken mechanically for a second incubation period. Assay diluent
(2.0 ml) was added and the tubes centrifuged (10 minutes, 1800 g). The
supernatants were then carefully removed using a Pasteur pipette attached
to a water pump (the pipette was fitted with a rubber collar which prevented
the tip disturbing the DASP precipitate). The wash and centrifugation procedure
was then repeated and the supernatant removed as before. The DASP
precipitate was counted.
Extraction of Endogenous PTH from Serum Using Quso G32, Ballotini or
Spherosil
Using a mechanical shaking device, normal serum was shaken with Quso G32,
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Ballotini or Spherosil (1.0 g/25 ml serum) overnight at 4° C. The adsorbents
were then precipitated by centrifugation (40 minutes, 1800 g) and the serum
supernatant separated. The supernatant was then re-centrifuged as before
in an attempt to ensure that the adsorbents were completely removed.
Ultrafiltration of Quso-Extracted Sera. Ultrafiltration of Quso-extracted
sera was carried out using an Amicon High Performance, Thin-channel
ultrafiltration system equipped with a DP06 membrane (average pore size
0.6 ym).
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3.1.5 Methods Used to Treat PTH Radioimmunoassay Data
1. Calculation of Assay Results
For each assay counts bound were expressed as a percentage of the total
counts added to the assay system (%B). Counts obtained were not corrected
for non-specific binding (NSB), but %B for NSB control tubes was carefully
monitored in each assay to ensure that it remained below 5%.
For the assay standards a plot of %B versus log PTH concentration led to
a dose-response curve, the standard curve. This curve was sigmoidal rather
than linear and log-Logit transformation of the data (Rodbard and Lewald,
1970) failed to yield a linear relationship between the response-parameter
and antigen concentration. As no data transformation was found to give
a linear dose-response relationship suited to computer analysis of assay
results the approach adopted was to plot %B versus log PTH concentration,
fitting the curve manually to the data points.
From the duplicate standard curves run in each assay a mean standard curve
was constructed, based on mean data obtained from four replicates for each
standard concentration and eight replicates at zero antigen concentration.
Occasional individual replicates with %B values showing exceptionally large
variance (%B > mean %B + 2SD) were eliminated.
The PTH concentration of unknown samples was determined from their respec¬
tive observed mean %B values by interpolation from the mean standard curve.
Normalisation of Assay Data. For inter-assay data comparison
the effect of variations in binding at zero antigen concentration (B0) was
removed by expressing the response-parameter as B_c^ where B is the
B"o
observed binding at the antigen concentration considered and B0 the binding
at zero antigen concentration.
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2. Determination of Assay Precision and Sensitivity
Precision has been defined as the extent to which a given set of measurements
of the same sample agrees with the mean (Midgley et al, 1969). The precision
of a radioimmunoassay system thus essentially describes its reproducibility.
Two components may be identified which contribute to assay precision: the
slope of the dose-response curve and the distribution of replicate determinations
of a sample about the true mean for that sample.
For the radioimmunoassay to be used reliably as an analytical procedure it
is necessary to:
i. Restrict the use of the dose-response curve to a range
of antigen concentrations within which assay precision
is acceptable
and
ii. To examine the precision of the assay method by determining
the agreement of repeated measurements of a sample both
within the same or repeated assays (intra - and inter-assay
precision, respectively).
i. Minimum Detection Limit (Sensitivity) and Upper Antigen Concentration
Limit of Assay
From inspection of a composite standard curve obtained for PTH (Figure 4-30,
p. 173) it was clear that the slope of the dose-response curve was shallower, and
the precision of analysis therefore diminished, at the curve's two extremes.
In order to achieve an acceptable degree of analytical precision it was
therefore necessary to exclude these extreme portions and to make use only
of the more central sections of the curve characterised by a steeply changing
dose-response.
Minimum Detection Limit. The sensitivity of an assay system has been defined
by Midgley e£al (1969) as the smallest amount of hormone which can be
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distinguished from no hormone. The sensitivity (minimum detection limit)
of an assay system is thus closely related to the precision of measurement
as antigen concentration approaches zero. Hunter (1967) has argued that
as the dose-response curve is inherently imprecise at the lower extreme
of antigen concentration and since non-specific assay effects are most
significant in this area of the curve a fall in binding of less than 10% of the
Bq value should not be accepted as representing a specific response. In
the light of these considerations an antigen concentration corresponding to
a %B value of 0.9 x B0 was taken to constitute the minimum detection limit
(sensitivity) of the assay.
Upper Detection Limit. An antigen concentration corresponding to a %B
value of 0. 2 x BQ was arbitrarily taken as the upper detection limit of the assay.
Samples with %B values less than the lower limit %B value were considered
to have undetectable PTH concentrations, whilst those with %B values greater
than the upper limit %B values were diluted in standard curve diluent so that
they fell within the accepted range of the dose-response curve when re-assayed.
ii. Intra-Assay and Inter-Assay Precision
Estimates of both intra - and inter-assay precision were based upon values
obtained for the repeated measurement of four quality control pools (A-D),
selected to have PTH concentrations falling on the standard curve between
the upper and lower detection limits, which were included in each assay.
Intra-Assay Precision. Each control pool was measured in duplicate towards
the start and towards the end of each assay. For a series of assays the
co-efficient of variation (CV) was calculated for each pool using the formula:
(Snedecor, 1952), where d = difference between the two results of a duplicate
determination as a percentage of their mean and N = the number of duplicate
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determinations.
For the overall assay, a root mean square (RMS) intra-assay CV was then
calculated for the four pool CV values obtained using the formula:
RMS CV =
2 '
E (pool CV) /n
where n = number of pools (4).
Inter-Assay Precision. Inter-assay precision for each control pool was
followed be determining the CV of the pool value obtained in a series of
20 consecutive assays (since unknown assay samples were only assayed
in duplicate once, only single duplicate determinations of each pool value
were used for this estimate, these being selected alternatively from either
the beginning or the end of each consecutive assay). The CV value for
each pool was calculated using the formula:
CV (%) = SD x 100
X
where X = mean value obtained and SD = standard deviation of the measurement.
For the assay overall an RMS inter-assay CV was then calculated based on
the four pool CV values obtained using the formula:
RMS CV =J Z(pool CV)2/n '
where n = number of pools (4).
3. Quality Control of Assay Performance
For each assay the following parameters were monitored:
i. B0, the %B at zero antigen concentration
ii. %B for NSB control tubes
iii. Minimum detection limit (sensitivity).
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This allowed any deterioration in assay performance to be detected at an early
stage and facilitated efforts to identify the assay components) responsible.
The values obtained for the control pools and the variance associated with
their measurement were also closely followed. If two (or more) of the
control pools in any assay gave values greater than + 2SD of their assigned
mean value the assay was rejected.
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3.2 DEVELOPMENT OF A RADIOIMMUNOASSAY FOR CALCITONIN




Two methods of iodination were investigated:
i. Direct iodination, using chloramine-T.
ii. Enzymatic iodination, using lactoperoxidase (Thorell
and Johansson, 1971).
i. Procedure for Direct Iodination, Using chloramine -T
Preparation of Human Calcitonin Solution. Human calcitonin for iodination was
dissolved in distilled water (acidified to pH 3.0 with a few drops of acetic acid
solution 0.01 mol/l) to give a solution of 0.1 g/l. Aliquots of 10 y I containing
1.0 yg human calcitonin were prepared in borosilicate glass tubes (10 x 75 mm)
and stored frozen at -20° C. One aliquot was used for each iodination procedure.
Iodination Step. 10 yl phosphate buffer, 0.25 mol/l, pH 7.4, was added to the
borosilicate glass tube containing the calcitonin, which served as the reaction
vessel. The following successive additions were made:
10 y I Na''""0! solution (1.0 mCi)
10 y I chloramine-T (1.6 g/l in phosphate buffer)
The reactants were mixed using a vortex mixer and the reaction allowed to
proceed for 10 seconds. The reaction was then terminated by the addition
of:
100 yl cysteamine hydrochloride (0.8 g/l in phosphate buffer)
or
100 yI sodium metabisulphite (0.8 g/l in phosphate buffer) (see
Section 4. 2.1, p.199).
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10 y I potassium iodide (10 g/l in phosphate buffer) was then added. The total
activity of the reaction mixture was counted (SD counter).
Initial Purification of Reaction Products by Gel-Filtration. Desalting of the
reaction products was carried out immediately after the iodination step.
0.4 ml elution buffer containing 5 g/l BSA was added to the reaction mixture
and the contents of the reaction tube mixed. Using a glass Pasteur pipette
the reaction mixture was quantitatively transferred to a short gel-filtration
column (5x1 cm) containing Sephadex G10. The activity remaining adsorbed
to the reaction tube was measured (SD counter) before the tube was discarded.
The material was eluted from the column using elution buffer containing 5 g/l
BSA. Using the routine fraction collecting system previously described
(Section 3.1.1, p. 55) 30 fractions (0.25 ml) were obtained and the elution
profile followed (Figure 3-3). The faster eluting peak of iodinated protein
was isolated and this material pooled and made up to a known volume (2.0 ml)
1?5
using the elution buffer. This preparation of partially purified ~ I human
calcitonin was distributed into suitable small aliquots (0.1 ml) in borosilicate
glass tubes and frozen using a solid CO^/ethanol freezing mixture. Aliquots
were stored at -20° C.
ii. Procedure for Enzymatic Iodination Using Lactoperoxidase
Preparation of Human Calcitonin Solution. Human calcitonin was dissolved in
distilled water (acidified to pH 3.0 with a few drops of acetic acid 0.01 mol/l)
to give a solution of 0.1mg/l. 50 pi aliquots of this solution (containing 5.0pg
human calcitonin) were prepared in borosilicate glass tubes and frozen at
-20° C. One aliquot was used for each iodination procedure.
Enzymatic Iodination Step. 25p I phosphate buffered saline (PBS) was added
to the tube containing the calcitonin. The following successive additions were
made:
10 Pi Na125I solution (1.0 mCi)
10 pi lactoperoxidase solution
10 pi hydrogen peroxide solution
Figure 3-3
Typical Elution Profile Obtained for Gel-Filtration on Sephadex G10 of Reaction







Gel-bed dimensions: 5x1 cm
Elution was carried out with elution buffer (see Section 2.1, p.31) containing
5 g/l BSA
Fraction volume: 0.25 ml
73
This reaction mixture was incubated at room temperature for three minutes.
The reaction was then terminated by the addition of 0.5 ml elution buffer
containing 5 g/l BSA. The total activity of the reaction mixture was counted
(SD counter).
Initial Purification of Reaction Products by Gel-Filtration. This was carried
out immediately after the iodination step on a gel-filtration column (50 x 1 cm)
packed with Sephadex G50 (the column was presaturated with protein by
passing 5-10 ml elution buffer containing 50 g/l BSA through it prior to its
equilibration with elution buffer containing 5 g/l BSA). Using a glass Pasteur
pipette the contents of the reaction tube were quantitatively transferred to the
column and the activity remaining adsorbed to the reaction vessel measured
(SD counter) before the tube was discarded. Fractionation was then carried
out, 80 fractions (1.0 ml) being collected. The elution profile was obtained
(SD counter) (Figure 3-4). Fractions centrally positioned in Peak III were
isolated and the material they contained pooled and made up to 10 ml using
125the elution buffer. This preparation of purified I human calcitonin was
distributed into suitable aliquots (0.5 ml) in borosilicate glass tubes and frozen
using the solid CC^/ethanol freezing mixture. Aliquots were stored at -20° C.
Methods Used in the Quantitative Assessment of Iodination Procedures for
Calcitonin
The general principles involved in the quantitation of iodination procedures
has been discussed with reference to PTH in Section 3.1.1, p. 49. For
calcitonin the procedure for purifying iodination reaction products was
considerably simpler than that for PTH and consequently the quantitative
assessment relatively straightforward. It should be noted, however, that
for the enzymatic iodination procedure it was necessary to apply corrections
for the high molecular weight iodinated products resulting from the iodination
of lactoperoxidase itself. Gel-filtration on Sephadex G50 (Figure 3-4)
clearly separated this material (Peak I). In the following treatment, when
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Figure 3-4
Typical Elution Profile Obtained for Gel-Filtration on Sephadex G50 of Reaction
Products from the Enzymatic Iodination of Human Calcitonin Using Lactoperoxidase
Gel-bed dimensions: 45 x 1 cm
Elution was carried out with elution buffer (see Section 2.1, p.31) containing
5 g/l BSA
Fraction volume: 1.0 ml
Fractions centrally positioned in Peak III (e.g. fractions 53-58) were selected
for further use
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applied to the enzymatic iodination procedure, the term 'protein' refers to
protein material corrected for the presence of Peak I material.
Estimate of Specific Activity
i. Mass of Protein in Reaction System
This was known at the start of the reaction.
1 25
ii. Amount of I in the Reaction System
125
This was also known since a measured volume of I
was taken corresponding to a known activity,
iii. Percentage Incorporation
An estimate of this value was available from the gel-
filtration profiles obtained during the purification
procedures.
Once again knowledge of these quantities (i-iii) allowed an estimate of the
specific activity to be made, since:
125
Activity due to I protein = Total activity x Percentage incorporation x 1
ITO
and
Specific activity = Activity due to protein
Mass of protein
Percentage Yield of Purification Process
From consideration of the gel-filtration procedure:
Activity transferred to column = Total activity in reaction - Activity due to
mixture adsorbed
protein
An estimate of the percentage of recovered counts in protein was obtained
from the gel-filtration profile.
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Then,
Activity in protein peak = % Recovered counts x Activity transferred to x 1
in protein column 100
and
% Protein recovered from column = Activity in protein peak x 100
(Purification Yield) Total activity in protein
(Total activity in protein = Activity in protein peak +Activity due to protein
adsorbed to glassware)
Knowledge of the purification yield allowed an estimate of the mass of protein
recovered on gel-filtration to be made:
Mass of protein recovered = % Protein recovered x Mass of protein (i) x 1
from column 100
1 OC
Procedures Used for the Further Purification of ^^1 Human Calcitonin
Preparations
125
i. Gel-Filtration on Sephadex G50/G10 . I human calcitonin preparations
produced by iodination were further purified by an additional gel-filtration step
prior to their use in the assay system. The gel-filtration system utilised
was the same as that routinely used for the pre-assay purification of preparations
125of I"BPTH (Section 3.1.1, p. 55) except that the material used to pack the
3 3
column was 8 cm Sephadex G50 above 2 cm Sephadex G10.
ii. Paper Chromatoelectrophoresis. 20 yl samples of solutions containing
125the partially purified I human calcitonin preparation (5 yl), normal serum
(10 yl), bromophenol blue solution (5 Ul) and 0.02 mol/1 sodium barbitone
buffer, pH 8.6 (50 yl) were separated using the paper chromatoelectrophoretic
system described in Section 3.1.1 , p.54 .
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iii. Starch Gel Electrophoresis
Preparation of Starch Gel. The dry starch was mixed with 0.03 moL/l glycine -
HCl buffer, pH 3.0 (91 g starch/l) to form a lump-free suspension.
The suspension was heated over an open flame, with continuous hand mixing,
until it thickened and then became less viscous. The suspension was then
degassed for one minute by partial evacuation under vacuum (water pump)
and allowed to cool slightly, it was then poured into a perspex frame
(18.0 x 5.0 cm) to a depth of 0. 5-0.75 cm. Cooling was then allowed, the
surface of the gel being covered with Parafilm (Gallenkamp and Co Ltd,
London) before the gel set. After setting of the gel was complete (4-6 hours)
the four side walls of the frame were removed, leaving the gel slab on
the perspex base plate.
Equipment for Electrophoresis. A horizontal electrophoretic system was
used (Figure 3-5). The starch gel slab, covered with Parafilm, and
supported on the base plate, was suspended horizontally in the electrophoretic
tank. The tank was divided into two separate electrode chambers, each of
which was further divided into two compartments to prevent changes in pH
originating at the electrode spreading into the gel. The compartments were
in electrical contact with each other via cottonwool wicks. The electrode
chambers were filled to a depth of about 0. 5 ml with the reservoir buffer,
0.3 mol/l glycine-HCl buffer, pH 3.0. Electrical connection between the
reservoir buffer and the gel was established using thick wads of filter
paper (Whatman, 3MM) pre-soaked in the same buffer.
Sample Application. Samples were applied to the starch gel by wetting small
rectangular pieces of filter paper (Whatman, 3MM) with the sample solutions.
These were then inserted into vertical slits cut in the starch gel at the origin.
The vertical length of the paper inserts was slightly less than the thickness
of the gel.
Conditions for Electrophoretic Run. Since the technique was used for separation
of radioactive material of high activity (up to 0.5 mCi) it was necessary to run
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Figure 3-5 Diagram Showing Apparatus Used for Starch Gel Electrophoresis





1. Negative electrode 6. Parafilm cover
2. Reservoir buffer 7. Filter-paper contact
3. Tank lid 8. Electrophoresis tank
4. Pad, presoaked in reservoir 9. Perspex base plate
buffer
10. Cotton wool
5. Starch gel slab
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the electrophoretic system in a specially constructed fume cupboard.
It was thus not possible to carry out the separation at low
temperature and the threat of over-heating, with consequent drying of the gel
by evaporation, presented a potential problem. However, evaporation was
reduced both by the Parafilm covering the gel and by the electrophoretic tank
lid, which was left in position throughout the run. The power supplied was
250 V (2 mA/cm) for 3 hours.
Method Used to Recover Radioactive Material from Starch Gels
i. The gel sections containing the activity peaks were isolated by manually
sectioning the gel slab into 1.0 cm sections. The required sections were
placed in plastic tubes.
ii. Gel structure was disintegrated by freezing the tube contents overnight
(-20° C) and then thawing them the following day. This resulted in the gel
becoming sponge-like in structure.
iii. 2.5 ml acetate-acetic acid buffer (0.01 mol/l) was added to the disintegrated
gel in each tube and the tubes mixed well on a vortex, mixer. The tubes were
then centrifuged (20 minutes, 1800 g) causing the starch to be precipitated.
The supernatants were removed from each tube using glass Pasteur pipettes
and combined to give single solutions containing the radioactive material
recovered from each peak originally selected.
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3.2.2 Anti-Calcitonin Sera
Dilution of Antisera to Working Concentrations. Dilution of antisera to the
working concentrations required in the assay system was made using assay
diluent containing Trasylol (1000 U/ml).
Immunisation Techniques Used to Raise Anti-Calcitonin Sera in Laboratory
Animals
Experimental Animal. The rabbit was chosen as the experimental animal.
New Zealand White Rabbits were obtained at age 10 weeks. The animals
were isolated for the first two weeks following their delivery prior to the
commencement of immunisation procedures. The rabbits received no
experimental treatment other than that described in this study.
Preparation of Emulsions for Injection. Emulsions for injection were prepared
immediately before use. The emulsion was prepared from:
i. An Aqueous Phase: unconjugated human calcitonin was dissolved
in sterile water acidified with one drop of 0.01 mol/1 acetic
acid solution. Any other components used in the aqueous phase
were similarly dissolved in this vehicle.
ii. An Oil Phase: the adjuvant used is described for each immuni-
sation procedure (see Section 4.2. 2, p. 201)-
A water-in-oil emulsion was prepared by adding the aqueous phase to the oil
phase whilst homogenisation was being carried out using a mechanical rotary
emulsifier. Before injection the integrity of the water-in-oil emulsion was
tested by allowing a few drops of the emulsion to fall into a beaker of cold
water. The emulsion was required to remain at the surface as a discrete
white spot, indicating that the aqueous phase containing the antigen was
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entirely enclosed within the oil phase.
Immunisation Route. All innoculations were made subcutaneously at a number
of sites (5-10) over the back and flank of the rabbits. The hair was not
clipped but care was taken to avoid any ulcers resulting from Arthus reactions
at the site of previous innoculations.
Bleeding of Animals. Blood (20-40 ml) was collected from an incision made
in the marginal vein of the rabbit's ear. Time was allowed for the blood to
clot in the container and for the clot to retract before the serum was separated.
A serum sample (5 ml) was taken for assessment, the remainder being stored
frozen at -20° C.
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3.2.3 Human Calcitonin Standard for Radioimmunoassay
Storage of Standard Preparations and Their Dilution to Stock Concentration.
Standard preparations of calcitonin were stored at -20° C in the dark. The
preparations were diluted to stock concentration (100 ng/ml) using the
procedure described for the dilution of PTH standards (see Section 3.1.3,
p. 57).
Preparation of Standard Solutions for the Standard Curve
An aliquot (0.1 ml) of stock standard was diluted with 0.9 ml standard curve
diluent to give a solution (A) of calcitonin concentration 10 ng/ml. 1.0 ml
solution A was then diluted with 2.125 ml standard curve diluent to give a
a solution (B) of concentration 3.2 ng/ml. Solution B was used to prepare
the standard curve according to the following dilution scheme:
Standard no. Standard Diluent Calcitonin concentration
yl yl (ng/l)
1 400 solution B + 400 1600
2 200 solution B + 600 800 .
3 100 solution B + 700 400
4 100 solution B + 1500 200
5 400 standard 4 + 400 100
6 200 standard 4 + 600 50
7 100 standard 4 + 700 25
8 50 standard 4 + 750 12.5
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3,2.4 Application of the Radioimmunoassay Technique to the Measurement
of Calcitonin in Serum and Plasma
Methods Used for the Separation of Antibody-Bound from Free Calcitonin
Two methods were used to achieve this separation:
i. Adsorption onto dextran-coated charcoal,
ii. Immunoprecipitation using a second antibody.
i. Adsorption onto Dextran-Coated Charcoal
This method was applied to the calcitonin radioimmunoassay system in the
same manner as it was applied to the PTH radioimmunoassay (see Section
3.1.4, p. 59).
ii. Immunoprecipitation Using a Second Antibody
The antiserum used for calcitonin radioimmunoassay studies, G1701, was
raised in a goat. The second antibody system used consisted of two
components:
1. An anti-goat IgG serum raised in a donkey (DAGS);
2. A non-immune sheep serum (NSS) as carrier.
(0.01 mol/l EDTA was present in the diluted second antiserum).
Separation Procedure. This was exactly analogous to the procedure described
for the PTH second antibody system (see Section 3.1.4, p. 60).
Optimisation of Second Antibody System. Again, this procedure was as for
the PTH second antibody system (see Section 3.1.4, p. 60).
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3.2.5 Methods Used to Treat Calcitonin Radioimmunoassay Data
Methods used to (1) calculate assay results; (2) determine assay precision
and sensitivity; and (3) achieve quality control of assay performance, were
as for the PTH radioimmunoassay (see Section 3.1.5, p.65).
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3. 3 DEVELOPMENT OF A RADIORECEPTOR ASSAY FOR CALCITONIN
Procedure for Isolation of Renal Membrane Preparations
This procedure was based on a method reported by Shiu et al (1973) for the
isolation of membrane preparations exhibiting prolactin binding activity
from rabbit mammary gland tissue. (All operations were carried out at
4° C or on ice).
Preparation of Tissue Homogenate in Sucrose Dense Medium. Fatty material
surrounding the kidney tissue was trimmed off and the tissue sliced, weighed
and suspended in ice-cold fractionation buffer (0.025 mol/l Tris-HCl containing
0.3 mol/l sucrose). The suspended tissue was homogenised for 45-60 seconds
using a Polytron homogeniser.
Fractionation of Tissue Homogenate by Differential Centrifugation in Sucrose-
Dense Medium. This procedure is shown in Figure 3-6 and involved the
following steps:
i. The tissue homogenate was centrifuged using an MSE 4L
centrifuge (15 minutes, 500 g, 4° C). The supernatant
fluid was decanted off and the pellet, containing unhomogen-
ised tissue and other crude material, discarded. This
centrifugation step was repeated.
ii. The supernatant fluid from (i) was centrifuged (60 minutes,
15000 g, 4° C) using an MSE Superspeed 50 Ultracentrifuge
with an eight-place 25 ml aluminium angle rotor. The




Flow Diagram Illustrating the Procedure for the Fractionation of Tissue
Homogenates by Differential Centrifugation in Sucrose-Dense Medium
i. Tissue homogenate in sucrose-dense fractionation buffer
Centrifuge (500 g, 15 minutes)
Pellet of crude material (discard)
Supernatant
ii. Centrifuge (15,000 g, 30 minutes)
15K Pellet (retain)
Supernatant
iii. Centrifuge (100,000 g, 60 minutes)
100K Pellet (retain)
Supernatant(discard)
(All operations at 4° C or on ice)
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iii. The supernatant obtained from (ii) was centrifuged
(60 minutes, 100,000 g, 4° C) using the same centri¬
fuge and rotor as in (ii). The supernatant was
removed and the sedimented pellet (100K) retained
on ice.
The 15K and 100K pellets from the centrifugation steps were resuspended in
10 ml 0.025 mol/l Tris-HCl buffer, pH 7.5. The suspensions formed
constituted the 15K and 100K membrane preparations used in further studies.
These preparations were dispensed into 1.0 ml aliquots in stoppered plastic
containers and frozen (-20° C).
Estimation of Protein Content of Membrane Preparations
Protein content was determined using a modification of the method of Lowry
et_ al_ (1951). The method was adapted to include a preliminary hydrolysis
step to solubilise particulate membrane protein. The estimation was carried
out as follows:
i. Samples (100 Pi) of the membrane preparations (neat
and at 1/10 dilution in distilled water) were taken.
Protein standards of BSA in distilled water were
prepared over the concentration range 0.05-5 mg/ml.
ii. 0.3 ml NaOH (1.0 mol/l) was added to both samples and
standards. The tubes were stoppered and boiled for
30 minutes in a water bath. The tubes were then
allowed to cool and 0.6 ml distilled water added to
give a total volume of 1.0 ml.
iii. Reagent C (4 ml) was added to all the tubes which were
then allowed to stand for 10 minutes at room temperature.
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iv. Reagent D (0.5 ml) was added to all tubes and their
contents mixed. The colour of the reaction product
was allowed to develop for 30 minutes at room
temperature.
v. The optical densities of both the samples and the
standards were read to 660 my on a spectrophoto¬
meter (Unicam SP 500). The protein concentrations
of the samples were estimated from a standard
curve relating the optical density of the standards to
their protein content.
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I-Calcitonin Preparations Used for Receptor Studies
125
I-calcitonin preparations for receptor studies were prepared from synthetic
human calcitonin (Organon) and synthetic salmon calcitonin (72/158) using
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iodination procedures previously described for the preparation of I human
calcitonin for radioimmunoassay studies (see Section 3.2.1).
Unless otherwise stated, immediately prior to their inclusion in the radioassay
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system all I calcitonin preparations were fractionated on Sephadex G50/G10
(using the routine procedure described in Section 3.2.1, p. 76). Only Peak 11
material was subsequently used.
3.4 OTHER METHODS USED IN THE STUDY OF PTH AND CALCITONIN
IN PREGNANCY AND THE NEONATE
Blood Sampling Procedures
i. Maternal and other adult specimens were obtained by
venepuncture from a forearm vein.
ii. Specimens of cord blood were obtained after delivery
from the umbilical vein.
iii. Infant specimens were obtained by heel prick and
collected in a fine capillary glass tube.
All samples were collected in lithium-heparin tubes and were separated by
centrifugation within one hour of collection. The plasma obtained was
divided into two aliquots and stored at -20° C until required for analysis.
Chemical Analyses Applied to Plasma Specimens
These analyses were performed by the Paediatric Research Laboratory,
Simpson Memorial Maternity Pavilion, Edinburgh.
i. Total Calcium and Magnesium. These were determined on the same
diluted plasma sample by atomic absorption spectrophotometry (Willis, I960).
10 yl of plasma was required for these analyses.
ii. Phosphorus. An ultramicro spectrophotometric method was used,
adapted from the method of Fiske and Subbarow (1925). 20 y I of plasma
was required for the analysis.
iii. Total Protein. An ultramicro spectrophotometry method involving
the use of a modified Biuret reagent was used. The method was adapted
from the earlier methods of Kings ley (1939) and Gornall et al (1949).
5 yl of plasma was used for this analysis.
Analysis for 25-hydroxyvitamin D by Competitive Protein Binding Assay
This analysis was performed by the Department of Chemical Pathology,
St Marys Hospital Medical School, London. A micromethod for
25-hydroxyvitamin D (Fairney et aj_, 1979), suited to the analysis of
small volume paediatric specimens, was used. This competitive protein
binding method was based on an earlier reported assay for 25-hydroxy-
vitamin D (McLaughlin et a_l_, 1974). 100 y I of serum was required for
the analysis.
The assay has limited specificity and significant cross-reaction with
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Parametric Methods of Analysis
Standard parametric methods of statistical analysis (Snedecor and Cochran, 1967)
were applied to data which were considered likely to follow a normal distribution.
Where appropriate, the statistical significance of observations was assessed using
the Student's t-test.
Non-Parametric Methods of Analysis
Various non-parametric methods of statistical analysis (Siegel, 1956) were applied
to assess data which did not follow a normal distribution (see Section 4.4.3, p.261).
McNemar Test. This was used to test the statistical significance of differences
in hormone concentration observed between pairs of selected specimens.
Mann-Whitney Test. This general technique was used to test the Null hypothesis
that two independent groups of specimens had been selected from the same
population. The test involved a comparison of the score values obtained for
each group after the specimens in each individual assay performed had been
ranked according to their measured hormone concentration. The Z-score,
a test statistic describing mean rank, was determined for one of the groups
of specimens considered and compared to a standard normal distribution. The
overall significance for the total data was then assessed by performing a t-test
on the Z-scores obtained for each individual assay.
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Kendall Rank Correlation Coefficient. This coefficient (R) was used as a measure
of the degree of correlation of various ranked assay data. Correlations obtained
within individual assays were tested for overall significant difference from zero
using t-tests.
Level of Significance
Throughout this Study an observation was considered significant if, using the
appropriate statistical test, the probability of significance determined for that
observation (p) was < 0.05. The following notation was adopted in the Tables
presented to denote the significance level of observations:
Level of significance












4.1 DEVELOPMENT OF A RADIOIMMUNOASSAY FOR PTH
1 25
4.1.1 Radioiodination of BPTH and Characteristics of I-BPTH
Comparison of Iodination Procedures
Direct and Indirect methods of iodination were compared in order to aLLow
selection of the most efficient procedure for use in subsequent studies.
Comparison was based on:
i. Quantitative assessment of the two methods (in terms
of estimated product specific activity and percentage
yield on purification).
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ii. Study of the quality of the I-BPTH preparations
produced using each method (as assessed by procedures
detailed in Section 3.1.1, p. 54).
i. Quantitative Assessment of Iodination Procedures
Direct Iodination Procedure
Data are presented from five consecutive iodinations, considered representative
of the many iodinations carried out using this procedure:
Estimation of Specific Activity. Specific activities of 85. 5-132 vCi/yg were
estimated (Table 4-1).
Estimation of Percentage Yield of Purification Process. For each of the five
iodination procedures under consideration the distribution of radioactivity
during Quso G32 purification is shown in Table 4-2.
The percentage yield was equivalent to the percentage of the total counts found




Estimation of Specific Activity of I-BPTH for Five Iodinations Carried out
by the Direct Iodination Procedure
Estimate Iodination no.
12 3 4
i. Mass of BPTH in reaction
system (yg) 2.0 2.0 2.0 2.0 2.0
ii. ^2^I in the reaction
system (yCi) 1500 1500 1500 1500 1500
iii. Percentage Incorporation.
% Activity adsorbed to
reaction vessel (from
Count 1) 2.6 4.2 3.8 5.2 4.8
+ % Activity due to ■^"'i - + + + + +
BPTH (from Sephadex G10
fractionation profile) 8.8 9.6 8.9 12.4 10.3
= % incorporation 11.4 13.8 12.7 17.6 15.1
Estimated Specific activity
of 125I B-PTH (yCi/yg)
(from i, ii and iii) 85.5 103.5 95.0 132.0 113.0
The method used to estimate specific activity is detailed in Section 3.1.1, p. 50.
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Table 4-2
Distribution of Radioactivity During Quso G32 Purification of the Reaction
Products of Five Direct Iodination Procedures
Purification fraction
(Count No.)
Percentage of Pre-Quso total (Count 2)
lodination No.
1 2 3 4 5
Adsorbed to reaction tube
(Count 1) 2.6 4.2 3.8 5.2 4.8
Post-Quso serum
(Count 3) 75.4 83.9 80.6 81.3 81.9
Water supernatant
(Count 4) 1.5 2.5 3.1 1.3 1.4
Final product (i.e. % yield)
(Count 5) 7.4 4.8 6.9 4.9 5.7
Quso/Amberlite residue
(Count 6) 3.8 3.4 2.4 3.2 2.3
Percentage of total counts
accounted for (Count 2) 90.7 98.8 96.8 95.9 96.1
The method used to follow the distribution of radioactivity during the purification
procedure is detailed in Section 3.1.1, p. 52.
Counts 1 -6 referred to in the Table are indicated in Figure 3-1, p.45.
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(These values correspond to mass estimates of 0.072-0.111 g BPTH). Count
rates obtained for 10 u I of the final product (Count 7) are shown in Table 4-3.
z:
Count rates greater than 0.75 x 10 cpm were considered satisfactory.
indirect Iodination Procedure
Five iodinations were carried out using this procedure. The example below
is based on values obtained for one of these.
Example: (For method of calculation see Section 3.1.1, p. 52-53).
Iodination Reaction. The yield of the iodination reaction for
NSHPP was 74%.
Conjugation Reaction. The activity in the conjugation reaction
mixture (Count C) was estimated to be 1.2 mCi, since it
represented 60% of the total activity (2 mCi) used in the
reaction. Of this, 75% (0.9 mCi) was transferred to the
gel-filtration column, the remainder (0.3 mCi) remaining
adsorbed to the reaction vessel (Count D). From the gel-
filtration profile (Figure 3-2, p. 48), 25% of the activity
transferred (0.22 mCi) was present in the protein peaks I and II.
The total activity in protein = Activity in protein + Activity adsorbed
peaks to reaction vessel
= 0.22 +0.3
= 0.52 mCi
This led to the estimated specific activity of 260 yCi/yg.
Furthermore,
The percentage total protein recovered = Activity in protein peak x 100









Count Rates (Count 7) Obtained for 10 ul Final Product of Quso Purification in
Five Direct Iodination Procedures for BPTH
(Count rates greater than 0.75 x 10^ cpm were considered acceptable)







Range of Values Obtained for Parameters Estimated in Five Indirect Iodinations
of BPTH
(For methods of calculation see Section 3.1.1, p. 52-53)
Estimate Range of Estimated Value
Yield of NSHPP iodination reaction (%)
Specific Activity (yCi/yg)





The range of values obtained for each of the parameters estimated is shown
in Table 4 -4.
ii. Comparison of the Quality of 12^I-BPTH Preparations Produced by Direct
and Indirect Iodination Procedures
Preparations of ^^I-BPTH produced by Direct and Indirect procedures were
compared in terms of their non-specific binding to glassware, their capacity
to bind dextran-coated charcoal and specific antisera and their degree of
homogeneity on paper chromatoelectrophoresis (Table 4-5). Profiles
obtained on Sephadex G100/G10 gel-filtration were also compared (Figure 4-1).
In addition, the immunoreactivity of each preparation in the PTH radioimmuno¬
assay system (see Section 4.1.4, p. 168) was examined. The standard curve
obtained using each labelled preparation as tracer in the assay system is
shown in Figure 4-2. Information collected, which allowed a comparison
of the quality of the labelled products of the two iodination procedures, is
summarised in Table 4-5 and shows that both procedures gave products with
essentially similar characteristics.
Selection of an Iodination Procedure for Further Development and Use in
Subsequent Studies
After consideration (see Section 5.1, p.281) of the quantitative and qualitative
data obtained for the Direct and Indirect iodination procedures for BPTH, the
Direct procedure was selected for further development and use in subsequent




Comparison of the Quality of 12^I-BPTH Preparations Produced by Direct
and Indirect Iodination Procedures
Characteristic Studied lodination Procedure
Direct Indirect
Non-specific binding (NSB) to
glassware
(%B + SD, n = 10)
Binding to dextran-coated charcoal
(%B + SD, n = 10)
Specific binding to antiserum AS 262








73.4+2.3 (NS) 71.4 + 3.4
66.3+2.9 (NS) 68.3 + 2.3
Both preparations gave electro-
phoretic profiles with, a single
non-migrating peak
The two preparations gave
comparable gel-filtration profiles
(Figure 4-1)





of observed difference (see




Comparison of the Gel-Filtration Profiles Obtained on Sephadex G100/G10
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Fractionation for I-BPTH Prepared by Direct and Indirect Iodination
Procedures





Comparison of the Standard Curves Obtained Using I-BPTH Prepared by
Direct and Indirect Iodination Procedures in the PTH Radioimmunoassay System
Identical standard curves were established. Solutions (100 ul) containing an
approximately equal mass of purified 125I-BPTH prepared by either Direct or
Indirect procedures were added to each.
Data points shown represent the mean binding observed for four replicates
at each concentration of standard.
PTH (,ig/l)
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Further Development of the Direct Iodination Method for BPTH
Selection of BPTH Preparation for Iodination
BPTH preparations obtained commercially (BPTH 869063) and from NIBSC
(BPTH 76/568) were iodinated using the Direct iodination procedure. The
two iodinations were carried out using a common set of reagents. A comparison
was made of the estimated specific activity and percentage yield achieved
using each material and of the quality of the corresponding final preparations
of "*""^I-BPTH (Table 4-6). Although the ^^I-BPTH prepared from the
BPTH 869063 appeared to be recovered more efficiently, there was no
apparent difference between the specific activities of the two preparations.
The only significant difference between the two preparations of *2^I-BPTH
in terms of quality of product was in the observed non-specific binding to
glassware. Since the BPTH (76/568) preparation gave rise to a preparation
characterised by a significantly lower NSB value (p < 0.001) this material
was selected for use in subsequent iodination procedures.
Reagent Used for Termination of the Iodination Reaction. It was found preferable
to use cysteamine hydrochloride rather than sodium metabisulphite to terminate
the iodination step.in the Direct iodination of human calcitonin (see Section
4.2.1, p.199). Although preparations of 12^I-BPTH produced using these
two reagents were not studied on gel-electrophoresis (as were the corresponding
preparations of human calcitonin), no difference was noted between the
two preparations on gel-filtration or in the PTH assay system. Although it was
considered unlikely that the choice of reagent used for termination of the PTH
iodination reaction was critical, cysteamine hydrochloride was used routinely
for this purpose in preference to sodium metabisulphite.
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Table 4 -6
Comparison of BPTH Preparations as Materials for Iodination
The 12^i-BPTH preparations were produced sequentially by Direct iodination
using a common set of reagents.
Parameter studied Material
BPTH 76/568 BPTH 869063







ii. Quality of ^2^I-BPTH
NSB (%B + SD, n = 10)
specific binding to antiserum








Both materials gave comparable electro-
phoretic profiles
iii. Immunochemical behaviour Both materials gave superimposable
in Radioimmunoassay System standard curves (when corrected for NSB)
iv. Gel-Filtration Profile Time after iodination
on Sephadex G100/G10
1 day 14 days 1 day 14 days
% of Recovered Peak I 6.6 8.6 6.0 8.8
counts in each Peak II 81.5 78.1 83.7 78.2
Peak (p.Ill) Peak III 11.8 13.4 10.3 13.0
Study of the Effectiveness of Purification Obtained Using Quso G32
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To investigate the effectiveness of purification achieved using Quso G32 the
addition of the material was deliberately omitted during the purification
procedure following an iodination. After the addition of cysteamine hydrochloride
terminating the iodination step, excess potassium iodide (10 g/l) was added
to the reaction mixture followed by 0.25 ml elution buffer, these additions
replacing the more usual addition of hypoparathyroid serum and Quso G32
at this stage. The reaction mixture was then fractionated on a Sephadex G10
column (5.0 x 0. 5 cm) to separate the labelled protein from the low molecular
weight constituents of the reaction mixture. The protein peak fractions
obtained were pooled and made up to 2.0 ml with elution buffer. Aliquots
of this material were then treated as follows:
i. By fractionation of Sephadex G100/G10 (Routine fractionation
procedure, p. 55)
ii. By Quso extraction, a sample of the final acetic acid-acetone
eluant recovered being fractionated as in (i).
The gel-filtration profiles obtained on Sephadex G100/G10 for the material
without (i), and with Quso extraction (ii) were compared (Figure 4-3).
Further Investigations of the Effectiveness of Quso G32 Purification of Iodination
Reaction Products
i. Determination of the Percentage of Counts TCA-Precipitable at Each
Stage of the Purification Process. During the course of three successive
Quso G32 purification procedures sampLes were withdrawn to allow the
determination of the percentage of counts precipitable with 10%TCA solution
(v/v) in the various purification fractions (Table 4-7). The difference in the
amount of TCA^recipitable material in the pre-Quso serum and the post-Quso
serum supernatant was attributable to protein uptake by Quso. Between 80%
and 85% of the final labelled product was TCA-precipitable protein.
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Figure 4-3
Comparison of the Fractionation Profiles Obtained on Sephadex G100/G10
Gei-Filtration of BPTH Iodination Products Following Purification on
Sephadex G10:
i. Without Subsequent Quso G32 Extraction
and
ii. With Subsequent Quso G32 Extraction
15
o o Without Quso Purification











( • • )
0 5 10 15
Fraction
20 25 30
Gel-filtration was achieved using the routine fractionation procedure
(see Section 3.1.1, p. 55)
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Table 4 -7
The Percentage of Counts TCA-Precipitable at Various Stages of the Quso G32
Purification of BPTH Iodination Reaction Products
Purification Fraction Percentage of counts TCA-Precipitable
(Range observed for three purifications)
i. Pre-Quso serum 10 - 14
ii. Post-Quso serum supernatant 8-12
iii. Water Supernatant 65 - 75
iv. Final labelled preparation 80 - 85
Samples from each purification fraction were taken into 10% TCA solution
(2.0 ml) and aliquots withdrawn after:
i. addition of 0.25 ml distilled water
or
ii. addition of 0.25 ml normal serum and
precipitation by centrifugation
allowing the % TCA precipitable counts to be estimated
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ii. Comparison of Gel-Filtration Profiles on Sephadex G100/G10 at Each
Stage of the Purification Process. During a typical Quso purification process




iv. Final labelled preparation
These samples were fractionated on Sephadex G100/G10 (Routine fractionation
procedure) and the resulting fractionation profiles compared. Figure 4-4
shows the percentage of the recovered counts obtained in each gel-filtration
peak (p.Ill) for each sample examined. It is evident that Quso purification
produces an increase in the proportion of labelled material eluting in Peak II.
iii. Comparison of the Homogeneity on Paper Chromatoelectrophoresis of the
Labelled Preparation Before and After Quso G32 Purification. The electro-
phoretic profiles obtained for samples of Pre-Quso serum and of the final
labelled preparation derived from the same iodination procedure are shown
in Figure 4-5.
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Qualitative Criteria Used to Test the Acceptability of I-BPTH Preparations
for Use in the Radioimmunoassay
The systems used to qualitatively assess the acceptability of •'"^I-BPTH
preparations for use in the radioimmunoassay were described in Section
3.1.1, p.54.
i. Binding to Dextran-Coated Charcoal. Preparations were
required to give > 60% binding. In general binding
> 70% was observed.
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Figure 4 -4
Histogram Showing the Percentage of Recovered Counts Present in Each
Peak (I-III) Following Gei-Filtration on Sephadex G100/G10 of Samples of:




iv. Final Labelled Product
Obtained During Quso Purification of BPTH Iodination Products




I II III I II III
(iii) Water-supernatant (iv) Final labelled product
48.1%
25.2% 26.7%
I II III I II III
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Figure 4-5
Comparison of Profiles Obtained on Paper Chromatoeiectrophoresis for
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procedure
Ill
iii. Binding to Specific Antisera. Preparations were required to give
> 60% binding to antiserum AS 262. In
general binding > 75% was observed.
- and
< 5% non-specific binding to glassware.
iv. Homogeneity on Paper Chromatoelectrophoresis. Final
labelled preparations were required to show a high
degree of homogeneity when examined. A typical
example of the comparison of the profiles obtained for
a pre-Quso sample and a sample of the purified
labelled preparation is shown in Figure 4-5 (p. 110).
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Gel-Filtration of I-BPTH Preparations
Selection of Sephadex Gel Type for Use in the Routine Fractionation Procedure.
Using the Routine fractionation procedure (see Section 3.1.1, p.55) the
IOC o
fractionation profiles obtained for a I-BPTH preparation using 10 cm
Sephadex G75, G100 and G150 were compared (Figure 4-6). Peak
separation was found to be most satisfactory using Sephadex G100. The
subsitution of 2 cm^ Sephadex G10 for G100 at the base of the column was
found to improve the resolution of peaks II and III without markedly influencing
the resolution of peaks I and II and consequently this combination of gels was
adopted for use in the routine fractionation procedure.
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Typical Gel-Filtration Profile for I-BPTH Preparation Obtained Using the
Routine Fractionation System. A typical gel-filtration profile obtained for
IOC
the fractionation of I-BPTH using the routine fractionation system is shown
in Figure 4-7. The profile showed three peaks eluting in order:
i. Peak I: minor peak of high molecular weight material
ii. Peak II: major peak
iii. Peak III: minor peak of low molecular weight material
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Figure 4 -6 Comparison of the Gel-Filtration Profiles Obtained for the
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Separation of an I-BPTH Preparation Using Sephadex G75,
G100 and G150
Fractionations were carried out using the routine gel-filtration






Typical Gel-Filtration Profile Obtained for an *2^I-BPTH Preparation Using
the Routine Fractionation System
(see Section 3.1.1, p. 55)
Column Characteristics
VQ = Void volume of column = 3.2 - 4. 5 ml
V,p = Total (salt) volume of column = 9.0 - 11.2 ml
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Examination of Peak Characteristics
i. Binding Characteristics of Peaks I-III. These were examined by
selecting central fractions in each peak, diluting the material they contained
with assay diluent to give solutions of comparable counting rate
(1.0-1.5 x 10^ cpm/ml) and using these solutions as the labelled preparations
in a binding trial to determine non-specific binding to glass tubes and specific
binding to excess anti-PTH sera (initial dilutions: AS 211/32 and PIE 12696 -
1/5000; AS 262 - 1/1000). Levels of binding obtained are indicated in
Table 4-8. Peak II material is characterised by the lowest non-specific
binding and the greatest affinity for specific antisera.
ii. TCA Precipitation of Peaks I-III. A gel-filtration profile obtained by
fractionation of ^^I-BPTH on Sephadex G100/G10 (routine fractionation
system) was examined. The protein present was precipitated using 10% TCA
(v/v) and the profile re-examined. The profiles obtained pre - and post-TCA
precipitation are shown in Figure 4-8. These data suggest that Peaks I and II
correspond to labelled protein.
Study of the Behaviour in an Assay System of Peaks I and II Obtained by
Gel-Filtration of 12^I-BPTH
A comparison was made between the material in Peak I and Peak II in respect
of their non-specific and specific binding in an assay system.
Non-Specific Binding (NSB). The labelled material (100y I) was incubated with
normal serum samples at final concentrations of 1/4, 1/8, 1/16, 1/32 or with
diluent alone (100 yl) (assay diluent was used to prepare serum dilutions). The
final incubation was made up to 0.4 ml with assay diluent. At the end of the
three-day incubation period a wash of assay diluent (2 ml) was added and the
tubes decanted and left to drain for 30 minutes. The NSB to glassware obtained
using material from either Peak I or Peak II as labelled preparation is shown
in Figure 4-9. The effect of serum concentration is indicated. Labelled
material from Peak II was found to give less non-specific binding than Peak I






Gel-Filtration Profile for I-BPTH on Sephadex G100/G10 Pre- and Post-
TCA Precipitation
Precipitation was achieved by adding 10% TCA solution (200 yl) to each fraction
collected. Efficient precipitation was ensured by adding 50yl normal serum




Non-Specific Binding (NSB) Using Peak I and Peak II Material from the Gel-
Filtration of ^^I-BPTH: Effect of Serum Concentration
Serum dilutions were made using assay diluent. Incubation was for 72 hours
at 4° C.
Mean binding observed + SD (n = 4)
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and was not markedly influenced by serum concentration.
Specific Binding to Antiserum. The labelled materials (100 yl) were used as
the tracer in the PTH radioimmunoassay system (see Section 4.1.4, p. 168).
Three sera (A, B and C) were assayed as samples at initial concentrations of
1/4, 1/8, 1/16 and 1/32. Diluent alone was also assayed as a control sample
(the diluent used was serum from a hypoparathyroid patient). Values obtained
in the radioimmunoassay for dilutions of sera A, B and C using each of the two
labelled preparations are shown in Figure 4-10. When Peak I material was
used as tracer the concentration of PTH measured for each sample was highly
dependent on sample dilution. Clearly the use of Peak Ilmaterial gives rise
to greater analytical consistency.
Stability of ^^I-BPTH Preparations
Using the Routine gel-filtration system fractionation of ^^I-BPTH preparations
was carried out at regular intervals over extended periods of up to three months.
Since the fractionation conditions on each occasion were identical it was
possible directly to compare the fractionation profiles obtained and hence
examine the decay of the profiles with time elapsed since iodination. Data
obtained for the successive fractionations of the ^^I-BPTH preparation used
in the Analysis period (see Section 4.4, p. 259) are displayed in Figure 4-11.
On several occasions (though not for the preparation considered in Figure 4-1 )
it was noted that if fractionation was carried out 8-10 weeks after iodination
an additional peak (IV) was obtained in the profile. This peak eluted between
Peaks II and III and was found to be TCA -precipitable. It was bound by excess
antiserum AS 262 to almost the same extent as Peak II material.
From these stability studies it is evident that the proportion of labelled material
in Peak II decreases steadily following iodination and that the amount of material
eluting in Peaks I and III increases accordingly as the elution profile decays.
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Figure 4-10 Variation with Serum Concentration of the Serum PTH Value
Determined in the Radioimmunoassay Using Labelled Material
from Gel-Filtration Peaks I and II
The sera assayed (A-C) were diluted using serum from a
hypoparathyroid patient. Data points shown represent
mean values for four replicates
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Figure 4-11
The Proportion of the Recovered Counts Present in Each Peak Obtained on
125Routine Gei-Filtration of an I-BPTH Preparation Over an Extended Period
These data relate to the 12^I-BPTH preparation used for the analysis of
specimens performed in this study. The Analysis period (see Section
4.4.1, p.259) is indicated above.
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Direct Comparison of the Immunoreactivity of Labelled and Unlabelled BPTH
As a test of the immunochemical integrity of the purified labelled BPTH preparation,
labelled Peak II material was assayed directly in the PTH radioimmunoassay
system (see Section 4.1.4, p. 168). A standard curve was set up using
BPTH (71/324) over the concentration range 0.16-10 Pg/1. A standard curve
was also constructed using labelled BPTH (Peak II material) as standard over
an estimated concentration range of 0.16-2. 5 y g/l. The two standard curves
obtained are compared in Figure 4-12. The similarity of the curves obtained
suggests that the immunoreactivity of the labelled BPTH is comparable with
that of the BPTH standard.
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Figure 4-12 Comparison of the Standard Curves Obtained in the PTH
Radioimmunoassay Using as Standard Increasing Concentrations
of;
i. BPTH (71/324)
ii. 125I-BPTH (Peak II material)
For each condition the mean percentage of the original added counts bound to
antibody at each standard concentration is shown (n = 4)
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4.1.2 Studies With Anti-PTH Sera
Cross-Reactivity of Antisera
Antiserum 211/32 (data of Dr. J.S. Woodhead, personal communication)
The cross-reactivity of the antiserum in a radioimmunoassay system with
1 -84 BPTH and N -terminal (1 -29) and C-terminal (53-84) fragments of PTH
is shown in Figure 4-13.
Antiserum PIE 12696(data of Dr. C.D, Arnaud, personal communication)
The cross-reactivity of the antiserum in a radioimmunoassay system with
two human PTH standards, HPTH ?2 and HPTH B-39, is shown in Figure 4-14
(HPTH ?2 is an adenoma culture media preparation. It is approximately
3% PTH, primarily C-terminal fragments. HPTH B-39 is extracted from
adenomas. It is approximately 10% pure and containing the 1 -84 PTH
molecule).
Dilution Curves for Antisera
Dilution curves were set up for the three antisera available.
Antiserum Range of dilution (initial)
AS 211/32 1/5000 - 1/640,000
PIE 12696 1/5000 - 1/640,000
AS 262 1/1000 - 1/128,000
Antiserum (100 yl) at each dilution was incubated for 72 hours at 4° C with
125i_bpth (100 hi) and assay diluent (100 y I). Control tubes (NSB) were
also incubated with assay buffer (200 pi) in the absence of antisera. At
the end of the incubation period separation of bound and free counts was
achieved using dextran-coated charcoal (see Section 3.1.4, p. 59 ). Anti¬
serum dilution curves for the three antisera studied are shown in Figure 4-15.




Cross-Reactivity of 1-84 BPTH, N-Terminal Fragment (1-29) and C-Terminal
Fragment (53-84) in a Radioimmunoassay Using Antiserum AS 211/32
(Data obtained from Dr. J.S. Woodhead)
Concentration (M x 10 10)
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Figure 4-14
Cross-Reactivity of Antiserum PIE 12696 with Human PTH Standards HPTH P?
and HPTH B-39 in a Radioimmunoassay System
(Data obtained from Dr. C.D. Arnaud)
HPTH P2 is a human PTH preparation, about 3% pure, obtained from an
adenoma culture and it contains mainly C -terminal fragments.
HPTH B-39 is extracted from adenoma tissues. It is about 10% pure
and contains 1 -84 HPTH.
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Figure 4-15
Dilution Curves for Anti-PTH Sera
Incubation of antiserum (100 yl) and 1^^I-BPTH (100 yl) with assay diluent (100u 1)

















Data points shown represent the mean binding obtained for four replicates
i
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Comparison of PTH Standard Curves of Selected Antiserum Dilutions
PTH standard curves were set up using antiserum AS 211/32 at initial dilutions
1/125,000 and 1/250,000, and antiserum PIE 12696 at initial dilutions 1/25,000
and 1/50,000. The proportion of the total counts bound to antiserum at a fixed
concentration of labelled BPTH is dependent on the antiserum concentration.
To allow standard curves obtained with different antiserum dilutions to be
compared the counts bound to antiserum were normalised. The standard
curves obtained for antisera AS 211/32 and PIE 12696 (normalised in terms
of B %) are shown in Figures 4-16 and 4-17 respectively. The %B in the
absence of antiserum (NSB) and at zero antigen concentration (B0) is indicated
in Table 4 -9.
For both antisera the position of the assay standard curve was displaced towards
the lower antigen concentrations at the greater of the two antiserum dilutions
examined. Though clearly increasing antiserum dilution results in greater
assay sensitivity for AS 211/32 in particular, this advantage was off-set by
the fact that the level of labelled antigen binding to antiserum became
unacceptably low (and correspondingly the significance of non-specific
binding of 125j;_bptH unacceptably high) as antiserum concentration was reduced.









Standard Curves for PTH Antiserum 211/32 At Initial Dilutions 1/125,000
and 1/250,000























Standard Curves for PTH Antiserum PIE 12696 At Initial Dilutions of 1/25,000
and 1/50,000










%B + SD (n = 8)
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4.1.3 Studies with PTH Standards
Investigation of Methods of Standard Curve Construction
The standard curve forms the basis of analysis by radioimmunoassay, there¬
fore its construction must be both accurate and precise. Since there was
a need to conserve the standard curve diluent serum (see Section 4.1.4, p.150)
it was necessary to devise a scheme for standard curve dilution which
required only small volumes of this material. In order to utilise the
dilution scheme which best satisfied these requirements a number of
alternative schemes were compared experimentally by following the precision
with which the activity of a solution containing ^^I-BPTH could be diluted.
A method involving two-step dilution from a stock standard was found to be
more reproducible than serial dilution from a single top standard. It was
also comparable in terms of precision with other schemes which involved
direct dilution to all lower standard concentrations and was preferable to
these in terms of diluent conservation. The method of standard curve
construction adopted for routine use was to take 0.1 ml from a fresh aliquot
of standard at stock concentration (100 ng/ml) and to dilute this according to
the following scheme:
Standard no. Standard (U I) Diluent (ul) PTH
concentration
(yg/D
1 100 stock + 1900 5.0
2 250 std 1 + 250 2.5
3 250 " + 750 1.25
4 100 " + 700 0.625
5 50 " + 750 0.313
6 100 std 3 + 700 0.156
7 50 " + 750 0.078
8 25 " + 775 0.039
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Formal Comparison of BPTH (71/324) and HPTH (75/549) in the Radioimmunoassay
System
Standard curves for each material were compared in the radioimmunoassay
system (see Section 4.1.4, p.168) using antiserum AS 211/32 (initial dilution
1/125,000).
Since the potency of preparation HPTH (75/549) is still under study by
International Collaborative Assay for the purposes of this comparison it was
necessary to assign the ampoule contents a nominal potency of 100 ng PTH.
The standard curves obtained using the two standards are compared in
Figure 4-18.
Although the two standard curves obtained appear to be parallel, the
assigned potency of BPTH (75/549) relative to BPTH (71/324) is evidently too great.
Consideration of the concentrations of each of the two standards that correspond
to various observed %B values leads to a constant ratio of 4.0 for the concen¬
tration quotient HPTH/BPTH (Table 4-10) and suggests that the PTH content of
the HPTH ampoule is overestimated by this same factor. On the basis of these
data it is possible to estimate that the HPTH peptide content of the ampoule
of standard is 25 ng.
Immunoreactive Behaviour on Dilution of BPTH (71/324) and HPTH Present in
Serum Samples from Patients with Hyperparathyroidism
Sera from four individuals showing elevated PTH levels (two patients, AA and
BB, with primary hyperparathyroidism and two, CC and DD, with secondary
hyperparathyroidism) were serially diluted in hypoparathyroid serum. Samples
(100 yl) from these series were than analysed in the radioimmunoassay system
against a standard curve (BPTH 71/324) diluted in the same serum. The serum
dilution curves obtained were virtually parallel with the standard curve (Figure 4-19
indicating that the HPTH in the samples examined was immunochemically
comparable with that in the standard preparation BPTH 71/324.
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Figure 4-18
Formal Comparison of Standard Curves Obtained in the PTH Radioimmunoassay
Using Standard Preparations BPTH (71/324) and HPTH (75/549)
The contents of the HPTH 75/549 ampoule were assigned a nominal potency of
100 ng PTH for the purpose of this comparison
Antiserum 211/32 (initial dilution 1/125,000) was utilised
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Table 4-10
Data Used in the Estimation of the Relative Potency of Preparations
HPTH (75/549) and BPTH (71/324)
Level of binding Corresponding concentration HPTH concentration
considered (%B) (ug/l) BPTH concentration















Comparison of Curves Obtained on Diluting Sera from Patients with Hyper¬
parathyroidism with PTH Assay Standard Curve (BPTH 71/324)
AA, BB: dilution curves for sera from patients with primary hyperparathyroidism
CC, DD: dilution curves for sera from patients with secondary hyperparathyroid¬
ism
Duplicate determinations were performed for all data points
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4.1.4 Application of the Radioimmunoassay Technique to the Measurement
of PTH in Serum and Plasma
Separation of Antibody-Bound from Free ^^^I-BPTH
Optimisation of Second Antibody System and Investigation of the Influence of
Plasma on the Separation. Since the assay system was to be used to measure
plasma samples it was necessary to examine the effect of plasma on the
separation system. Hypoparathyroid plasma (100 y I) or assay diluent (100 y I)
were added to the tubes in the optimisation grid described previously (see
Section 3.1.4, p.60). The second antibody system components, at a series
of dilutions, were then added and separation completed. Results obtained
for this optimisation are shown in Figure 4-20.
No difference was observed between the separation achieved in the presence
of either assay diluent or plasma, except at a NGPS dilution of 1/50, when
the system behaved sub-optimally.
The dilutions of the second antibody system components selected for routine




Optimisation of Solid Phase Second Antibody System. The effect of altering
two of the components of this separation method was studied. The variables
investigated were:
i. Length of incubation with DASP preparation
ii. Amount of DASP added (0. 5, 0.25, 0.125 or 0.025 ml of
DASP preparation made up with assay diluent to a total
volume of 0. 5 ml)
Figure4-20OptimisationofSecondAntib dyepar tionystemf rPTH:ThInfl e cefl maotSeparation Eitherhypoparathyroidl smaass ydiluentw sdd dtoinc batesiosep rati n.Quadrupl catedetermin ti n
ofbindingweremadfeachcon itioinv stigat da nvaluesrshow .Separ t oc ndi ic si e dop mal areindicat d NoPlasmaDonkeyanti-guin a-pigser mc centration
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The system to be separated, a series of identical tubes containing I-BPTH
with antiserum AS 211/32 (initial dilution 1/125,000) at a total incubation
volume of 0.3 ml, was incubated for 72 hours at 4° C. The results of the
optimisation are illustrated in Figure 4-21.
The conditions selected for the use of DASP as a separation agent were to add
to each tube 0.25 ml DASP preparation (made up to a total volume of 0.5 ml
with assay diluent) and to shake the suspension for two hours before separating
the solid phase by centrifugation.
Comparison of the Two Alternative Approaches to Second Antibody Separation
of the PTH Radioimmunoassay System: Liquid Phase Versus Solid Phase
Using conditions previously optimised, the separation achieved using the
liquid phase second antibody system (donkey anti-guinea pig serum with non¬
immune guinea pig serum) and the solid phase second antibody system (DASP
prepared from the same second antibody) was compared. The assay tubes
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separated consisted of incubations of I-BPTH (100y I) with antiserum
(AS 211/32, 1/125,000 initial dilution), made up to a total volume of 300Pi
with either 100 yl normal serum or 100 y I assay diluent. NSB control tubes
containing assay diluent in place of specific antisera were also separated.
The separation achieved using the two alternative systems is indicated in
Table 4-11. It was evident that binding at zero antigen concentration was
significantly reduced (p < 0.001) when the solid phase separation system was
employed. Consequently the liquid phase second antibody system was used
for the routine separation of PTH assays.
















Comparison of the Assay Separation Achieved Using Liquid and Solid Phase
Second Antibody Systems
Assay tube separated Binding Significance
(mean%B+SD; n = 10) of
difference














Study of the Significance in the Radioimmunoassay of the Tendency for PTH
to Adsorb to Glassware
125
Preliminary Binding Trial. A preparation of I-BPTH, purified on Quso G32
but not additionally by gel-filtration, was diluted in assay diluent to give
4
3x10 cpm/ml and added to a set of test tubes constructed from the various
materials (details of the type of tube investigated are given in Section 2.1,
p. 35). After 72 hours incubation at 4° C, 2.0 ml assay diluent was added
to the tubes, which were then tipped and allowed to drain onto absorbent
paper before being counted. The NSB of counts obtained using each type of
tube is shown in Table 4-12. No significant reduction in the value of NSB
was achieved by repeating the washing procedure.
Since low levels of NSB in the radioimmunoassay were required, borosilicate
glass tubes were selected for use in further studies designed to reduce NSB
to more acceptable levels as these gave the lowest NSB values of the four
types of tube investigated in this preliminary study.
Investigation of Factors Affecting NSB. Since NSB had been found to be
unacceptably high in the preliminary binding trial a number of investigations
were undertaken to ascertain factors which affected NSB in order that
measures could be undertaken to reduce its significance.
i. A binding trial was set up as for the Preliminary binding
trial except that the *^-BPTH preparation was further purified
by gel-filtration on Sephadex G100/G10, only Peak II material
being used. Figure 4-22 shows the effect on the NSB observed
of the following:
pH of the incubation diluent (range 6.4-8.4)
BSA concentration of the incubation diluent (1-5 g/l)





NSB of I-BPTH to Various Types of Tube Investigated in a Preliminary
Binding Trial
Type of Assay Tube NSB
(mean %B + SD; n = 10)
i. borosilicate glass 12.4+0.9
ii. neutral glass 19.3 + 1.0
iii. polypropylene 14.7 + 0.8
iv. polystyrene 33.9+1.6
Figure 4-22
Investigation of the Effect of Assay Diluent pH, BSA Concentration and
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PH
Mean %B + SD (n = 5)
BSA concentration (g/i)
No Triton X-100





ii. A comparison was made of the NSB observed in a binding
125
trial using unfractionated I-BPTH and Peak I and Peak II
material obtained by Sephadex G100 and G10 fractionation of
the same preparation. Incubation was at 4° C in assay diluent
containing either 1 g/l BSA with no Triton X-100 or 5 g/l BSA
with 0.1 g/l Triton X-100. The NSB obtained for each
condition is shown in Table 4-13.
iii. A binding trial was set up using assay diluent containing
0.1.g/l Triton X-100 to investigate the effect on NSB of the
addition to the incubation of serum. The influence of the
addition of the proteinase inhibitor Trasylol (1000 U/ml)
was also investigated, as was the effect of adding Triton X-100
to the wash diluent (Table 4-14).
Measures Adopted to Reduce NSB in the PTH Radioimmunoassay System. From
125
these studies it was apparent that NSB of I-BPTH could be reduced to accept¬
able levels (%B < 5) in the presence of serum by adopting the following
measures and procedures:
1. Using borosilicate glass tubes for assay incubations
125
2. Fractionating I-BPTH preparations by gel-filtration
and using only Peak II material in the assay system
3. Including the following in the incubation medium:
5 g/l BSA
0.1 g/l Triton X-100
1000 U/ml Trasylol
and
4. Including 0.1 g/l Triton X -100 in the wash diluent.




NSB Obtained in a Binding Trial Using Unfractionated I-BPTH and Peak I
and Peak II Material Obtained on Gel-Filtration(Sephadex G100/G10)
Diluent composition NSB (mean %B + SD; n = 5)
unfractionated Peak I material Peak II material
125I-BPTH
lg/lBSA 17.2 +2.1 20.3 + 1.9 7.7 + 0.9
5 g/l BSA 0.1 g/l
Triton X -100 3.9 +0.7 4.2 + 0.6 2.4 + 0.4
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Table 4-14
The Effect on NSB of Various Additions to the Incubation or Wash Diluents
in a Binding Trial for 125I-BPTH
Addition investigated Test condition NSB
(mean %B + SD;
n = 5)
Addition of serum to + serum 3.1 + 0.4
incubation diluent + assay diluent 7.4 + 0.6
Addition of Trasylol (1000 U/ml) serum ( +Trasylol) 2.1 + 0.5
to incubation diluent serum (no Trasylol) 3.5 + 0.4
buffer (+ Trasylol) 8.4 + 0.7
buffer (no Trasylol) 12.4 + 1.2
Addition of Triton X-100 No Triton X TOO 3.3 + 0.5
to wash diluent 0.1 g/l Triton X-100 2.7 + 0.6
0.5 g/l Triton X-100 2.6 + 0.9
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Selection of Assay Incubation Conditions
A number of standard curves were set up in assay diluent using BPTH (71/324)
1
standard and antiserum AS 211/32 (initial dilution 1/125,000). I-BPTH
was added either at the start of the incubation (immediate addition) or after
a preliminary period of preincubation of antiserum and standard alone
(delayed addition). At the end of each assay separation was achieved using
125
the second antibody method. I-BPTH binding at zero antigen concentration
(Bu), NSB and specific binding to antiserum (BQ-NSB) for each incubation
scheme investigated is shown in Table 4-15. The normalised standard curves
obtained at 4° C for schemes involving incubations of 24 hours (immediate
125
addition of I-BPTH) and of 48 hours (immediate and delayed addition of
125
1-BPTH) are compared in Figure 4-23. Consideration of the data obtained
in this investigation (see Section 5.1., p. 288) led to the use in the PTH
radioimmunoassay method developed of the following incubation scheme
involving delayed addition of ^^^I-BPTH:
i. Preincubation at 4° C (72 hours)
ii. incubation with *2^I-BPTH at 4° C (72 hours)
The Effect of Serum on the PTH Standard Curve
The radioimmunoassay system under development was to be used to analyse
circulating concentrations of PTH. It was therefore important to investigate
the influence of serum and plasma on the assay standard curve.
Standard curves for BPTH (71/324) were set up with antisera AS 211/32 (initial
dilution 1/125,000) and PIE 12696 (initial dilution 1/50,000) in the presence of
either 100 y I assay diluent or normal serum. Serum samples (lOOy I) from
patients with primary hyperparathyroidism (n = 5), hypoparathyroidism (n = 2)
and from a control group of normal individuals (laboratory workers with
serum calcium concentrations within the reference range 2.12-2.62 mmol/l;
n = 10) were included in the same assay. The standard curves obtained in



























































Comparison of Standard Curves Obtained for Three PTH Assay Incubation
Schemes
Incubations were made using BPTH (71/324) standard and antiserum AS 211/32.
125i_bpth was added either at the start of the incubation (non-delayed addition)
or after a period of preincubation of antiserum and standard alone (delayed
addition)
Normalised standard curves shown below are based on mean values for









O O 4°C, 24 hours (non-delayed addition)
A & 4°C, 48 hours (non-delayed addition)









the presence and absence of serum using each antiserum and the binding
observed for the samples included in the same assay are shown (Figure
125
4-24, a and b). The depression of I-BPTH binding to antiserum observed
in the presence of serum was also seen when serum was replaced by plasma.
This general effect was seen for all plasma®and sera investigated.
Measurement of Physiological Concentrations of PTH: Demonstration of the
Importance of the Addition of a PTH-Free Serum to the Assay Standard Curve
Standard curves were set up for BPTH (71/324) diluted in assay diluent, anti¬
serum 211/32 (initial dilution 1/125,000) and 100 yl of either normal serum
or serum from a patient known to have severe hypoparathyroidism. Serum
samples (100 yl) were also included in the assay from the following:
i. Normal individuals in control group (n = 10)
ii. Pregnant women at delivery (n = 10)
iii. Infants at delivery (n = 10); cord sera withdrawn from
umbilical vein at delivery.
The standard curves obtained and the binding observed for the samples
(i-iii) are shown in Figure 4-25.
Search for an Acceptable Alternative to the Use of Hypoparathyroid Serum
as a Standard Curve Diluent
It was evident that the addition of serum or plasma to the PTH standard curve
125caused a non-specific reduction in the level of binding of I-BPTH to anti¬
serum. In order to apply the radioimmunoassay technique to the measurement
of PTH in serum or plasma it was clearly necessary to compensate for this
effect. Furthermore it was apparent that, if the low physiologicaL concentrations
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Figure 4 -24 (a)
The Effect of Normal Serum on the PTH Standard Curve (Antiserum AS 211/32)
Standard curves (for BPTH 71/324) in the presence of assay diluent and hypopara-
thyroid serum are shown. (Each point pLotted represents the mean of
quadruplicate determinations). The levels of binding observed for patients with
primary hyperparathyroidism (n = 5), hypoparathyroidism (n = 2) and for a group
of normal individuals (n = 10) are indicated by open circles
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Figure 4 -24 (b)
The Effect of Normal Serum on the PTH Standard Curve (Antiserum PIE 12696)
Standard curves (for BPTH 71/324) in the presence of assay diluent and hypo-
parathyroid serum are shown. (Each point plotted represents the mean of
quadruplicate determinations). The levels of binding observed for patients
with hyperparathyroidism (n = 5), hypoparathyroidism (n = 2) and for a group





PTH Standard Curves Obtained in the Presence of Normal and Hypoparathyroid
Serum
The standard curves presented are based on quadruplicate determinations of the
binding at each concentration of the PTH standard (BPTH 71/324) and were
obtained using antiserum AS 211/32 (initial dilution 1/125,000)
Open circles indicate the level of binding observed in the same system for








































of PTH in circulation were to be detected, any material added to the standard
curve in an attempt to achieve this compensation required to be free of
endogenous PTH. An obvious material of choice for this purpose appeared
to be serum (or plasma) from a patient with severe hypoparathyroidism.
A number of practical difficulties arose from such a choice of material.
For assay stability it was essential that all material added to the standard
curve produced the same degree of reduction of specific binding to antiserum.
However, not all the sera from hypoparathyroid patients which were studied
were found to behave uniformly in this respect. Furthermore, individual
patients found to give donations of suitable sera on one occasion subsequently
were often found to provide material with different characteristics. The
acquisition of a large uniform pool of suitable hypoparathyroid serum was
thus found to be problematical.
In an attempt to overcome these difficulties a study was undertaken to investigate
the possibility that the non-specific effect of serum and plasma samples might
be compensated for in an alternative manner, by adding to the standard curve
material of non-pathological origin. This would be advantageous since such
material could be produced in the laboratory in a consistent manner over
extended periods. Two such materials were investigated:
i. Treated normal sera
and
ii. Assay diluent of increased protein concentration
i. Investigation of the Use of Treated Normal Sera as Standard Curve
Diluent
Normal Serum Treated by Repeated Freeze-Thawing. PTH is unstable at
ambient temperatures and the instability of PTH on repeated freeze-thawing
has been investigated in this Study (see Section 4.1.4, p.168). An attempt
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was made to produce a pool of serum low in immunoreactive PTH from
a normal serum by subjecting it to repeated freeze-thawing. However, in
the radioimmunoassay standard curves obtained in the presence of normal
serum which had been subjected to four freeze-thaw cycles (each consisting
of 24 hours at -20° C, followed by 24 hours at room temperature) were found
to be superimposable with those in the presence of untreated normal serum.
Normal Serum Treated by Extraction. Since PTH is known to adsorb readily to
many substances attempts were made to extract endogenous PTH from normal
serum using a number of materials. The following were investigated
as potential PTH absorbents:
Material Physical nature
Ballotini glass Glass spheres, diameter 0-60 vm
Spherosil XOA 400 Porous glass beads, diameter
100-200 Pm
Quso G32 Microfine silica particles, diameter
1.0 -1. 5 y m
The PTH adsorptive properties of these materials were compared (Table 4-16)
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by following the efficiency with which they removed exogenous I-BPTH from
a pool of normal serum using the extraction method described in Section 3.4.1
(p.63).
Of the three materials investigated, Quso G32 was found to remove PTH most
efficiently from serum and this material was subsequently used to treat
normal serum pools, which were then examined in the PTH radioimmunoassay
system. PTH standard curves (BPTH 71/324 in assay diluent with antiserum
AS 211/32 at an initial dilution of 1/125,000) established in the presence of
Quso treated and untreated normal serum were compared (Figure 4-26).
Although the standard curve obtained in the presence of Quso treated serum
was characterised by higher levels of binding at all standard concentrations,




Comparison of the Efficiency of the Removal of Exogenous ^I-BPTH from
a Serum Pool by a Number of Materials
Material added to serum Activity in 100 y I Extraction efficiency
serum after (% of exogenous *^I-BPTH















PTH Standard Curves Obtained in the Presence of Quso Treated and Untreated
Normal Serum
The standard curves presented, obtained with BPTH 71/324 and antiserum AS 211/32
(initial dilution 1/125,000), are based on quadruplicate determinations at each
standard concentration
PTH ( yg/1)
O O Quso treated serum
• « Non-treated serum
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was merely due to the increased NSB observed after serum treatment. It
seemed likely that this increased NSB was at least partially due to a co-
125
precipitation with the second antibody of I-BPTH adsorbed to residual
Quso particles, since some difficulty had been experienced in completely
removing Quso particles from the treated serum by centrifugation at the
end of the extraction process. In order to ensure the complete removal
of Quso following extraction an Ultrafiltration process was employed (see
Section 3.1.4, p.64). Four 25 ml serum pools (A - D) were prepared from







125The NSB and specific binding at zero antigen concentration (Bq) of I-BPTH
in the PTH radioimmunoassay system in the presence of each of these four
sera (A - D) were compared with corresponding values obtained in the
presence of the same volume of assay diluent or hypoparathyroid serum
(Table 4-17). Although the inclusion of the ultrafiltration treatment (Serum A)
effectively decreased the NSB previously found to be characteristic of Quso
extraction of serum, the binding at zero antigen concentration was also
markedly increased over that obtained for the control serum (serum D)
and hypoparathyroid serum. This suggested that the process of ultra¬
filtration itself in some way altered the properties of the serum in this
respect, a hypothesis that found support in the observation that serum Ct
treated by ultrafiltration alone, also showed an increase in B0. Thus, no
combination of Quso extraction and ultrafiltration of normal serum was
found to produce a material suitable for use as a standard curve diluent.
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Table 4-17
The Effect of the Addition of Various Diluents on the NSB and Binding at Zero
Antigen Concentration (Bo) Obtained in the PTH Radioimmunoassay
Diluent added Treatment NSB Br
(mean%B + SD; (mean %B + SD;
























ii. Investigation of the Use of Assay Diluent of Increased Protein Concentration
as a Standard Curve Diluent
This investigation was undertaken in order to determine whether the protein
content of the assay diluent could be manipulated in such a way that standard
curves obtained in the presence of hypoparathyroid serum and assay diluent
were superimposable, since this would remove the requirement for the use
of the former material in each assay run. Standard curves for BPTH (71/324)
in assay diluent with antiserum AS 211/32 (initial dilution 1/125, 000) in the
presence of 100 u I of the following diluents were compared:
i. Assay diluent (containing 5 g/1 BSA)
ii. Assay diluent (containing 35 g/1 BSA)
iii. Assay diluent (containing 70 g/l BSA)
iv. Hypoparathyroid serum
v. Hypoparathyroid serum: Assay diluent (It 1 v/v)
vi. Hypoparathyroid serum: Assay diluent (1*. 13 v/v)
The effect of increasing the BSA content of the standard curve diluent is shown
in Figure 4-27 (a), whilst the effect of diluting the hypoparathyroid serum
added to the standard curve is depicted in Figure 4-27 (b). Although the
protein concentration of the assay diluent was found to markedly influence the
position of the PTH standard curve, no adjustment of this factor gave rise
to a solution suitable as a replacement for hypoparathyroid serum as standard
curve diluent in the PTH radioimmunoassay.
Selection of Hypoparathyroid Sera for Use as Standard Curve Diluent
Since no acceptable alternative had been found, single serum donations
(100-200 ml) were collected from seven hypoparathyroid patients (AA-GG)
to allow selection of the ones best suited for use as standard curve diluents.
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Figure 4 -27 (a)
Effect of Increasing the BSA Concentration of the Assay Diluent on the Position
of the Standard Curve in the PTH Radioimmunoassay
PTH (pg/1)
Standard Curve Diluent
i. o o Assay diluent (5 g/l BSA)
ii. • • Assay diluent containing 35 g/l BSA
iii. 0-——0 Assay diluent containing 70 g/l BSA
lv. v V Hypoparathyroid serum
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Figure 4 -27 (b)
The Effect of Diluting the Hypoparathyroid Serum Used as Standard Curve
Diluent on the Position of the PTH Radioimmunoassay Standard Curve
60 i
I— 1 1 1 I









Hypoparathyroid serum : assay diluent (1:1 v/v)
Hypoparathyroid serum : assay diluent (1:13 v/v)
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Standard curves for BPTH (71/324) in assay diluent with antiserum AS 211/32
(initial dilution 1/125,000) were set up in the presence of 100 yl of either:
i. additional assay diluent
ii. normal serum
or
iii. hypoparathyroid serum (AA-GG)
Serum samples (100 yl) were also included from the following groups:
Normals, N: normal individuals from control group, n = 20
Maternals, M: pregnant women at delivery, n = 20
Cords, C: infants at delivery (umbilical cord sera), n = 20
The standard curves obtained and the binding observed for the sample groups
are shown in Figure 4-28. Sera FF and GG were selected for use in the
PTH radioimmunoassay system, since they were associated with the standard
curves least displaced from the standard curve established in assay diluent
alone and allowed a greater proportion of the serum samples to be measured.
These two sera were mixed to give a singLe pool of 240 mis. This material
was distributed into a number of small aliquots (24 x 10 ml) and stored at
-20° C. A fresh aliquot of this pooled material was thawed, centrifuged
and used for standard dilution each time an assay was set up, thereby
ensuring that the assay standard curve diluent displayed consistent
characteristics throughout the Analysis period (see Section 4.4, p.259).
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Figure 4-28




o o Assay diluent
G G Serum GG
F F Serum FF
Sera AA-EE
Normal serum
Mean values of %B for cord (C), normal (N) and maternal (M) serum samples
are indicated thus: ^
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Behaviour of Samples in the PTH Assay System
i. Comparison of Results Obtained Using Serum and Plasma Samples.
Kubasik and Sine (1978) reported differences in the results obtained using
serum and plasma samples in a number of radioimmunoassay systems.
A study was thus undertaken to determine whether any such difference was
observed for the PTH radioimmunoassay system. Venous blood (20 ml)
was taken from 24 healthy adults and divided equally between plain glass
tubes (for serum) and lithium-heparin tubes (for plasma). The blood
was separated within 30 minutes of collection. The serum and plasma
specimens were frozen ( -20° C) within one hour of collection. The PTH
values obtained for paired serum and plasma samples were compared
(Table 4-18). Using the two types of sample PTH values obtained were not
significantly different on a sign test (serum > plasma in 10 cases; serum
< plasma in six cases; serum = plasma, or both values undetectable,
four cases) or on a paired t-test (applied to the 15 individuals with detectable levels
of PTH for both serum and plasma samples, 0.10 < p < 0.20).
ii. Effect of Sample Haemolysis. In this study a large proportion of the
infant specimens, particularly cord sera obtained at delivery, were subject
to haemolysis at collection. It was thus essential to determine whether
sample haemolysis influenced the PTH concentration obtained on analysis.
A donation of venous blood (100 ml) was obtained from a normal individual.
A portion of this blood (40 ml) was subjected to partial haemolysis by
vigorously shaking it. A further portion (10 ml) was severely haemolysed by
subjecting it to freezing and thawing. These haemolysed blood specimens
and the remaining non-haemolysed portion (50 ml) were then separated, and
PTH standard curves established in each of the sera obtained. The levels
of NSB and Bo observed are shown in Table 4-19.
Although the presence of severely haemolysed serum profoundly depressed
specific binding in the PTH radioimmunoassay system, no difference was
observed between standard curves obtained in the presence of non-haemolysed
and partially haemolysed sera.
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Table 4-18 Comparison of Results Obtained in the PTH Radioimmunoassay




2 < 0.22 < 0.22
3 0.25 < 0.22
4 0.51 0.49
5 0.26 0.25




10 < 0.22 < 0.22










Significance of difference between serum and plasma obtained:
i. Sign test (n = 20): (NS)




The Effect of Haemolysed Serum on the Binding of I-BPTH in the Radioimmuno
assay System
Degree of haemolysis NSB BQ





iii. Effect of Freeze-Thawing a Sample on the Concentration of PTH
Measured by Radioimmunoassay. BPTH (71/324) was added to hypoparathyroid
serum to give recovery standards of concentration 0.31, 0.62, 1.25 and
2. 50 yg/l. Each of these standard solutions was divided to give four
separate aliquots, thereby giving four sets (I-IV) of each recovery standard.
These sets received the following freeze-thawing treatment:





(Each freeze-thaw cycle consisted of 24 hours at -20° C followed by six hours
at room temperature). All four sets of each recovery standard were then
measured in the same PTH radioimmunoassay against BPTH 71/324 standard,
diluted in hypoparathyroid serum. Values obtained in the radioimmunoassay
for each recovery standard after 1 -4 freeze-thaw cycle treatments are shown
in Figure 4-29. Repeated freeze-thawing tended to reduce the amount of
immunoreactive PTH recoverable on assay, though the degree of reduction
observed was highly variable.
PTH Radioimmunoassay System Developed for Sample Analysis
The PTH radioimmunoassay system described below was developed as a result
of studies described in this Section. This system was used for the PTH
analysis of maternal and neonatal samples (see Section 4.4, p.254).
Radioimmunoassay Procedure
(The assay was carried out in borosilicate glass tubes (10 x 75 mm). All
dilutions were made in assay diluent unless otherwise stated).
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Figure 4 -29
Effect of Repeatedly Freeze-Thawing a Sample on the Concentration of PTH
Measured by Radioimmunoassay
Each freeze-thaw cycle to which the recovery standards were subjected consisted



























Number of freeze-thaw cycles
Values shown were derived from mean levels of binding obtained for duplicate
determinations made for each condition
Preincubation
Assay tubes were set up to contain:
i. 100 yl sample (neat plasma or serum)
or 100 yl standard BPTH (71/324) diluted in selected
hypoparathyroid serum
or 100 p I hypoparathyroid serum (ZA)
ii. 100 yl guinea pig anti-PTH serum 211/32 (initial
dilution 1/125,000)
or 100 p I antiserum diluent (NSB)
72 hours incubation, 4° C
Incubation with -^^I-BPTH
iii. 100 pi ^^I-BPTH (76/568) added (approximately
3000 cpm, diluted in assay diluent with 0.1 g/l
Triton X-100 added). Only Peak II material
from routine gel-filtration procedure used
72 hours incubation, 4 C
Separation
The components of the second antibody system were then added (at their
respective optimal concentrations):
iv. 50 y I non-immune guinea pig serum (NGPS)
v. 50 pi donkey anti-guinea pig serum (DAGPS)
16-18 hours incubation, 4° C
vi. 2 0 ml assay wash diluent was then added and the
assay tubes centrifuged (30 minutes, 1800 g, 4° C)
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The supernatants were decanted from the immuno-
precipitates and the inverted tubes allowed to drain
onto absorbent paper for 30 minutes. The tubes
were then counted.*
Radioimmunoassay Format
The following arrangement of assay components was adopted for each assay
undertaken. The number of assay tubes in each dilution is indicated (n).
i. Standard curve comprising:
NSB controls (n = 4)
ZA standards (n = 4)
Standards (eight PTH concentrations, n = 2 for each)
ii. Internal quality control samples:
Serum pools A,B,C,D (n = 2 for each pool)
iii. Unknown samples (n = 2 for each sample)
iv. Internal quality control samples (as in ii)
v. Duplicate standard curve (as in i)
* Note concerning radioactive counting. To ensure the statistical accuracy
of the radioactive counting procedure each assay tube was counted for a period
which was sufficient for 10,000 counts to be collected from counting




4.1.5 Characteristics of the PTH Radioimmunoassay Developed
The following data were obtained from the 20 consecutive PTH assays used to
analyse maternal and neonatal samples during the Analysis period (see Section
4.4, p.259). Methods used to treat assay data were considered in Section
3.1.5, p.65.
Composite Standard Curve
A composite standard curve based on the normalised data obtained in the
20 assays is shown in Figure 4-30. The mean values for NSB and for
specific binding and B0 were as follows:
mean %B + SD (n = 20)
NSB 2.89+0.34
Bq 45.71+1.64
Assay Precision and Sensitivity (over the Analysis Period)
i. Minimum Detection Limit (Sensitivity) and Upper Detection Limit
Minimum detection limit (0.9 x B0) = 0.21 + 0.04 yg/1 (mean + SD; n = 20)
Upper detection limit (0.2 x B0) = 3.32 + 0.34 yg/1 (mean + SD; n = 20)
ii. Intra - and Inter-Assay Precision
On the basis of the two estimates (each performed in duplicate) in each of the




Composite PTH Standard Curve Based on Data Obtained in the Twenty Assays
During the Anaiysis Period
The mean positions of the lower and upper detection limits are indicated by
interrupted lines
The mean values assigned to the quality control pools (A-D) are also shown
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Intra-Assay Precision. For each pool, intra-assay comparison
of values obtained in the 20 assays considered led to an estimate
coefficient of variation (CV) (Table 4-20), These CV values led
estimate of intra-assay precision over the Analysis period:
RMS CV (intra -assay) = 10.6%
Inter-Assay Precision. For each pool, inter-assay comparison of single
values obtained in the 20 assays considered led to an estimate of inter-assay
CV (Table 4-21). These CV values allowed an overall estimate of the inter-
assay precision over the Analysis period to be made:





One important validation of an assay is the demonstration of the quantitative
recovery of endogenous hormone added to the assay system. Solutions of
BPTH (71/324) were prepared in hypoparathyroid serum at concentrations
of 0.25, 0.50, 1.0 and 2.0 pg/l (expected concentrations). The concentration
of each standard solution was then measured in the PTH assay system
(observed concentration). The percentage recovery of the PTH in each
standard solution was then calculated using the expression:
% Recovery = Observed PTH concentration x 100
Expected PTH concentration




Intra-Assay Coefficient of Variation (CV) for Each Control Pool for the Twenty
Assays During the Analysis Period
(For method of calculation see Section 3.1.5, p. 67)








Inter-Assay Coefficient of Variation (CV) for Each Control Pool for the Twenty
Assays Daring the Analysis Period
(For methods of calculation see Section 3.1.5, p.68)

























Recovery of Standards in the PTH Radioimmunoassay
Recovery standard Mean concentration % Recovery
concentration obtained for standard of standard







4.2 DEVELOPMENT OF A RADIOIMMUNOASSAY FOR CALCITONIN
125
4.2.1 Radioiodination of Calcitonin and Characteristics of I-Calcitonin
Quantitative Assessment of Calcitonin Iodination Methods
Data obtained from ten iodinations using the Direct, chioramine-T method
and five using the enzymatic method with lactoperoxidase are compared
in Table 4-23. The Direct, chloramine-T method gave rise to the more
highly labelled product and was consequently used routinely in the preparation
1 OCT
of ^^1-human calcitonin for radioimmunoassay studies.
Examination of the Sephadex G50/G10 Gel-Filtration Profile Obtained for
125i -Human Calcitonin
125
Typically, the gel-filtration profile obtained on routine fractionation of I-
human calcitonin on Sephadex G50/G10 displayed three peaks (Figure 4-31):
Peak I : high molecular weight material, TCA precipitable
Peak II : major peak, TCA precipitable
Peak III: low molecular weight material, not TCA precipitable
Immunoreactivity Across Gel-Filtration Profile. The immunoreactive
characteristics of the three peaks (I-III) were examined by selecting fractions
positioned centrally in each peak and diluting the material they contained to
4
give solutions with comparable counting rates (1.0-2.0 x 10 cpm/ml). These
solutions were then used as labelled preparations in a binding trial. An
examination was made of specific binding to excess anti-calcitonin serum
G1701 (initial dilution 1/1000) and NSB to glass tubes in the absence of
antiserum. Incubations were carried out for 48 hours at 4° C and separation
was achieved by second antibody precipitation. The binding characteristics
of each peak are shown in Table 4 -24. Material for Peak II was found to give




Quantitative Assessment of Fifteen Human Calcitonin Iodination Procedures
(Ten by Direct, Chloramine-T Method, Five by Enzymatic Method with
Lactoperoxidase)
(Methods used to obtain these estimates are described in Section 3.2.1, p. 73-76)
Estimate Iodination Procedure
Direct Enzymatic
i. Mass of protein tug)





iii. % Incorporation (range) 45-60 60-80
Specific activity (MCi/yg) (range) 450-600
'
120-160




Typical Gel-Filtration Profile Obtained for Fractionation of I-Human
Calcitonin on Sephadex G50/G10
(Fractionation conditions are described in Section 3.2.1, p. 76)
Column characteristics
V0 = Void volume = 2.2 -4.5 ml
Vp = Total (salt) volume = 8.1 - 10.3 ml
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Table 4 -24
Comparison of the NSB and Specific Binding to Antiserum G1701 of Material
125
from Peaks I-III Obtained on Gel-Filtration of I-Human Calcitonin
Labelled NSB Specific binding to antiserum
material (mean%B+SD; n = 10) (mean %B + SD; n = 10)
Peak I 0.58 + 0.81 26.9^1.8
Peak II 0.25 + 0.14 56.4 + 2.1
Peak III 0.48 + 0.43 3.8 + 1.3
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Study of the Stability of the I-Human Calcitonin Preparation Used During
the Analysis Period
125
The stability of I-human calcitonin used in the radioimmunoassay system
during the Analysis period was carefully followed. Immediately following
the iodination procedure the labelled preparation was examined by gel-
filtration and paper chromatoelectrophoresis. Subsequently, the gel-
125
filtration profile was examined on each occasion that I-human calcitonin
was added to an assay throughout the Analysis period. The examination
of the gel-filtration profile was continued at intervals for 75 days following
iodination. At the end of this period the paper chromatoelectrophoretic
profile was re-examined. The data obtained from gel-filtration studies
over this extended period are shown in Figure 4-32. Electrophoretic profiles
obtained immediately after iodination and 75 days later are compared in
125
Figure 4-33. It is evident that the structural integrity of I-human calcitonin
progressively declines from the time of iodination.
Separation of the Products of the Human Calcitonin Iodination Reaction:
Preliminary Comparison of the Profiles Obtained on Gel-Filtration and Starch
Gel Electrophoresis
Human calcitonin was iodinated using the Direct chloramine-T iodination
procedure, the iodination reaction being terminated with sodium metabisulphite
and potassium iodide. Normal serum (10 y I) and bromophenol blue solution
(5 yl) were added to the reaction mixture and the contents of the reaction tube
divided into two portions of approximately 75 yl each.
i. The first portion was fractionated on Sephadex G50/G10
using the Routine gel-filtration system (see Section 3.2.1,
p. 76). The gel-filtration profile obtained using the SD counter




The Percentage of the Recovered Counts Obtained in Each Peak (I-III) on
12S
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Recovered
Counts
These data relate to the 125i_human calcitonin preparation used for the
analysis of specimens performed in this study
The Analysis period (see Section 4.4.1, p.259) is indicated above
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Figure 4 -33 Comparison of the Profiles Obtained on Paper Chromatoelectro
125
Phoresis of an I-Human Calcitonin Preparation:
i. immediately following iodination
and
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ii. The second portion of the reaction product was separated
using the starch gel electrophoresis system (see Section
3.2.1, p.77). A band of activity was observed to move
rapidly off the gel into the reservoir buffer of the anode.
At the end of the electrophoretic run the starch gel was
sectioned manually by cutting the gel slab transversely into
1 cm slices. These slices were counted (SD counter),
allowing the electrophoretic profile to be examined (Figure
4-34 (b)). The profile displayed three peaks (1 -3).
The band of activity moving rapidly anodally on gel electrophoresis of the
125 125
reaction products corresponded to I (salt), since I and Peak III
material from gel-filtration were found to behave in the same way on
electrophoresis. Thus, three peaks of activity corresponding to labelled
protein were obtained on starch gel electrophoresis of the calcitonin iodination
products, whilst only two protein peaks (I and II) were obtained on gel-filtration
of the same material. The unexpected presence of this additional peak on
starch gel electrophoretic separation was the stimulus for a series of further
investigations.
Further Examination of Human Calcitonin Iodination Products on Starch Gel
Electrophoresis: Influence of Factors in the Iodination Procedure
Iodination. Human calcitonin (1.0 yg) was iodinated using a modified Direct
125
chloramine-T iodination procedure. Incubation of calcitonin with I was
allowed to proceed for 10 seconds in the usual manner. At the end of this
time the reaction volume was divided, 20 yl being taken into 50 ul sodium
metabisulphite (0.8 g/l phosphate buffer), whilst 50 yl potassium iodide
(10 g/l in phosphate buffer) was added to the 20 yl reaction mixture which
remained in the reaction tube. After termination of the reaction 5 yl of
normal serum and 5 yl bromophenol blue solution were added to both portions
of the reaction mixture.
Figure 4-34 (a)
Fractionation Profile Obtained for Human Calcitonin Iodination Products
Using Gel-Filtration
(Gel-filtration was performed on Sephadex G50/G10 using the routine
Fractionation system - see Section 3.2.1, p.76)
Fraction
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Figure 4 -34 (b)'
Fractionation Profiles Obtained for Human Calcitonin Iodination Products Using
Starch Gei Electrophoresis
Starch gel dimensions: 18 x 10 cm. Electrophoresis was carried out at pH 3.0
and the power supplied was 250V (2 mA/cm). At the end of the electrophoretic








Distance from origin (cm)
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An additional band of activity (not shown) moved rapidly off the starch gel into
the reservoir buffer at the anode
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Starch Gel Electrophoresis. Samples of the two reaction mixtures (50 yI)
were applied to the origins of identical starch gels, and run in parallel in
the electrophoretic system. In both cases a band of activity was observed
to move rapidly towards the anode and off the gel. At the end of the run the
two starch gels were monitored for radioactivity using a radiochromatogram
scanner. The radiochromatogram scans of the starch gel electrophoretic
profiles obtained for separation of calcitonin iodination products following
termination of the reaction with either sodium metabisulphite or potassium
iodide are shown in Figure 4-35 (a and b) respectively. As for the previous
experiment, three peaks of activity (1 -3) were obtained for the reaction
terminated using sodium metabisulphite. When the iodination reaction was
terminated with excess potassium iodide rather than sodium metabisulphite
only two peaks (4 and 5) were obtained. Thus, the reagent used to terminate
the iodination reaction was found to influence the nature of the reaction product.
This influence was apparent only on gel electrophoretic separation, and was
not revealed by gel-filtration alone. Since this observation was potentially
a significant one in terms of the radioimmunoassay of calcitonin a further
investigation was undertaken to study the nature of the material in each of the
electrophoretic peaks.
Investigation of the Nature of the Material Recovered from the Starch Gels
Used to Separate Calcitonin Iodination Products
Using the extraction methods described in Section 3.2.1 (see p.79), solutions
were prepared containing the ^^1-labelled material extracted from activity
peaks obtained on starch electrophoresis in the previous experiment. The
material recovered from each peak was studied in two ways:
i. By gel-filtration of Sephadex G50/G10 (Routine fractionation
procedure)
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Figure 4-35 (a and b)
Radiochromatograms Obtained on Starch Gel Electrophoresis of Human Calcitonin
Iodination Products after Termination of the Iodination Reaction with:
(a) Sodium metabisulphite
and
(b) Excess potassium iodide
Starch gel dimensions: 18.0x5.0 cm. Electrophoresis was carried out at
pH 3.0 and the power supplied was 250V (2 mA/cm) for three hours
For both (a) and (b) a band of activity (not shown) moved rapidly off the gel into
the reservoir buffer at the anode
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and
ii. By studying the standard curve obtained in the calcitonin
radioimmunoassay system (see Section 4.2.4, p.223)
using the material as the labelled preparation
i. Gel-Filtration on Sephadex G50/G10. Fractionation profiles for the
material recovered from each of the activity peaks (1 -5) obtained on starch
gel electrophoresis (Figure 4-35 a and b) are compared in Figure 4-36 (a-e).
It is evident that peaks 1 and 4 contain a greater proportion of high molecular
weight aggregated protein than do the remaining peaks, in which material
IOC
corresponding to monomeric -human calcitonin (Figure 4-31, p. 180)
predominates.
ii. Immunochemical Behaviour in the Radioimmunoassay System. Standard
curves obtained using the material recovered from each activity peak
(1-5) as the labelled preparation in the calcitonin radioimmunoassay system are
shown in the presence and absence of normal serum (Figure 4-37 a and b).
As indicated in Table 4-25, with labelled material from Peaks 1, 2 and 4
in the radioimmunoassay system, specific binding observed in the presence
of normal serum was significantly lower than that obtained in its absence.
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Figure 4 -36 (a - e) Sephadex G50/G10 Gel-Filtration Profiles for Material
Recovered from Peaks 1 -5 Obtained on Starch Gel
Electrophoresis of Calcitonin Iodination Products
A sample of the radioactive material from each peak (Figure 4-35 a and b)
was fractionated using the routine fractionation procedure (see Section 3.2.1,
p. 76)
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Figure 4-36 (c and d)
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Figure 4-37 (a and b) Standard Curves Obtained in the Calcitonin Radioimmuno¬
assay System Using Material. Recovered for Starch Gel
Peaks 1 -5 (Figure 4-35 a and b) as label
(a) In the absence of normal serum










The Effect of Serum on the Binding Obtained at Bp Using Material Recovered





(mean %B + SD;
n = 4)
B0 (no serum)




Peak 1 11.7 +1.3 17.0+1.5
Peak 2 17.7 +0.6 24.9 +1.2 ^
Peak 3 23.4 +0.9 24.8 +1.7 (NS)
Peak 4 10.9+1.5 14.0 +1.0 (*)
Peak 5 24.8 +1.8 25.1 +3.2 (NS)
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A Further Investigation of the Influence of the Reagent Terminating the Iodination
Step
Human calcitonin (l.Opg) was iodinated using the Direct, chLoramine-T
procedure. As in the previous experiment, at the end of the reaction with
chloramine-T the reaction mixture was divided into two. The reaction was
terminated with either:
25 yl sodium metabisulphite (8 g/1 in phosphate buffer)
or
25 pi cysteamine hydrochloride (8 g/1 in phosphate buffer)
Samples of each reaction mixture obtained were treated in the following manner:
i. 10 yl samples of each reaction mixture were taken and
normal serum (10 pi) and bromophenol blue (5 pi) added to
each. The solutions obtained were separated by starch
gel electrophoresis (see Section 3.2.1, p. 77)
ii. The portions of each reaction mixture remaining
(about 40 pi) were made up to a volume of 0. 5 ml with
elution buffer containing 5 g/1 BSA and separated by
sequential gel-filtration on Sephadex G10 and Sephadex
G50/G10, as in the purification procedure used routinely
following iodination
Radiochromatograms of the starch gel electrophoretic profiles obtained for the
separation of calcitonin iodination products from reactions terminated with
sodium metabisulphite and cysteamine hydrochloride are shown in Figure 4-38
(a and b). The corresponding gel-filtration profiles obtained on Sephadex
G50 (after desalting on Sephadex G10) are shown in Figure 4-39 (a and b).
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Figure 4 -38 (a and b)
Radiochromatograms Obtained on Starch Gel Electrophoresis of Human Calcitonin




Starch gel dimensions: 18.0x5.0 cm. Electrophoresis was at pH 3.0 and the
power supplied was 250V (2 mA/cm) for three hours
Distance from origin (cm)
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Figure 4-39 (a and b)
Sephadex G50/G10 GeL-Filtration Profiles Obtained for the Separation of Human




(Low molecular weight material was removed by fractionation on Sephadex G10






















Selection of a Reagent for the Termination of the Iodination Step in the Direct,
1 9S
Chloramine-T Iodination Method for the Preparation of ^°I-Human Calcitonin
After consideration of the results of investigations described in this Section, it
was decided that cysteamine hydrochloride would be used to terminate the
iodination step in the routine preparation of 12calcitonin for
radioimmunoassay studies since sodium metabisulphite appeared to induce
additional chemical damage to the calcitonin molecule during iodination which
was detrimental to the performance of the labelled preparation in the assay
system.
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4.2.2 Studies with Anti-Calcitonin Sera
i. Antiserum Used for Radioimmunoassay Studies (Antiserum G1701)
Antiserum Characteristics
Various characteristics of antiserum G1701 have been examined and described
by G.W. Sizemore (Heath and Sizemore, 1977), one of its original co-producers:
Sequence-Specific Recognition Sites. The sequence -specific recognition sites
of the antiserum were determined by comparing the abiLity of synthetic human
calcitonin and various synthetic peptide fragments containing portions of the
1 31
human calcitonin amino acid sequence to inhibit the binding of J I -human
calcitonin to antiserum. Inhibition of binding comparable with the complete
sequence (1 -32) was obtained using the H-ll -28-OH fragment, but not with
other fragments (H-17-32-OH; H-17-28-OH). On the basis of these studies
a "central" sequence recognition was assigned to the antiserum since the
major immunochemical determinants appeared to reside in the region 11-28.
Cross -Reactivity. The specificity of the antiserum was assessed by assaying
salmon calcitonin, porcine calcitonin, pentagastrin, secretin, cholecystokinin-
pancreozymin at concentrations up to 100 ng/tube. No significant cross-
reactivity was observed using any of these substances.
Antiserum Dilution Curve
A dilution curve was set up for antiserum G1701 covering the range of initial
dilutions 1/500 - 1/16,000. Antiserum (50hi) at each dilution was incubated
for 72 hours at 4° C with -calcitonin (50 y I) and assay buffer (100 y I).
NSB control tubes containing assay buffer (150 y I) in the absence of antiserum
were also incubated. The final assay volume was 200 y I. At the end of the
incubation period separation of bound and free counts was achieved using the
charcoal separation method (see Section 3.1.4, p.59). The dilution curve
obtained is shown in Figure 4-40.
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ii. Anti -Calcitonin Sera Raised in Laboratory Animals
In an attempt to raise an anti-calcitonin serum suitable for use in the radio¬
immunoassay of human calcitonin a number of rabbits were immunised with
human calcitonin. The two immunisation procedures used are detailed below.
The corresponding immunisation schedules are shown in Figure 4-41 (a and b).
Procedure I
Rabbits. These were coded CI -C6:
Initial Innoculation. Each rabbit received 2.0 ml emulsion
(oil-in-water; 1:2 v/v). The aqueous phase contained
unconjugated human calcitonin (100 yg/ml) and a dispersion
of bovine tubercle bacillus (BCG vaccine) (4 pg/ml). The
adjuvant was Marcol 52 containing 10% Arlacel A as
a stabiliser (v/v).
Boost Innoculations. Each rabbit received 2.0 ml emulsion
prepared as for the initial innoculation but with the aqueous
phase containing only 50 ug/ml human calcitonin. No BCG
vaccine was administered.
Procedure II
Rabbits. These were coded C7-C9;
Initial Innoculation. Each rabbit received 2.0 ml emulsion
(oil-in-water; 1:1 v/v). The aqueous phase contained
unconjugated human calcitonin (500 yg/ml). The oil phase
was Complete Freunds Adjuvant.
Figure 4 -40

















(Each point plotted represents the mean of eight replicates)
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Figure 4 -41 (a)
Immunisation Schedule Used to Raise Anti-Human Calcitonin Sera in Rabbits:
Procedure I
(Rabbits CI - C6)















(Boost I was given one month after the Initial Innoculation. Subsequent Boost
innoculations were also given at one-monthly intervals. Bleeds were carried
out 12-14 days after each Boost)
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Figure 4 -41 (b)
Immunisation Schedule Used to Raise Anti-Human Calcitonin Sera in Rabbits:
Procedure II
(Rabbits C7 - C9)












(Boost I was given one month after the Initial Innoculation. Subsequent Boost
innoculations were also given at one-monthly intervals. Bleeds were carried
out 12-14 days after each Boost)
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Boost Innoculations. Each rabbit received 2.0 ml emulsion.
The aqueous phase contained human calcitonin (100 Vg/ml).
The oil phase consisted of Incomplete Freunds Adjuvant.
After the initial series of innoculations the animals were
left untreated for the period of one year, and then re-immunised.
Re-immunisation. Each rabbit received 2.0 ml emulsion.
The aqueous phase contained 200 yg/ml unconjugated human
calcitonin. The oil phase was Incomplete Freunds Adjuvant.
Boost. After one month the rabbits received a boost
innoculation (as detailed above).
Response to Immunisation
The response of each rabbit to immunisation was monitored by following changes
in the avidity of *^I -calcitonin binding activity at each bleed (antiserum avidity
was assessed by determining the percentage of ^^^1-human calcitonin bound
at initial antiserum dilution 1/3000 in the radioimmunoassay system). Data
obtained in a single experiment at the end of each immunisation procedure
indicating the response of each animal are presented (Figure 4-42 (a), Procedure
I; Figure 4-42 (b), Procedure II).
Assessment of Antisera Raised in the Radioimmunoassay System
Antiserum dilution curves were obtained for a number of the sera which showed
high avidity. Dilution curves for sera obtained at the following bleeds are























Thedatapresentedw robtain dinsinglexperimentathdoftimmunisa ioprocedur .Meap cent ge bindingof^^I-humancalcitonintinit lan iserumdil io1/3000sshow(=4).RabbitsC3,46fa edt respondtoimmunisation












fBleed ☆RabbitC7diedfterseven monthsfoll wingarespiratory disorder
Thedatapresentedw robtainedinsinglexp rim ntatthoftImmunisationp oc dure.Mp rcentage bindingof*2^I-humacalcitonintinit lantiserumdilu1/3000show(=4)
208
Figure 4 -43
Antiserum Dilution Curves for Selected Sera Collected from Rabbits
Immunised with Human Calcitonin
Bleeds studied: Rabbit C5, Bleed 3; Rabbit C7, Bleed 3; Rabbit C9, Bleed 3
Each point plotted represents mean percentage binding of -human calcitonin
(n = 4)




Standard curves for human calcitonin (70/234) diLuted in 100 Vl assay diluent
were established using the following antisera (100 v I):
Antiserum Initial dilution
Goat 1701 1/10,000
Rabbit C5 Bleed 3 1/1500
Rabbit C7 Bleed 3 1/1500
Rabbit C9 Bleed 3 1/1500
Standards and antisera were incubated at 4° C for 72 hours. After this pre-
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incubation 100 yl I-human calcitonin was added and incubation continued
at 4° C for a further 72-hour period. Assay separation was achieved using
second antibody precipitation with systems previously optimised for use with
rabbit and goat first antibodies. The standard curves obtained for each
antiserum are shown in Figure 4-44. The data are normalised for the
purposes of comparison. Corresponding values for Bo are shown in
Table 4-26. At comparable levels of labelled antigen binding the standard
curve produced using goat antiserum 1701 in the assay system was considerably
more sensitive to changes in the concentration of competing unlabelled
calcitonin than were those associated with the three rabbit antisera examined.




Antiserum Initial dilution B0
(mean%B+SD; n = 4)
Goat G1701 1/10,000 23.9
Rabbit C5 Bleed 3 1/1500 , 28.8
Rabbit C7 Bleed 3 1/1500 29.0
Rabbit C9 Bleed 3 1/1500 27.4
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Figure 4 -44
Comparison of the Standard Curves Obtained in the Calcitonin Radioimmunoassay
System Using Various Anti-Calcitonin Sera
T 1 1
20 lOO 200 lOOO 2000
Calcitonin (ng/1)
Antiserum dilutions (initial) used
Goat 1701 1/10,000
Rabbit C 5 1/1500
Rabbit C7 1/1500
Rabbit C 9 1/1500
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4.2.3 Human Calcitonin Standard
Comparison of the Behaviour on Dilution of Calcitonin in the Serum of Four
Patients with Hypercalcitoninaemia and the Human Calcitonin Standard (70/234)
Used in the Radioimmunoassay System
Sera from four patients with elevated serum calcitonin concentrations, three
with chronic renal failure (CRF) and one with medullary carcinoma of the
thyroid (MCT) were serially diluted in serum donated by a patient who had
undergone total thyroidectomy (TTX serum). The TTX serum was presumed
to be hypocalcitoninaemic.
Samples from these series were analysed in the calcitonin radioimmunoassay
system against a standard curve of human calcitonin (70/234) diluted in the
same TTX serum. The dilution curves obtained were compared with the assay
standard curve (Figure 4-45). The dilution curves for the sera from the patients
with CRF were found to be parallel with the standard curve but this relationship
did not hold good for the sera from the MCT patient.
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Figure 4-45
Comparison of Binding Curves Obtained on Dilution of Sera from Four Patients
with Hypercaicitoninaemia with the Calcitonin Assay Standard Curve (HCT 70/234)
Data points for the sera examined are based on duplicate determinations, whilst
the assay standard curve represents mean data obtained from quadruplicate
determinations at each concentration of standard.
The serum from the patient with medullary carcinoma of the thyroid was initially




4.2.4 Application of the Radioimmunoassay Technique to the Measurement
of Calcitonin in Serum and Plasma
Separation of Antibody Bound and Free ^"^1 -Human Calcitonin
Optimisation of the Second Antibody Separation System: An Investigation of
the Influence of Plasma on the Separation Procedure
The results of a second antibody system optimisation procedure are shown in
Figure 4-46. The effect on separation efficiency of the addition of normal
plasma immediately prior to the addition of the second antibody system
components is also indicated.
No significant difference was observed between the separation achieved in
the presence of either assay diluent or plasma.
The dilutions of the second antibody system components selected for routine




Investigation of Various Assay Incubation Schemes
A number of standard curves were set up in assay diluent using human calcitonin
(70/234) and antiserum G1701 (initial dilution 1/7500). After preincubation
o X 25for 24, 48 or 72 hours (4 C or room temperature) I-human calcitonin was
added and incubation continued at the same temperature for further periods
of 24, 48 and 72 hours respectively. Separation was achieved by second
antibody precipitation.
The normalised standard curves obtained for each of these conditions are
compared in Figure 4-47, and values of B0 and NSB are indicated in Table 4-27.
















Figure 4-47 Standard Curves Obtained in the Calcitonin Radioimmunoassay
System for Various Assay Incubation Schemes
Calcitonin (ng/1)
Incubation Conditions Investigated
Pre-incubation Incubation with Temperature
(hours) 12^I-calcitonin
(hours) Room temperature 4° C
24 24 • • o O
48 48 ▼ ▼ -0-——&
72 72 A A
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Consideration of these data (see Section 5. 2, p. 294) led to the adoption of
the same incubation scheme for the calcitonin radioimmunoassay as was used
for the PTH radioimmunoassay, i.e.:
1. Pre-incubation at 4° C (72 hours)
2. Incubation with *"^1 -calcitonin at 4° C (72 hours)
Study of the Effect of the Presence of Various Diluents on the Assay Standard
Curve
A series of calcitonin standard curves (human calcitonin 70/234 with antiserum
G1701, initial dilution 1/5000) were established in the presence of the following
diluents:
i. Assay diluent (containing 5 g/l BSA)
ii. Assay diluent (containing 70 g/l BSA)
iii. TTX serum (presumed to be hypocalcitoninaemic)
iv. Normal serum
Serum samples (100 Pi) from the following groups were included in the same
assay:
Normal individuals from control group (n = 20)
Pregnant women at delivery (n = 20)
Infants at delivery (cord sera withdrawn from the
umbilical vein) (n = 20)
The standard curves obtained and the binding observed for the samples are shown
in Table 4-48. Many of the samples analysed were found to give %B values
above or close to the B0 values observed for the various standard curves
examined. The use of a standard curve established in assay diluent for
sample analysis allows a greater proportion of these to be measured than
would be possible if the curve were established in normal or TTX serum.
Standard curves in normal serum and TTX serum were virtually superimposable.
Figure4-48TheEffectofVariousD lu nttPos tionS ndardC rvilc oninRadioimmu oassay 251 %B6 20 15■ 10 5- H1— 20—!1 1002 Calcitonin(ng/1)—il 1000200073 O oo od c Q) +-> d S °8» O o Samplesd E U o °I o oo or25 "20 15 •10 .5 JJL%B
Diluentsinvestiga ed Assaydiluent
(5g/lBSA) Assaydiluent (70g/lBSA) TTXserum Normalserum
Valuesofbindingbservedfindivi ualsamplesi clu dthamsayrcatyp nirclo<
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Behaviour of Samples in the Assay System
Experimental procedures used to examine the behaviour of samples in the
calcitonin radioimmunoassay system were directly analogous to those
previously described for corresponding investigations involving the PTH
radioimmunoassay system (see Section 4.1.4 pp. 165 -168).
i. Comparison of Results Obtained Using Serum and Plasma Samples. No
significant difference was observed between the calcitonin concentration
obtained on radioimmunoassay using paired serum and plasma samples
collected from 24 healthy adults (on a sign test, serum > plasma in five
cases, plasma < serum in three cases, 16 paired values undetectable).
ii. Effect of Sample Haemolysis. NSB and B0 obtained in the presence of
non-haemolysed, partially haemolysed and severely haemolysed serum are
shown in Table 4-28 . Only the severely haemolysed serum was found to
significantly affect binding in the assay system. Standard curves obtained
in the presence of non-haemolysed and partially haemolysed serum were
superimposable.
iii. Effect of Freeze-Thawing a Sample on the Concentration of Calcitonin
Measured by Radioimmunoassay. Values obtained in the radioimmunoassay
for recovery standards, set up in TTX serum at calcitonin (70/234) concen¬
trations of 50, 100, 200 and 400 ng/l, after 1-4 freeze-thaw cycle treatments
are shown in Figure 4-49. Though repeated freeze-thawing of the standard
solutions did not influence the recovery of calcitonin achieved in a consistent
manner it is evident that freeze-thawing of samples should be avoided so as to
ensure their consistent behaviour in the assay system.
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Table 4 -28
The Effect of Haemolysed Serum on the Binding of ^^^1-Human Calcitonin in
the Calcitonin Radioimmunoassay System
Degree of haemolysis NSB Bo
(mean%B+SD; n = 4) (mean %B + SD; n = 4)
None 0.4 + 0.2 22.8 + 0.9
Partial 0.3 + 0.2 23.4 + 1.2
Severe 0.8 + 0.6 2.0 + 0.3
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Figure 4-49 Effect of Repeatedly Freeze-Thawing a Sample on the Concentration
of Calcitonin Measured by Radioimmunoassay
Each freeze-thaw cycle to which the recovery standards were subjected






















i 1 1 1
12 3 4
Number of freeze-thaw cycles
Values shown were derived from mean levels of binding obtained for duplicate
determinations made for each condition
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Calcitonin Radioimmunoassay System Developed for Sample Analysis
The following calcitonin radioimmunoassay system, developed as a result of
studies in this Section, was used for the sample analysis described in Section
4.4 (see p.254).
Radioimmunoassay Procedure
(The assay was carried out in borosilicate glass tubes (10 x 75 mm). All
dilutions were made in assay diluent unless otherwise stated).
Preincubation
Assay tubes were set up to contain:
100 yl sample (neat serum or plasma)
100 h I standard human calcitonin (70/234) diluted
in assay diluent
100 y I assay diluent (ZA)
50 yl goat anti-calcitonin serum G1701 (initial
dilution 1/7500)
50 y I antiserum diluent (NSB)
72 hours incubation, 4° C
Incubation with -Human Calcitonin
12S
iii. 50 u I I-human calcitonin added (approximately
3000 cpm, diluted in assay diluent with 0.1 g/l
Triton X-100 added). Only Peak II material from
the gel-filtration purification was used







The optimised components of the second antibody system were then added:
iv. 50 yl non-immune sheep serum (NSS)
v. 50 yl donkey anti-goat serum (DAGS)
16-18 hours incubation, 4° C
vi. 2.0 ml assay wash diluent was added and the assay
tubes centrifuged (30 minutes, 1800 g, 4° C). The
supernatants were decanted from the immunopre-
cipitates and the inverted tubes allowed to drain onto
adsorbent paper for 30 minutes. The tubes were
then counted *
Radioimmunoassay Format
The following arrangement of assay components was adopted for each analysis
undertaken. The number of assay tubes in each division is indicated (n):
i. Standard curve comprising:
NSB controls (n = 4)
ZA standards (n = 4)
Standards (eight calcitonin concentrations, n = 2 for each)
ii. Internal quality control samples:
Serum pools W,X, Y, Z (n = 2 for each pool)
iii. Unknown samples (n = 2 for each sample)
iv. Internal quality control samples (as in ii)
v. Duplicate standard curve (as in i)
* See footnote regarding radioactive counting, p. 171
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4.2.5 Characteristics of the Calcitonin Radioimmunoassay Developed
The data presented in this Section were obtained from the 20 consecutive calcitonin
assays run during the Analysis period (see Section 4.4, p.259). Methods used
to treat assay data are indicated in Section 3.2.5, p.84 .
Composite Standard Curve
A composite standard curve (Figure 4-50) was constructed from normalised
assay data obtained during the Analysis period. The mean values for NSB
and Bo were:
Mean %B jSD (n = 20)
NSB 0.9+0.3
B0 22.7 +2.3
Assay Precision and Sensitivity over the Analysis Period
i. Minimum Detection Limit (Sensitivity) and Upper Detection Limit
Minimum detection limit (0. 9 x Bo) = 26+6 ng/l (mean +_ SD; n = 20)
Upper detection limit (0.2 x B0) = 578 +_ 94 ng/l (mean + SD; n = 20)
ii. Intra - and Inter-Assay Precision
On the basis of the two estimates (each performed in duplicate) in each of the
20 assays carried out, mean values were assigned to the quality control
pools W-Z (Table 4-29).
226
Figure 4-50
Composite Calcitonin Standard Curve Based on Data Obtained in the Twenty
Consecutive Assays During the Analysis Period
Calcitonin (ng/1)
The mean positions of the lower and upper detection limits are indicated by
interrupted Lines.
The mean values assigned to the quality control pool (W-Z) are also shown
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Table 4 -29
Intra-Assay CV for Each Control Pool for the Twenty Assays During the Analysis
Period







Intra-Assay Precision. For each pool, intra-assay comparison of the pairs
of values obtained in the 20 assays considered led to an estimate of intra-assay
CV (Table 4-29). These CV values allowed an overall estimate of intra-assay
precision during Analysis period to be made:
RMS CV (intra-assay) = 12.2%
Inter-Assay Precision. For each pool, inter-assay comparison of single
values obtained in the 20 assays considered led to an estimate of inter-assay
CV (Table 4-30). These CV values led to an overall estimate of the inter-
assay precision during the Analysis period:
RMS CV (inter-assay) = 19.8%
Quantitative Recovery Experiment
Solutions of human calcitonin (70/234) were prepared in assay diluent of
concentrations of 50, 100, 200 and 400 ng/l (Expected concentrations). The
concentration of each standard solution was then measured in the calcitonin
assay system (Observed concentration). The percentage recovery of the
calcitonin standard solution was calculated using the expression:
% Recovery = Observed calcitonin concentration x 100
Expected calcitonin concentration




Inter-Assay CV for Each Control Pool for the Twenty Assays During the
Analysis Period
Pool Mean value obtained for single estimate Standard CV (%)
(ng/l) deviation
(SD)
W 60 13 21.6
X 68 12 17.6
Y 172 28 16.2
Z 316 73 23.1
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Table 4 -31
Recovery of Standards in the Calcitonin Radioimmunoassay
Recovery standard concentration Mean concentration % Recovery
(expected (ng/l) obtained for standard of standard
on assay(observed)






4.3 DEVEOPMENT AND USE OF A RADIORECEPTOR ASSAY FOR CALCITONIN
4.3.1 Isolation of Rabbit Renal Membrane Preparations
Rabbit renal membrane preparations (15K and 100K) were prepared from 20.43 g
renal tissue freshly removed from a New Zealand White rabbit aged one year
using the isolation procedures described earlier (see Section 3.3, p.85).
Estimation of Protein Content of Preparations. The protein content of each of
the two resuspended membrane preparations as determined by the modified
Lowry method (see Section 3.3, p.87) was as follows:





The 12^1-calcitonin binding properties of the two preparations obtained in this
pilot experiment were examined.
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4.3.2 Binding of I-Calcitonin by Rabbit Renal Membrane Preparations
125
Initial Study of Binding of I-Calcitonin by Membrane Preparations. The
15K and 100K preparations isolated (see Section 4.3.1, p.231) were resuspended
in RRA diluent at protein concentrations of 1.0 mg/ml and 0.25 mg/ml
respectively. Incubations consisting of:
100 yl membrane preparation of RRA diluent (control)
125
100 yl I-calcitonin (10,000 cpm)
100 yl salmon calcitonin (72/158),0.4 yg, or RRA diluent
200 yl assay diluent
were carried out in borosilicate glass tubes (12 x 75 mm) for 12 hours at 4° C.
ioc
All dilutions were made in RRA diluent. The I -calcitonin preparations
125 125used were I-human calcitonin and I-salmon calcitonin prepared by
Direct, chloramine-T iodination to estimated specific activities of approximately
500 yCi/yg. At the end of the incubation period 3 ml ice-cold RRA wash diluent
was added and the assay tubes centrifuged (20 minutes, 1800 g, 4° C). The
tubes were inverted to tip off the supernatants from the precipitated membrane
material and then allowed to drain onto absorbent paper. The drained tubes
were counted. Binding:
i. To glassware in the absence of membrane preparation (NSB)
ii. To membrane preparation at zero antigen concentration (ZA)
and
iii. To membrane preparation in the presence of 0.4 yg salmon
calcitonin
was measured. Values determined for specific binding to membrane preparation
(%Bg) are indicated (Table 4-32). Specific binding was considered to be that
portion of the binding observed at zero antigen concentration not displaced by
excess competing antigen. It was evaluated by subtracting the level of binding
in the presence of 0.4 yg salmon calcitonin (iii) from that in the absence of
antigen (ii). Specific binding of 125I-salmon calcitonin, but not 125I-human
calcitonin, was observed for both the 100K and the 15K membrane preparations,
























tion aLone (ZA) 2.5 0.8 32.1 30.1
iii. Prepara¬
tion SCT









tion alone (ZA) 3.5 1.9 10.4 8.7
iii. Prepara¬
tion SCT





The Effect of Altering Certain Incubation Conditions on the Specific Binding of
^^1-Salmon Calcitonin to the 15K Membrane Preparation in the Radioassay
Using the basic radioreceptor assay procedure described for the previous
experiment the effect of manipulating a number of the assay conditions was
investigated:
i. Concentration of Membrane Protein. The effect of altering
the concentration of membrane protein in the radioassay system on
lit
the binding of 1-salmon calcitonin at zero antigen concentration
is shown in Figure 4-51. A linear relationship between these factors
was seen over a limited range of membrane protein concentrations only.
ii. pH of Assay Diluent. RRA diluent was adjusted using HCl
and NaOH solutions to give solutions over the pH range 4-11.
These solutions were used to adjust the pH of the assay system.
125A pH profile for binding of 1-salmon calcitonin to the membrane
preparation is shown in Figure 4-52. Binding was optimal at pH 6-8.
iii. Divalent Cation Content of Assay Diluent. The effect of
altering the divalent cation content of the assay system, by the
addition of calcium chloride or the chelating agent EDTA for
the assay diluent was investigated (Table 4-33). Specific binding
of -salmon calcitonin decreased as the concentration of Ca^+
in the incubation medium was increased.
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Effect of Time and Temperature on the Binding of 1-Calcitonin to the Rabbit
15K Membrane Preparation
Groups of assay incubates (0.5 ml) were set up comprising 100Pi membrane
125
preparation (15K, l.Omg/ml), 100 yl I-salmon calcitonin (10,000 cpm)
and 300 pi RRA diluent. Incubation was carried out at either 4° C or room
temperature. 30 minutes and 1,2,5 and 18 hours after the start of the
incubation, groups of assay incubates were withdrawn and the incubation
terminated by the addition of 3.0 ml ice cold RRA wash diluent. This
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Figure 4-51
Effect of Amount of Membrane Protein on Specific Binding of ^-^^1-Salmon
Calcitonin
The mean value (n = 4) obtained for the percentage of -salmon calcitonin





Effect of pH on the Specific Binding of I-Labelled Salmon Calcitonin to
Rabbit 15K Membrane Preparation
The RRA diluent used in.the incubation was adjusted between pH 4 and pH 11
using HC1 and NaOH solutions.
Mean values (n = 4) for the specific binding of 125I-salmon calcitonin to the
membrane preparation are shown
237
Table 4 -33
Effect of Adjusting the Assay Diluent Divalent Cation Content of the Specific
Binding of -Salmon Calcitonin to 15K Membrane Preparation
Composition of assay diluent Specific binding
mean %B +_ SD (n = 8)
RRA diluent
RRA diluent + 10 mM Ca2+
RRA diluent +100 mM Ca2 ^







allowed the time course of binding of I-salmon calcitonin to the 15K membrane
preparation at the two temperatures to be compared (Figure 4-53).
Experimental Conditions Adopted for Radioassay Studies. In further studies
to be described all radioassay incubations were carried out at 4° C for 12
hours. The RRA assay diluent was buffered at pH 7.5 and no adjustments
were made to its ionic composition. The amount of membrane protein used
varied for different experiments and is stated, in terms of membrane protein
concentration, for each experiment.
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Further Study of the Binding of I-Salmon Calcitonin to Membrane Preparations:
Binding Inhibition Curves
Radioassay incubations were set up comprising:
100 y I -salmon calcitonin (10,000 cpm)
100 Pi membrane preparation (15K, 1.0 mg/ml or 100K, 0.5 mg/ml)
100 yl salmon calcitonin (72/158), 0.01 -100 ng in RRA diluent
or RRA diluent alone
200 yl RRA diluent
Control tubes, monitoring NSB to glassware, for which membrane preparation
was replaced by 100 yl assay diluent, were also set up. Bound counts obtained
were corrected for NSB to glassware and NSB to membrane protein (by subtraction
of counts bound in the presence of excess competitor, salmon calcitonin,
100 ng/tube) as previously described. Curves displaying the inhibition of
125
specific binding of I-salmon calcitonin to the membrane preparations are
shown in Figure 4-54. Specific counts bound are expressed as B %
where B = specific %B at the calcitonin concentration considered; and





Effect of Time and Temperature on the Binding of I-Salmon Calcitonin to
15K Membrane Preparation
Data points shown represent the binding of *2% -salmon calcitonin to the membrane
preparation in the absence of competing unlabelled salmon calcitonin, and are
mean values for four incubates withdrawn at the times indicated
Incubation time (hours)
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F igure 4 -54
125
Inhibition Curves for the Specific Binding of I-Salmon Calcitonin to Rabbit
Renal Membrane Preparations (15K and 100K)
Specific counts bound are expressed as B_%, where:
B0
B = specific %B at the calcitonin concentration considered
B0 = specific %B with no calcitonin competitor present




Binding of I-Salmon Calcitonin to the 15K Membrane Preparation: Study
of the Specificity of Binding Inhibition and of the Comparative Potencies of
Salmon Calcitonin, Human Calcitonin as Binding Inhibitors
In the radioassay 100 yl 15K membrane preparation (1.0 mg/ml) was incubated
with 100 yl 12^I-salmon calcitonin (10,000 cpm) and either 100 yl RRA diluent
or RRA diluent containing competitor. The competitors studied were:
Salmon calcitonin (Armour), 0.25-1000 ng/100 hi
Human calcitonin (Organon), 100-1000 ng/lOOyl and 20 yg/100 yl
Gastrin (68/439), 100 ng/100 yl
Insulin (66/304), 100 ng/100 yl
Control tubes were also set up without standard (ZA) and without membrane
preparation (NSB). All incubation volumes were made up to 0.5 ml with RRA
diluent.
Specificity of Binding Inhibition. Values observed for the total binding of
IOC
iZ,JI-salmon calcitonin to the membrane preparation in the presence of the
potential binding competitors are shown in Table 4-34. Gastrin and insulin
did not compete with *2^I-salmon calcitonin for binding sites on the membrane
preparation studied. Furthermore, unlabelled human calcitonin competed
less effectively than unlabelled salmon calcitonin for these sites.
Comparison of the Potency of Salmon Calcitonin and Human Calcitonin as
Binding Inhibitors. Inhibition curves for the binding of -salmon calcitonin
to the membrane preparation in the presence of salmon calcitonin and human
calcitonin competitor are compared in Figure 4-55. The data obtained
confirmed that human calcitonin is a far less potent binding inhibitor than




Total Binding of I-Salmon Calcitonin to Rabbit 15K Membrane Preparation
in the Presence of Various Potential Competitors
Competitor (ng/tube) Total binding B_ ^
mean %B (n = 4) Bq 0
(corrected for NSB to glassware)
No competitor 29.3 (B0) 100
Salmon calcitonin (100) 8.4 28.6
Human calcitonin (100) 25.1 85.6
Gastrin (100) 29.2 99.6




Inhibition Curves Obtained for the Binding of I-Salmon Calcitonin to Rabbit





Examination of the Tissue Specificity of Membrane Calcitonin Binding Activity
Isolation of Membrane Preparations. Portions of tissue (of about 5.0 g wet









These were sliced, accurately weighed and homogenised and each tissue
homogenate was then taken through the differential centrifugation fractionation
procedure described previously (see Section 3,3, p.85). The 15K and 100K
membrane fractions isolated from each tissue were resuspended in 10 ml RRA
diluent and stored in 1.0 ml aLiquots at -20° C. The protein content of
a sample of each membrane preparation was determined by the modified Lowry
procedure (see Section 3.3, p.87).
IOC
^1 -Salmon Calcitonin Binding Properties of the Membrane Preparations
Isolated. Radioreceptor assay incubations were set up as previously described
(see p. 232) to measure the specific binding of ■'■^^I-salmon calcitonin to each
membrane preparation (adjusted to a protein concentration of 2.0 mg/ml).
125
The I-salmon calcitonin binding properties of each membrane preparation
isolated are shown in Table 4-35. Only those membrane preparations derived




I-Salmon Calcitonin Binding Properties of Membrane Preparations Isolated
from Various Tissues of the Rabbit
Tissue source Membrane %B0 %B in presence of %Bg
of membrane preparation excess competitor



































































4.3.3 The Attempted Isolation of Membrane Preparations with Calcitonin
Binding Activity from Human Renal Tissue at Various Stages of
Development
Collection of Renal Tissue
Human kidney tissue was collected from the following sources:
i. Early fetuses (20-26 weeks' gestation; n = 2); prostaglandin
induced therapeutic terminations of pregnancy
ii. Fetuses (26-32 weeks'gestation; n = 3); spontaneous terminations
iii. Neonates at term (37-42 weeks' gestation; n = 3); kidney
removed at post-mortem
iv. A three-month infant; kidney removed at post-mortem
v. An eight-month infant; kidney removed at post-mortem
vi. Adult patients requiring nephrectomy (n = 2); kidney removed
at surgery
As soon as the tissue was made available it was frozen, in all cases within
12 hours of termination, post-mortem or surgery. Tissue was stored at
-20° C for up to three months prior to use.
Isolation of Membrane Preparations from Renal Tissue
The renal tissue was thawed and 5.0 g portions from each source (i-vi) were
homogenised and taken through the differential centrifugation fractionation
procedure (see Section 3.3, p.85). The 15K membrane preparations obtained
were retained on ice, and then resuspended in 10 ml ice-cold 0.025 mol/l
Tris-HCl buffer, pH 7.5. This suspension was divided into aliquots of
1.0 ml, which were stored at -20° C. The protein content of a sample of
each membrane fraction was determined by the modified Lowry procedure
(see Section 3. 3, p. 87).
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Calcitonin Binding Properties of the Human Renal Membrane Preparations
Isolated
125
Radioassay incubations were set up to measure the specific binding of I-
125
salmon calcitonin and I-human calcitonin to the 15K renal membrane
preparation isolated at each developmental stage (membrane protein concen¬
tration 2.0 mg/ml). Data collected regarding the ability of the human renal
125 125membrane preparations to specifically bind I-human calcitonin and I-
salmon calcitonin are shown in Table 4-36. Binding is compared with that
observed for a rabbit renal membrane preparation (15K) suspended at the
same membrane protein concentration. Neither the rabbit renal preparation
nor any of the human tissue preparations specifically bound -human
125calcitonin and only the rabbit renal preparation was found to exhibit I-salmon
calcitonin binding activity. 1

































































4.3.4 Use of Membrane Receptor Preparations to Study Various Aspects of
the Calcitonin Iodination Procedure
Influence of the Nature of the Radioiodination Procedure Used on the Specific
125
Binding of I-Calcitonin to the Membrane Preparation
125









Direct iodination with chioramine-T
(cysteamine-HCl terminated)
Direct iodination with chloramine-T
(sodium metabisulphite terminated)
Enzymatic iodination with lacto-
peroxidase
Direct iodination with chloramine-T
(cysteamine-HCl terminated)









15K rabbit membrane preparations (1.0 mg/ml) isolated from rabbit and adult
125human renal tissue were incubated in a radioassay with each of the I-calcitonin
125
preparations. Tables 4-37 (a and b) show the specific binding of each I-
I O C
calcitonin to the membrane preparations isolated from each tissue. I -salmon
calcitonin with membrane preparation derived from rabbit kidney was found
to be the only combination of labelled preparation and receptor which gave
significant calcitonin-membrane binding. The nature of the radioiodination
procedure did not appear to influence this interaction.
125













Salmoniv.Direct (cysteamine-HCl)26.7.46.220.5 v.Enzymatic (lactoperoxidase)24.624.06 518.1
125
Table4-37( )BindingObtainedforNumb rfI-Calc toniPrep ratio swi h15KMe branePr parat onIsol t d fromAdultHumanRen lTissue (Allcountswerecorrect dfNSBtglassware) CalcitoninlabelledIodinatioprocedureBi d gobs rved (mean%B;n=4) NocompetitorHCT(100ng/tube)Specificbi d ng (1)23-3) Humani.Direct (cysteamine-HCl)0.91 12-0.3 ii.Direct (metabisulphite)0.678-0.2 iii.Enzymatic (lactoperoxidase)1.021-0.1 Salmoniv.Direct (cysteamine-HCl)5.24 63 71-5 v.Enzymatic (lactoperoxidase)4.4..23.1
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Comparison of the Binding to Rabbit 15K Membrane Preparation of Labelled
Fractions Obtained on Sephadex G50/G10 Gel-Filtration of -Salmon Calcitonin
A preparation of ^^^1-salmon calcitonin (prepared by the iodination method) was
fractionated on Sephadex G50/G10. The specific binding of labelled material
from Peaks I and II in the radioassay system was compared, using a 15K
membrane preparation (1.0 mg/ml) isolated from rabbit kidney (Table 4-38).
Specific binding of labelled calcitonin to the membrane preparation was
markedly reduced when Peak I material was used in the radioassay system.
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Table 4-38
Comparison of the Binding in the Radioassay of Material from Peaks I and II
Obtained by Gel-Filtration of -Salmon Calcitonin
Fractionation of the ^^1-salmon calcitonin was carried out on Sephadex G50/G10
using the routine fractionation procedure (see Section 3.2.1, p.76)
Labelled material Binding (mean %B; n = 4)











4.4 APPLICATION OF RADIOIMMUNOASSAY PROCEDURES TO THE STUDY OF
MINERAL HOMEOSTASIS IN PREGNANCY AND THE NEONATE
4.4.1 Organisation of the Study
Design and Operation of Vitamin-D Clinical Trial
PTH and calcitonin analyses were performed on specimens collected in a Clinical
Trial in which supplementary vitamin-D was given to expectant mothers during
pregnancy. From September 1977 to September 1978 pregnant women (at
about the 12th week of pregnancy) attending their first ante-natal clinic at the
Simpson Memorial Maternity Pavilion, Edinburgh, were admitted to the Clinical
Trial and allocated, in an alternating manner, to one of two treatment groups
(I or II). Following this allocation, the clinical care of all the women and their
newborn infants was that normally practised except that women in Group I
received vitamin-D supplementation throughout the remainder of their pregnancy,
whilst Group II women acted as a control group and were given no additional
vitamin-D supplementation. The supplementation was given in the form of
capsules which the women admitted to the Trial were asked to take daily for the
remainder of their pregnancies. The capsules contained either 1000 International
Units (IU) vitamin-D2 (Group I) or were a placebo, containing no vitamin-D2
(Group II). The total number of women admitted to the Trial was 1659. This
initial entry was reduced by a number of factors as the Trial progressed; these
factors included the failure of mothers to attend ante-natal clinics, miscarriages
during pregnancy and movement of women from the Trial catchment area.
Clinical and sociological details were recorded for each expectant mother admitted
to the Trial. The infants were carefully observed during the neonatal period for
the presence of hypocalcaemic convulsions or other symptomatic indications of
disturbed mineral homeostasis.
Collection of Blood Specimens. Specimens of blood were taken from individuals
admitted to the Trial and their newborn infants according to the following schedule:
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Spl 1st maternal During 12th week of pregnancy
During 24th week of pregnancy
During 34th week of pregnancy
at delivery
Sp5 1st infant at delivery
at 6th daySp6 2nd infant
(Procedures used for blood sampling were described in Section 3.4, p.89).
Whilst every effort was made to avoid specimen haemolysis it was noted that
infant specimens (Sp5 and Sp6) were more frequently haemolysed than maternal
ones, reflecting the greater degree of difficulty experienced in the collection
of blood specimens from the infants. Furthermore, the volume of specimen
Sp6 obtained was often small, imposing a limit on the range of analyses that
could be undertaken.
Specimen Analysis
Specimens were analysed for PTH and calcitonin using the radioimmunoassay
methods described in detail earlier (see Section 4.1.4, p.168 for PTH, and
Section 4. 2.4, p.223 for calcitonin). In addition, determinations of total
calcium, magnesium, phosphorus and total protein were carried out on a pro¬
portion of the selected specimens, whilst a small number were also analysed
for 25-hydroxyvitamin-D. The methods used for these additional analyses
were described in Section 3.4, p.89. The total number of specimens collected
in the Clinical Trial was about 10,000 and exceeded the analytical capacity
of the radioimmunoassays developed. The analytical capacity of the assays
was defined by the following factors:
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i. The Duration of the Analysis Period. The quality of the
labelled preparation of antigen used has been shown to be a
critical factor affecting assay performance and preparations
125 125
of 1-BPTH and I-human calcitonin have also been shown
to deteriorate with time (Figure 4-11, p.120; Figure 4-32,
p. 183). As it was essential to ensure that the quality of the
labelled preparations used remained high throughout the
analysis it was decided that use would only be made of
material produced at single iodination procedures. The
effective useful lifetime of these preparations limited the
duration of the analysis period.
ii. The Total Number of Assays Performed and Their Size.
To ensure that no decrease in assay precision occurred over
the Analysis period it was necessary to restrict both the total
number of assays performed and their overall size (the number
of samples included in each assay was therefore limited to
a maximum of 90 and 20 assays were performed for each hormone).
This limited analytical capacity necessitated the selection for analysis of only
a proportion of the specimens collected during the Clinical Trial.
Selection of Specimens for Analysis
Two criteria were used to select samples from the large number of specimens
collected in the Clinical Trial:
1. Specimens were only selected from pregnancies for which
the complete set of specimens (Spl - Sp6) was available
(or nearly so)
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2. Sets of specimens from a pregnancy were only selected
if there was sufficient volume of plasma in specimen Sp6
to allow the full range of analyses to be undertaken
(600 yl, minimum)
This method of selection ensured that the sampling procedure resulted in the
optimum use of the potential information available and, as far as could
be ascertained, no statistical bias resulted from its use. At the time when
this selection was made, only those specimens collected during the first eight
months of the one-year Clinical Trial were available. A total of 227 pregnancies
were selected from those under consideration in the Trial (130 from Group I;
97 from Group 11). In addition specimens were analysed from the following groups:
i. Twenty-two non-pregnant women of child-bearing age who
were attending the Royal Infirmary of Edinburgh for
gynaecological treatment (a Control group)
ii. Four infants with symptomatic neonatal hypocalcaemia
(specimens were also collected post-natally from their
mothers, who were not included in the Clinical Trial)
Survey to Establish the Regularity with which Expectant Mothers on the Clinical
Trial took Their Capsules
Of the 227 expectant mothers studied, 170 (74.8%) were questioned towards the
end of their pregnancies about the regularity with which they took their treatment
capsules. The outcome is shown in Table 4-39. Qnly 18 (10.6%) of the mothers
had not taken an active part in the Trial in this respect.
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Table 4 -39
Outcome of a Survey in Which Expectant Mothers were Questioned Regarding
the Regularity withWhich They had Taken Their Capsules During the Clinical
Trial
(Total questioned = 170)
Regularity with which Number of mothers % of Total
capsules were taken
Taken regularly 130 76.5
} 152 } 89.4
Taken irregularly 22 12.9
Not taken 18 10.6
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Organisation of PTH and Calcitonin Analysis
The Analysis Period. Pairs of radioimmunoassays for PTH and calcitonin were
established concurrently over two consecutive weeks. A total of 20 assays were
performed for each hormone.
Organisation of the Samples for Analysis. Samples were organised into 20 batches„
so that each batch contained all the samples available from any one pregnancy
(Spl - Sp6). Batches typically contained about 12 sets of samples. These sets of
samples were assigned to batches in such a way that:
i. Approximately equal numbers of vitamin-D supplemented
pregnancies occurred in each batch
ii. Each batch contained specimens relating to pregnancies
which were characterised by similar dates for maternal
entry into the Study.
The sequence of batch analysis was a random one so that any seasonal influence on
plasma PTH and calcitonin concentration could be examined without the possibility
that any change in assay characteristics during the Analysis period would produce
an effect which could have been mistaken for a seasonal influence. Such a possi¬
bility would not have been precluded had the specimens been analysed simply
in chronological order.
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4.4.2 The Quality of Performance of the Analytical Methods Used in the Study
PTH and Calcitonin Radioimmunoassays
Assay characteristics during the Analysis period have previously been stated
for PTH (see Section 4.1.5, p.172) and for calcitonin (see Section 4.2.5, p.225).
The quality control procedures described for each of these two assays (see
Section 3.1. 5, p.68 and Section 3.2. 5, p.84 ) were carried out during these
analyses. However, the variance of the control pool values observed was such
that none of the assays performed required to be rejected. Furthermore,
examination of the control pool values, plotted in the form of Quality Control
Charts (Levey and Jennings, 1950; Whitehead, 1977) suggested that no noticeable
drift occurred for either assay over the Analysis period.
Chemical Determinations
The following estimates of inter-assay precision, based on values observed for







Competitive Protein-Binding Assay for 25-Hydroxyvitamin-D
The following assay characteristics have been reported (Fairney et al, 1979):
Intra-assay CV = 7-9%
Inter-assay CV = 7-9%
Lower limit of assay sensitivity = 1.5 ng/ml
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4.4.3 Results of the Study of Mineral Homeostasis in Pregnancy and the Neonate
I. Chemical Analyses
Results obtained for the analysis of specimens Spl -Sp6 for calcium, magnesium,
phosphorus and total protein are given in Table 4-40 (a and b). Significant
differences (Mann-Whitney test) between the two treatment groups are indicated.
The mean data for each of the treatment groups (vitamin-D supplemented and
non-supplemented) are also shown in Figure 4-56. An indication of the reference
range relating to non-pregnant women for each of these analyses was obtained
from the analysis of specimens collected from the control group (see Section
4.4.1, p.257).
Reference range
(mean -k 2SD) n = 22
Calcium (mmol/l) 2.04 -2.84
Magnesium (mmol/l) 0.55 -1.03
Phosphorus (mmol/l) 0.67 -1.27
Total protein (g/l) 60.2 - 85.8
II. PTH and Calcitonin Analysis
Statistical Considerations
A proportion of the specimens studied were found to have PTH and calcitonin
concentrations which fell below the cut-off points imposed by the assays' lower
detection limits. Consequently the only statistical information available for
these particular specimens was that their PTH and calcitonin concentrations
were below the antigen concentration corresponding to the detection limit of
the particular assays in which they were included. This lack of information
effectively meant that the population of specimens could not be treated as if it
were normally distributed with respect to the concentration of these two hormones.
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Table 4 -40 (a) Results of Analyses for Calcium and Magnesium for Specimens
Selected from the Clinical Trial
Specimen
number















Mean SE n Mean SE n Mean SE n
Calcium (mmol/l)
Spl 2.46 (0.02) 205 2.50 (0.03) 115 2.41 (0.04) 90 NS
Sp2 2.42 (0.02) 176 2.46 (0.03) 103 2.37 (0.02) 73 *
Sp3 2.39 (0.02) 204 2.42 (0.03) 113 2.35 (0.03) 91 NS
Sp4 2.35 (0.02) 181 2.33 (0.03) 102 2.36 (0.03) 79 NS
Sp5 2.79 (0.02) 200 2.79 (0.03) 113 2.80 (0.03) 87 NS
Sp6 2.34 (0.03) 209 2.37 (0.04) 116 2.31 (0.04) 93 NS
Magnesium (mmol/l)
Spl 0.77 (0.01) 205 0.78 (0.01) 115 0.76 (0.01) 90 NS
Sp2 0.73 (0.01) 176 0.73 (0.01) 103 0.73 (0.01) 73 NS
Sp3 0.72 (0.01) 204 0.72 (0.01) 113 0.73 (0.01) 91 NS
Sp4 0.69 (0.01) 181 0.68 (0.01) 102 0.71 (0.01) 99
*
Sp5 0.76 (0.01) 201 0.74 (0.01) 114 0.79 (0.01) 87
*
Sp6 0.71 (0.01) 209 0.70 (C.02) 116 0.72 (0.02) 93 NS
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Table 4-40 (b) Results of Analyses for Phosphorus and Total Protein for
Specimens Selected from the Clinical Trial
Specimen
number



















Spl 0.95 (0.02) 69 0.91 (0.03) 35 0.99 (0.03) 34 NS
Sp2 0.87 (0.03) 47 0.87 (0.03) 27 0.87 (0.04) 20 NS
Sp3 0.92 (0.02) 45 0.90 (0.03) 23 0.94 (0.04) 22 NS
Sp4 0.91 (0.03) 34 0.89 (0.04) 20 0.94 (0.05) 14 NS
Sp5 1.64 (0.04) 31 1.61 (0.07) 16 1.67 (0.06) 15 NS
Sp6 2.18 (0.13) 25 2.24 (0.19) 15 2.10 (0.17) 10 NS
Total protein (g/l)
Spl 65.0 (1.0) 66 65.9 (1.2) 36 63.8 (1.6) 30 NS
Sp2 61.1 (1.2) 42 61.3 (1.5) 25 60.7 (1.9) 17 NS
Sp3 57.6 (1.2) 40 57.3 (1.6) 22 57.9 (1.9) 18 NS
Sp4 57.7 (2.1) 32 55.5 (2.7) 19 60.9 (3.2) 13 NS
Sp5 53.2 (1.6) 26 52.3 (2.0) 14 54.3 (2.7) 12 NS
Sp6 59.6 (1.3) 24 60.1 (1.5) 15 57.5 (2.3) 9 NS
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Figure 4 -56 Mean Plasma Concentrations of Calcium, Magnesium, Phosphorus
and Total Protein Observed for Maternal and Infant Specimens








































Treatment group I (Vitamin-D supplemented)
Treatment group II (Unsupplemented)
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Parametric statistical methods were thus not applicable to data obtained for these
two analyses, it was possible to rank the specimens contained in each assay
with respect to their respective hormone concentrations, however, thereby
allowing non-parametric techniques of statistical analysis to be applied to the
ordered assay data. The ranking of data within each individual assay also
ensured that hypothesis testing was performed in a way which was independent
of influences resulting from differences between individual assays performed
during the Analysis period. Subsequent overall consideration of the non-parametric
test statistics derived for each individual assay allowed general conclusions to
be drawn from the total data collected with minimal interference from any influences
attributable to inter-assay variation.
Comparison of Plasma PTH and Calcitonin Concentrations Obtained on Analysis
of Specimens Spl -Sp6
One method of data inspection which suggested that there were differences in the
concentrations of PTH and calcitonin between the various groups of specimens
studied was the comparison of the percentage of the specimens which were found
to have detectable hormone concentrations on analysis (Table 4-41). A more
satisfactory method of examining the data for hormone concentration differences,
and one suited to the application of statistical tests of significance, was based
onMcNemar's test (see Section 3.5, p. 91). For both PTH and calcitonin the
hormone concentration measured for pairs of samples associated with a single
pregnancy was inspected and the differences found classified (as increases or
decreases). The frequency of increase (I) and decrease (D) was then compared
using the formula:
X2 = ((I - D) - I)2
I + D
2
the values of X obtained being tested for significance. The outcome of these
analyses is shown in Table 4-42 (a and b). Highly significant increases in the
concentration of plasma PTH were found to occur in expectant mothers from the
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Table 4 -41
The Percentage of the Specimens Analysed for PTH and Calcitonin Which had






% Detectable Sample size
(n)
% Detectable
Spl 233 36 233 43
Sp2 190 48 210 45
Sp3 210 60 209 52
Sp4 190 64 187 51
Sp5 203 26 204 86
Sp6 217 54 216 87
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Table 4-42 (a)
Examination of Differences in the Plasma Concentration of PTH for Pairs of
Specimens Associated with the Same Pregnancy
(Using the McNemar Test)
V2
Specimens Sample Frequency of: A Direction
compared si2e (and significance)
(n) Increase Decrease No of change
Change
Spl -* Sp2 174 84 41 49 14.11 Increase (***)
Sp2-> Sp3 171 78 47 46 7.20 Increase(**)
Sp3-> Sp4 175 104 43 28 24.49 Increase(***)
Sp4 -*■ Sp5 174 13 150 11 113.47 Decrease (***
Sp5 Sp6 194 141 27 26 76.00 Increase (***)
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Table 4-42 (b)
Examination of Differences in the Plasma Concentration of Calcitonin for Pairs of
Specimens Associated with the Same Pregnancy
(Using the McNemar Test)
x2
Specimens Sample Frequency of: Direction
compared size (and significance)
(n) Increase Decrease No of change
Change
Spl -> Sp2 174 50 50 74 0.00 No change (NS)
Sp2-*- Sp3 171 48 49 74 0.00 No change (NS)
Sp3->- Sp4 173 61 48 64 1.32 No change (NS)
Spl **■ Sp4 176 69 43 64 5.58 Increase (*)
Sp4 •> Sp5 174 152 12 10 117.81 Increase (***)
Sp5 -*■ Sp6 195 87 94 14 0.20 No change (NS)
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twelfth week of their pregnancy to delivery. Furthermore, PTH concentrations
observed for umbilical venous specimens (Sp5) tended to be significantly lower
than those which were observed for mothers at delivery (p < 0.001) or for the
infants at the sixth day of life (p < 0.001). A significant increase in maternal
plasma calcitonin concentration was observed only when specimens collected at
the 12th week of pregnancy and at delivery were compared (p < 0.05). However,
at delivery umbilical venous plasma showed significantly greater calcitonin content
than did maternal plasma (p < 0.001), and the infant's plasma calcitonin remained
high at the sixth day compared with maternal plasma calcitonin at delivery.
Effect of Vitamin-D Supplementation During Pregnancy on the Changes in Hormone
Concentration Observed. A reconsideration of these same data with reference to
the treatment group origin of the specimens, using the Mann-Whitney test, showed
that the only significant distinction which could be made between the two groups
was that in the vitamin-D supplemented mothers:
i. the increase in PTH concentration observed between the
12th week and the 34th week of pregnancy was less pro¬
nounced than for mothers in the control group (p < 0.05) .
and
ii. the slight increase in maternal calcitonin concentration
between week 12 of pregnancy and delivery was less
marked than it was for the non-supplemented mothers (p < 0.05)
Investigation of the Possible Influence of a Number of Factors on the Concentration
of Plasma PTH and Calcitonin
The effect of a number of ante - and post-natal factors on the plasma concentration
of PTH and calcitonin was examined by Mann-Whitney analysis.
i. Pregnancy. PTH and calcitonin concentrations obtained for specimens
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taken from pregnant women (Spl - Sp4) were compared with values obtained for
specimens collected from non-pregnant women in the control group, which had
been analysed in the same assays. For specimens obtained at the 12th and 24th
i
weeks of pregnancy PTH values were significantly lower (p < 0.01) than were
control values for non-pregnant women (Table 4-43), Calcitonin values in the
pregnant and non-pregnant condition were not significantly different.
ii. Vitamin-D Supplementation During Pregnancy. PTH and calcitonin concen¬
trations in vitamin-D supplemented mothers and their infants were compared
with values obtained for non-supplemented mothers and their newborns. Plasma
PTH concentrations in mothers at delivery (Spl) and infants at day 6 (Sp6) were
significantly lower in the supplemented group than in the non-supplemented
group (p < 0.001). No other significant differences between the two groups
of specimens were observed. It has been established that there is a seasonal
variation in the circulating concentration of vitamin-D and its metabolites
(Stamp and Round, 1974) and an earlier study conducted in the Simpson Memorial
Maternity Pavilion, Edinburgh, has shown that this variation is also seen in
expectant mothers (Cockburn et al, 1979). Consideration of the analytical data
collected in the present Study did not lead to the identification of any seasonal
effect on plasma PTH or calcitonin concentrations, however.
iii. Infant Feeding Regimen. PTH and calcitonin values for groups of sixth-day
infants (Sp6) fed by different regimen were compared. PTH values were signifi¬
cantly higher for artificially fed infants than for breast fed infants or infants fed
by breast plus artificial complement (p < 0.01 in both cases).
iv. Sex of Infant. No significant differences in plasma PTH or calcitonin were
found between male and female infants, either at delivery or at the sixth day of
life.
v. Prematurity. The only significant difference between the concentrations of
either PTH or calcitonin determined for samples associated with 12 pre-term
infants (of less than 37 weeks gestation) and term infants included in the same
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Table 4-43
Comparison of Plasma PTH and Calcitonin Concentrations Determined in Pregnant
and Non-Pregnant Women (Mann-Whitney Test)
Pregnancy specimens (n) PTH Calcitonin
compared with 22
control specimens
Combined Significance Combined Significance
Z score of difference Z score of difference
Spl (n = 39) -2.76
Sp2 (n = 35) -2.02
Sp3 (n = 40) -0.15






assays was found at delivery; mothers giving birth to pre-term infants were
found to have calcitonin concentrations significantly higher than mothers who
gave birth to full-term infants (p < 0.01).
vi. Multiple Births. Specimens from seven sets of twins were analysed.
No significant difference was found between the PTH and calcitonin concentrations
observed for specimens associated with single and multiple pregnancies.
Correlation Analysis
Correlations between the data obtained for each substance determined, and
for PTH and calcitonin, were sought for specimens Spl -Sp6 using Kendall
Rank correlation analysis (see Section 3.5, p.92). Similar correlations
were investigated for vitamin-D for specimens Sp4, Sp5 and Sp6 only, since
other vitamin-D data were unavailable. Significant correlations identified
are shown in Table 4-44. In addition, significant positive correlations
(p < 0.001) were found for both PTH and calcitonin between values determined
for specimens Sp4 and Sp5, Sp5 and Sp6, and Sp4 and Sp6.
III. Study of Hypocalcaemic Infants
Comparison of Hypocalcaemic and Normocalcaemic Infants
Of the 234 infants born to mothers selected from the Clinical Trial for study,
30 (12.8%) were hypocalcaemic with sixth day plasma calcium concentrations
of less than 1.85 mmol/1. Clinically, 25 of these hypocalcaemic infants
were asymptomatic whilst five displayed the symptoms associated with the
condition of neonatal hypocalcaemia (convulsions and neuromuscular
irritability). The 30 hypocalcaemic infants were compared with the 204
normocalcaemic infants with regard to:
i. their plasma PTH concentrations (specimens Sp5 and Sp6)
and those of their mothers at delivery (Sp4)
and
Table4-44SignificantCorrelatio s(Kend llR nkAnalysis)FoundBetwe nthPl smancentr tionsoftV ri u SubstancesDetermin dforMater al(Spl-Sp4)dInf t5,6Specimens VariablesPTHC lcitoninitamin-Dlc umMagnesiumPhosphorusT talprotein PTHSp5+ve6-ve )̂(**) CalcitoninSp5+vep6- (**) Vitamin-DSp6-vep4+ve (*) Sp5+ve Dataonvitamin-D(25-hydroxyvitamin-D)wereo lyv ilab ef rspecimensS 4,5ndp6
Co
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ii. a number of ante-natal and post-natal influences (Table 4-45)
No significant difference was found between the two groups when the direction of
the change in PTH concentration observed for the pairs of specimens Sp4 and Sp5,
Sp5 and Sp6, and Sp4 and Sp6 were compared using an X ^-test. Although no
significant difference was found between the two groups of infants when they
were compared with regard to the Treatment group distribution of the infants'
mothers, the incidence of pre-term births, or the sex of the infants,
a significantly greater proportion of the hypocalcaemic infants were found to
have been artificially fed in the neonatal period.(p < 0.001).
Comparison of Infants with Symptomatic and Asymptomatic Hypocalcaemia
in the Neonatal Period
A total of nine infants with symptomatic neonatal hypocalcaemia were available
for study; five from the Clinical Trial, together with four others from whom
specimens had been collected even though their mothers had not been admitted
to the Trial (see Section 4.4.1, p.257). All nine infants were classified
clinically as late neonatal hypocalcaemics on the basis of the delayed onset
of their convulsions, which were first noted between five and ten days after
delivery. Analytical data for sixth-day plasma specimens (Sp6) from a group
of infants with symptomatic neonatal hypocalcaemia (n = 7) and a control group
of asymptomatic hypocalcaemic infants (n = 12) were compared using the
Mann-Whitney test. (All the infants selected for the control group were born
to mothers who received no supplementary vitamin-D during pregnancy).
No significant difference in plasma calcium, magnesium, PTH or calcitonin
concentration was found between the two groups of infants. Symptomatic
and asymptomatic hypocalcaemic infants were further compared (Table 4-46)
with regard to the ante-natal and post-natal influences previously considered.
They were not found to differ in the manner in which they had been fed in
the neonatal period, though it was notable that all but six of the 34 hypocalcaemic
infants considered received artificial feeding. A significant difference was
found between the symptomatic and asymptomatic infants when their mothers'
distribution between the two Treatment groups in the Clinical Trial was
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examined; all the disturbed hypocalcaemic infants were born to mothers who
were non-vitamin-D supplemented during pregnancy, whereas the mothers
of the asymptomatic infants were evenly distributed between the two groups.
Clinical Treatment of Infants with Neonatal Hypocalcaemia
Following the onset of their convulsions all nine affected infants were transferred
to the Neonatal Special Care Unit where they were treated with magnesium
sulphate (Turner et a\_, 1977). Calcium gluconate was administered additionally
to three of the infants. Satisfactory responses to treatment were obtained in
eight of the nine infants, who were subsequently discharged before they had
attained the age of 20 days. However, one of the infants (Baby F) did not
respond to treatment with calcium gluconate, magnesium sulphate or
vitamin-D3 and displayed severe, prolonged fitting until day 30. Clinical
examination of this infant's mother suggested that she had primary hyper¬
parathyroidism. This diagnosis was subsequently confirmed by analysis
of her serum PTH and calcium concentrations (PTH was elevated at 2.10 yg/l,






A number of conditions must be fulfilled before the technique of radioimmunoassay
may be applied to the specific measurement of an antigen in the circulation.
A labelled preparation of the antigen, a specific antiserum and a suitable
standard preparation must all be available, and a clear demonstration of the
validity of the technique with respect to the analysis of serum or plasma is
essential. The way in which each of these requirements was satisfied in
the present study and the characterisation and validation of the radioimmunoassays
developed for PTH and calcitonin will be discussed for each hormone.
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5.1 THE PTH RADIOIMMUNOASSAY
The Labelled PTH Preparation
Some indication of the Lack of acceptance of any single method of iodination
equally suited to all proteins may be gained from the fact that a wide range
of methods have been used to prepare labelled antigens for radioimmunoassay
studies (Hunter, 1974). Iodination methods may be divided into two groups:
Direct methods, in which the radioiodine is incorporated directly into the
tyrosine (or histidine) residues of the protein's amino acid sequence
(Hughes, 1957); and Indirect methods, which involve the iodination of
a separate compound, generally an ester, which is subsequently conjugated
to the protein of interest (Bolton and Hunter, 1972; 1973). Indirect methods
of iodination were originally devised to protect the antigen from the detrimental
influence of the chemical reagents and the high levels of radiation associated
with the iodination step itself. Following the example set by Berson et al (1963)
radioiodine labelled BPTH preparations for radioimmunoassay studies have
usually been prepared using a Direct method of iodination based on that of
Greenwood et a I (1963). However, iodination of BPTH has often proved to
be problematical since the molecule tends to lose its immunochemical
integrity (Buckle, 1974) and it was considered worthwhile to examine both
Direct and Indirect methods of iodination to determine whether the use of
an Indirect iodination procedure might lessen iodination damage. Efforts
were made to compare the two alternative iodination procedures both
quantitatively and qualitatively (see Section 4.1.1, p. 94). To allow the
iodination procedures to be followed quantitatively it was first necessary
to devise acceptable methods of assessing both the specific activity of the
labelled product and the product yield achieved (see Section 3.1.1, pp.49-55).
These methods of assessment proved to be valuable when comparisons were
undertaken of successive iodinations performed using a single procedure
(Tables 4-1 to 4-4, pp. 95-98) but attempts to directly compare the two
alternative procedures on the basis of these quantitative parameters were
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largely unsuccessful because the methods of estimation used were themselves
necessarily dependent upon the individual nature of the procedures.
12 S
The qualitative comparison of the I-BPTH preparations produced by each
of the two iodination procedures proved a more acceptable basis on which
to select a procedure for further use. Although the labelled product of the
Direct procedure was characterised by a significantly reduced tendency to
bind non-specifically to glassware (p < 0.05) a number of other qualitative
comparisons (Table 4-5, p. 100) suggested that there was little difference
between the two preparations. They showed similar behaviour on gel-filtration
(Figure 4-1, p.lOD and chromatoelectrophoresis (Table 4 -5, p. 100), indicating
that they did not differ markedly in respect of their physical integrity, and
the standard curves to which they gave rise in the PTH radioimmunoassay
system were virtually superimposable (Figure 4-2, p. 102), suggesting that
they were immunochemically identical when examined with the anti-PTH
serum AS 211/32.
As no experimental evidence was produced to indicate that the use of the
Indirect procedure reduced iodination damage to the PTH molecule the
Direct procedure was adopted for routine use since it was found to be the
more convenient of the two procedures to perform. However, it is clear
from these studies that the Indirect iodination of BPTH represents an
acceptable alternative to the commonly favoured procedure. Indeed, when
HPTH becomes more widely available for utilisation in homogenous immuno¬
assay systems for PTH the use of the Indirect method may well prove to
be advantageous since HPTH, unlike BPTH, does not appear to have a tyrosine
residue at position 43 (Keutmann et al, 1977) and Neuman et al (1975) have
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shown that it is this residue which is heavily favoured as a site of I
substitution in the Direct iodination of the BPTH molecule.
The use of an immunochemically heterogeneous labelled antigen preparation
in a radioimmunoassay system is likely to result in loss of assay specificity
and, to a lesser extent, sensitivity (Hunter, 1967). It is, therefore, essential
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to purify labelled antigen preparations to ensure their homogeneity. Various
separation methods have found use in the post-iodination purification of
labelled BPTH. Unreacted radioiodine has been removed by Sephadex
gel-filtration (Lequin, 1969), adsorption onto cellulose (Berson et aj_, 1963;
Arnaud et al, 1971) and ion-exchange with a suitable resin (Buckle, 1974)f
whilst BPTH damaged during the iodination procedure has also been removed
by column chromatography.
In this study, initial purification of 1^^I-BPTH was carried out using Quso G32
(Yalow and Berson, 1966), removal of unreacted iodine being ensured by the
inclusion of an Amberlite ion-exchange resin during this procedure. The
effectiveness of the purification achieved was investigated by comparing
the gel-filtration profiles obtained for the iodination reaction products at each
stage of the purification procedure (Figure 4-3, p. 106; Figure 4-4, p. 109).
The efficient removal of high molecular weight, aggregated protein material
(Peak I) and of unreacted radioiodine (Peak III) was demonstrated. Inspection
of the purified material by paper chromatoelectrophoresis confirmed that
the purification scheme was effective (Figure 4-5, p. 110); rapidly migrating,
damaged material present in the unpurified material was shown to be absent
from the final labelled product. The initial purification procedures adopted
1 OC
generally gave rise to preparations of JI-BPTH which were acceptable by
the qualitative criteria established (see Section 4.1.1, p. 108).
It has generally been accepted that deterioration of labelled preparations of
BPTH severely limits their useful lifetime in the radioimmunoassay and
preparations have often only been used for periods of one week or less
(Arnaud et a_l, 1971; Woo and Singer, 1974). The consequent need to
re-iodinate BPTH at very frequent intervals is wasteful of the hormone
preparation and likely to give rise to considerable variation in the quality
of assay performance since variability in the characteristics of the labelled
preparations produced tends to be reflected in a lack of consistency in
assay behaviour. Although deterioration of ^2^1-BPTH does occur after
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iodination (Figure 4-11, p. 120) the routine inclusion of an additional purification
step for the labelled material immediately prior to its inclusion in the assay
system effectively extends the useful lifetime of such labelled preparations.
Gel-filtration of 12^I-BPTH on Sephadex G100/G10 using a simple fractionation
system resolves three peaks of activity (Figure 4-7, p.113) and allows material
other than that corresponding to the 1 -84 PTH molecule to be excluded from
the radioimmunoassay incubation. In particular, the elimination of high
molecular weight, aggregated material (Peak I) is important since studies
undertaken here demonstrate that this material displays extensive non-specific
binding to glassware, which varies with serum concentration (Figure 4-9,
p. 117), and reduced affinity for specific antisera relative to the
material from Peak II (Table 4-8, p. 115). Thus, although a demonstration
of non-parallel behaviour on dilution for assay standard and samples may
generally be assumed to indicate a lack of immunochemical identity between
the standard preparation and the material being measured, this assumption
is only likely to be valid for the PTH assay if aggregated material is
excluded from the labelled antigen preparation. Hunter (1974) cited the PTH
assay as an extreme example of a situation in which the week-to-week viability
of a radioimmunoassay is threatened by the loss of affinity of antigen for
antiserum following iodination. However, it is evident that the regular
inspection of the ^2,=T-BPTH gel-filtration profile allows tracer deterioration
to be monitored and permits steps to be taken to ensure that labelled BPTH
used is immunochemically homogeneous. Decline in assay quality as
the labelled antigen preparation ages may thus be avoided.
1 9 C
Direct measurement of the purified ^JI-BPTH preparation in the radioimmuno¬
assay system (Figure 4-12, p. 122) demonstrated the high degree of immuno¬
chemical integrity retained by the labelled antigen and the slight non-parallelism
observed may be attributable to technical difficulties encountered in the
performance of this comparison rather than to the presence of labelled antigen
with reduced immunoreactivity towards the assay antiserum.
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Anti -PTH Sera
Two anti-PTH sera suitable for use in radioimmunoassay systems for the
measurement of circulating HPTH were available, AS 211/32 and PIE 12696.
Available information suggested that they differed with regard to the amino
acid sequences which they recognised in the PTH molecule.
Although AS 211/32 has often been considered to be predominantly directed
against the N-terminal region of the PTH molecule (Woo and Singer, 1974;
Franchimont and Heynen, 1976) data available from cross-reaction studies
with various PTH fragments (Figure 4-13, p. 124) show that the antiserum
interacts with antigenic determinants in both the N-terminal (1 -29) and
C-terminal (53-84) portions of the molecule.
Data obtained from a study of the interaction of PIE 12696 with HPTH
standards (Figure 4-14, p. 125) suggest that this antiserum cross-reacts
extensively with C -terminal PTH fragments. This is in accordance
with the opinion expressed by Arnaud (a co -producer of the antiserum)
that it is predominantly C-terminally directed and exhibits cross-reactivity
similar to that of the antiserum GPIM, which has been designated "anti-C"
by Flueck et al (1977). (Dr. C.D. Arnaud, personal communication).
Views have been expressed that antisera directed towards the N-terminal
region of the PTH molecule are most useful for following acute changes
in the concentration of circulating PTH (Schmidt-Gayk et al, 1976) whilst
the use of C-terminal directed antisera facilitates the study of PTH
concentrations in chronic conditions (Dibella et al, 1978). These ideas
gain support from the empirical observations of a number of investigations
and findings of this type presumably reflect the fact that the biologically
active 1-84 PTH molecule released from the parathyroid glands has a short
half-life in serum and undergoes peripheral cleavage with loss of the
N-terminal region of the molecule (Habener, 1975) which is known to be
responsible for the biological activity of the hormone (Potts et al, 1971b).
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In the present study, although higher values of immunoreactive PTH
concentration were generally observed using the putative C-terminal
antiserum (PIE 12696) no consistent analytical advantage accrued from
the use of either antiserum and results obtained in these studies have
tended to emphasise similarities rather than differences in their
characteristics.
The PTH Assay Standard
Demonstration of the parallel behaviour on dilution of the working assay
standard, BPTH (71/324), and the proposed International Reference
Preparation for HPTH (75/549) in the radioimmunoassay system (Figure 4-18,
p. 133) provides justification for the use of a heterologous assay system to
measure circulating HPTH. In addition, the comparison of the two
preparations allowed an estimate of the potency of the International Reference
Preparation to be made. The value of 25 ng PTH peptide obtained (see
Section 4.1.3, p. 132) is in excellent agreement with values reported by
International Collaborative assay (17-38 ng; J. Zanelli, NIBSC, London;
personal communication).
Further validation of the assay system developed comes from the demonstration
of the parallel binding behaviour on dilution of the working assay standard and
a number of sera from patients with hyperparathyroidism (Figure 4-19,
p.135).
Application of the Radioimmunoassay Technique to Serum and Plasma
The general requirement for a system allowing the separation of free antigen
and antigen bound to antiserum at the end of the radioimmunoassay incubation
(p. 10) was originally satisfied for PTH by chromatoelectrophoresis
(Berson et,al, 1963). This has remained the classical reference method
but it is only suitable for handling a small number of samples and other
separation techniques have superseded it. Although the methods employed
have generally been found to be comparable in their separative efficiency
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(PaLmieri et al, 1971) those most widely adopted involve adsorption onto
dextran-charcoal or immunoprecipitation using a second antibody. The
former has proved to be a reliable technique in the hands of a number of
investigators (for example, Schopman et al, 1970; Arnaudetal, 1971)
but, arguably, it is not robust enough to handle large assays satisfactorily.
The use of second antibody separation has been preferred in this study.
The use of solid-phase second antibody separation (Den Hollander and
Schurrs, 1971) was initially investigated since this promised to confer some
advantage in the simplicity and speed of assay separation. However, the
solid-phase system compared unfavourably with the more conventional
liquid-phase system in a direct comparison of their separation efficiency
(Table 4-11, p. 140). It remains a possibility that the true potential
separation efficiency of the solid-phase system was not realised since only
one DASP preparation was examined and its preparation may not have been
optimal. The liquid-phase second antibody system was adopted for routine
use and it proved to be a rugged and dependable high sample capacity
separation method. When optimised (Figure 4-20, p. 137) it was independent
of plasma protein concentration.
Despite the fact that the strong adsorption of PTH to glassware and other
materials has been a severe technical obstacle to the development of
radioassays for the hormone there have been few systematic studies
designed to minimise this problem. It has long been recognised that
loss of BPTH from solutions is minimised by reducing their pH but
immunochemical constraints dictate that the radioimmunoassay system be
operated at approximately physiological pH. It is thus not practical to
reduce PTH adsorption simply by reducing the pH of the assay system.
The tendency for PTH to adsorb non -specifically to assay tubes is of
analytical significance since sera tend to differ with regard ter the amount
of incubation damage to the molecule they promote and hence the degree
of non-specific binding they elicit. Compensation for this inter-specimen
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variability may be achieved by running control tubes without antiserum
for each of the specimens examined and correcting for the respective degree
of non-specific binding observed. This approach was not feasible in
the present study as the volume of specimens available for analysis was
often limited (see Section 4.4.1, p.255 ). Rather, efforts were made
to reduce non-specific binding to more acceptable levels so as to minimise
the effects of its variability (It should be stressed that in the studies
undertaken to this end it has been assumed that labelled and unlabelled
PTH show identical adsorptive properties, there being no evidence to the
contrary).
In a preliminary study (Table 4-12, p. 142) binding of ^^I-BPTH t0 ai^
types of assay tube investigated was unacceptably high, a finding in
agreement with that of Barrett and Neuman (1978) who also observed
125
extensive adsorption of I-BPTH to all the materials they investigated.
The inclusion of 5 g/1 albumin in the assay diluent markedly reduced this
adsorption, as did the addition of Triton X-100 detergent (Figure 4-22, p. 143).
Berson and Yalow (1966) and Schopman et al (1970) reported that the proteinase
inhibitor Trasylol reduced PTH adsorption to glassware and this observation
was confirmed in the present study (Table 4-14, p. 146), although Buckle (1974)
had found the inhibitor ineffective in this respect. The observation that
Trasylol reduces the non-specific binding of ^^I-BPTH in the absence of
serum (Table 4-14, p. 146) suggested that this effect may only partially
be attributable to a reduction in serum induced incubation damage. As
has previously been discussed (p.283) the elimination of aggregated material
125from the labelled preparation of I-BPTH was particularly effective in
reducing non-specific binding of radioactivity to the assay tubes (Table 4-13,
p.145).
As a result of this series of investigations a number of measures were adopted
(see Section 4.1.4, p. 144) which brought about a very marked reduction in
non-specific binding of PTH. The attainment of consistently low levels of
non-specific binding of antigen represents a significant improvement in the
characteristics of the PTH assay system.
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Various assay incubation schemes were investigated (Table 4-15, p. 148).
Assay sensitivity was increased considerably by delaying the addition of
labelled BPTH, a general artifice which has been discussed by Hunter (1967)
and analysed mathematically by Rodbard et £^(1970). Comparison of the
standard curves obtained for incubation schemes involving delayed and
non-delayed addition of *^I-BPTH for the same total incubation time
(Figure 4-23, p. 149) showed the advantage to be gained from such strategy.
For maximum assay sensitivity and an acceptable level of labelled antigen
binding a non-equilibrium incubation scheme was adopted which involved
a 72-hour pre-incubation of serum and standard (or sample) at 4° C, followed
by a further 72-hour incubation with ^^I-BPTH at the same temperature.
In various radioimmunoassays standard curves established in the presence
of serum or plasma have been found to deviate significantly from standard
curves set up in buffer (Morgan et al, 1963; Franchimont, 1970; Reuter
et^aj., 1973). This effect appears to be particularly severe in the PTH
radioimmunoassay. The origin of the non-specific interference remains
obscure, although it is presumed to represent an influence of serum proteins
on the primary antigen-antibody interaction, since its expression is not
dependent on the mode of assay separation adopted.
Both PTH antisera investigated in this study were shown to be prone to this
effect of serum (Figure 4-24 a and b, pp.151 -152). This necessitated
the addition of an antigen-free serum (or some equivalent material)
throughout the standard curve to compensate for the non-specific decrease
in the binding of labelled antigen to antiserum ellicited by plasma samples.
Serum from a hypoparathyroid patient was shown to be a suitable material
for use in this respect, enabling the measurement of PTH in samples from
normal adults, expectant mothers and infants to be undertaken (Figure 4-25,
p. 153). However, a number of difficulties were encountered when attempts
were made to procure adequate supplies of suitable sera from hypoparathyroid
patients (see Section 4 .1. 4, p. 154). These provided the impetus for a series
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of experiments designed to investigate the possibility that a suitable antigen-
free diluent might be produced in the laboratory. The repeated freeze -
thawing of a normal serum failed to produce a serum displaying suitably
altered characteristics in the radioimmunoassay despite the fact that this
process tended to reduce the recovery of immunoassayable BPTH (Figure 4-29,
p. 169). These apparently discordant results may be attributable to the
production of PTH fragments with variable immunoreactivities by the freeze-
thawing process. Clearly the avoidance of unnecessary freeze-thawing
of specimens for PTH analysis is judicious since the effects of this are
unpredictable.
Quso G32 silica was found to be the most efficient of the materials investigated
for the extraction of PTH from serum (Table 4-16, p. 156) and indeed this was
the substance used by Christensen (1976) to effect pre-assay extraction of the
hormone from specimens for analysis. Nonetheless, attempts to produce
a satisfactory PTH-free serum by simple Quso-extraction of normal serum
were unsuccessful since the treated serum was associated with increased
non-specific binding of labelled antigen in the assay system (Figure 4-26,
p. 157). As it was thought likely that this was due to incomplete removal
of the extraction agent a filtration step was introduced into the experimental
extraction procedure. Although no combination of Quso-extraction and
filtration produced a serum which behaved in the assay system in a manner
comparable to the reference hypoparathyroid serum it was apparent that
the filtration process itself altered the effect of serum on the binding of
antigen to antiserum (Table 4-17, p. 159). This alteration in serum
behaviour was not attributable to protein fractionation since the porosity of
the filter selected (mean pore size 0.6 ym) was low enough only to ensure
the retention of Quso particles and did not effect any macromolecular
separation. A likely explanation is that the material of the filter disc,
a cellulosic polymer, was responsible for adsorption of endogenous PTH
from the serum. The utilisation of such a cellulose-filter system to
produce antigen-free sera for use in the PTH assay may merit further
investigation.
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Increasing the albumin content of the assay diluent to 70 g/1, comparable to
that of normal serum (Fiereck, 1970), reduced the binding of ^^I-BPTH
to antiserum but neither manipulation of the protein content of the standard
curve diluent (Figure 4~27a, p.161) nor dilution of hypoparathyroid serum
used (Figure 4-27b, p. 162) suggested that the non-specific interference of
serum in the assay system was simply attributable to the effect of serum
protein concentration.
Although no completely satisfactory alternative was found to the use of
hypoparathyroid serum in the standard curve, it became evident that not
all such sera were equally well suited for this purpose. Differences in
12S
the level of I-BPTH binding observed at zero antigen concentration (B0)
for sera collected from a series of hypoparathyroid patients (Figure 4-28,
p. 164) suggest that such patients display differing degrees of glandular
hypofunction. An alternative explanation is that the observed differences
in binding were attributable to inter-serum variation in the degree of
non-specific interference with the immune reaction. The possible
existence of this form of variation may detract from assay specificity
but until the origin of the non-specific effect of serum becomes apparent
it is not possible to eliminate this potential source of variation, which
remains a continuing problem for the PTH assayist.
In contrast to the findings of Reiss and Canterbury (1968), who observed
erratic behaviour of heparinised plasma in their PTH assay, no significant
difference between the behaviour of serum and plasma was observed in the
assay system developed here (Table 4-18, p. 166), and sample haemolysis
did not invalidate analysis unless very severe (Table 4-19, p. 167).
The PTH radioimmunoassay developed represents one in which many of the
technical difficulties previously encountered (p. 11) have been largely
overcome. Precautions have been adopted to ensure that the hormone's
inherent instability did not detract from assay performance. In particular,
the effect of the loss of the immunochemical heterogeneity of PTH on
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iodination wag significantly reduced by the careful purification of labelled
preparations of the hormone following their production and prior to their
inclusion in the assay. The analytical significance of various non-specific
interferences in the assay system has also been minimised; adsorption
of PTH to glassware has been reduced to a consistent level of less than
5% and compensation has been made for the effect of serum and plasma
on the antiserum-antigen reaction. The PTH radioimmunoassay used
for the analysis of plasma samples in this study was thus capable of a high
level of performance, as testified by the analytical characteristics
presented (see Section 4-1.5, p. 172).
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5.2 THE CALCITONIN RADIOIMMUNOASSAY
Calcitonin appears to be more resistant to gross iodination damage than PTH,
a difference that is reflected in the relative simplicity of the procedures
adopted to achieve the purification of labelled preparations of the two hormones
following their iodination. However, preparations of ^25p-calcitonin
deteriorated on storage, as was demonstrated in studies by gel-filtration
(Figure 4-32, p. 183) and paper chromatoelectrophoresis (Figure 4-33, p. 184).
As for "^^I-BPTH, this decay of *^I-human calcitonin was of analytical
significance since labelled material other than the monomeric 1-32 peptide
(Peak II, Figure 4-31, p. 180) was of inferior quality when examined in the
radioimmunoassay system (Table 4-24, p. 181) and the radioreceptor assay
(Table 4-38, p. 253). Routine pre-assay purification of the labelled antigen
was again necessary to ensure homogeneity.
Whereas difference in molecular size is the primary factor affecting separation
by gel-filtration, this is combined with resolution based on molecular charge
in starch gel electrophoresis, a technique first described by Smithies (1955).
Examination of the products obtained from the Direct iodination of human
calcitonin by starch gel electrophoresis revealed additional protein heterogeneity
not apparent when the preparation was purified by gel-filtration; three protein
peaks (1-3) were seen in the electrophoretic profile (Figure 4-34b, p.187) whilst
only two protein peaks (I and II) were seen on gel-filtration (Figure 4-34a, p. 186).
This additional protein peak was only present when the iodination reaction was
terminated with sodium metabisulphite and was not seen when this reagent was
replaced with either excess potassium iodide (Figure 4-35, p. 189) or cysteamine
hydrochloride (Figure 4-38, p. 198). Gel-filtration profiles for the separation
of the products of sodium metabisulphite and cysteamine hydrochloride terminated
iodinations were similar (Figure 4-38, p. 197), suggesting that the additional peak
on electrophoresis is attributable to the presence of calcitonin with altered moleculai
charge. It thus seems likely that sodium metabisulphite produces chemical damage tc
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calcitonin which is detectable by virtue of the altered charge which the
damaged molecules carry. Only the disulphide bonds in proteins are
generally susceptible to mild reduction and it is proposed that this
damage may be due to reductive cleavage of the 1-7 disulphide bridge
present in the molecular structure of calcitonin by reactive sulphite ions
(S03^-) arising from the ionisation of sodium metabisulphite.(Tne dianion
predominates in solutions close to neutral pH).
Since termination of the iodination with cysteamine hydrochloride appeared
to prevent this chemical damage it was used routinely in preference to
sodium metabisulphite in the iodination procedure.
Further study of the labelled material in each of the starch gel activity peaks
(Peaks 1-5, Figure 4-35, p.189) suggested that the chemically damaged
material was contained in the Peak 2. The non-migrating material in Peaks
1 and 4 was found on gel-filtration to contain mainly aggregated calcitonin
(Figure 4-36 a and d, p. 191) which displayed reduced affinity for the
anti-calcitonin serum (Figure 4-37 a and b, p. 194). The remaining
three peaks each contained material which corresponded to monomeric
calcitonin on gel-filtration (Figure 4-36, b,c and e, p.191), but material
from Peak 2 was immunochemically atypical since it showed significantly
decreased immunoreactivity towards specific antiserum (p < 0.001) in the
presence of serum (Table 4-25, p. 195).
Anti-Calcitonin Sera
Of nine rabbits immunised with unconjugated synthetic human calcitonin all
but three produced anti-calcitonin sera (Figure 4-24 a and b, pp. 206-207).
This satisfactory frequency of immunological response to the unconjugated
hormone is in agreement with earlier findings by a number of workers
(Deftos et al, 1971a; Frolich et al, 1971; Heath and Sizemore, 1977),
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aLthough in contrast to that of Hufner and Hesch (1971) and Sizemore et al_(1973),
who managed to eLlicit an immune response only after prior conjugation of
the hormone to albumin. Despite the fact that the number of rabbits
responding in the present study was encouraging, hopes of producing an
anti-sera suitable for use in a highly sensitive radioimmunoassay system for
human calcitonin were not realised and the rabbit antisera raised compared
unfavourably with the goat anti-calcitonin sera, G 1701, in a radioimmunoassay
system (Table 4-26, p. 210; Figure 4-44, p.211).
The Calcitonin Assay Standard
On dilution sera from three patients with chronic renal failure gave rise to
1 OC
inhibition curves for the binding of I-human calcitonin to the assay
antiserum ( G 1701) which were parallel with that obtained for the human
calcitonin standard preparation (Figure 4-45, p. 213). However, this
immunochemical equivalence between circulating calcitonin and the assay
standard was not seen when serum from a patient with medullary carcinoma
of the thyroid was similarily examined. Pronounced immunochemical
heterogeneity of serum calcitonin in patients with this condition has
previously been reported (Deftos et a^, 1974; Sizemore et a^, 1975).
Application of the Radioimmunoassay Technique to Serum and Plasma
Although the separation of free and antigen-bound hormone in the calcitonin
assay may be achieved by chromatoelectophoresis (Tashjian, 1969) or
adsorption to dextran-charcoal (Clark et al, 1969), a second antibody
separation technique was found to be both satisfactory and convenient in
the present study.
As for the PTH radioimmunoassay developed, a non-equilibrium
incubation scheme at 4° C, involving a 72-hour pre-incubation
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followed by a 72-hour incubation with labelled antigen was used in the
calcitonin radioimmunoassay. This resulted in a sensitive standard
curve (Figure 4-47, p.216) and an acceptable level of labelled antigen
binding. Calcitonin standard curves diluted in normal plasma were
slightly displaced from a similar curve established in assay diluent
(Figure 4-48, p. 219). This reduction in the specific binding of 125i-
human calcitonin to antiserum in the presence of plasma was not attributable
to endogenous hormone since the curve obtained in normal plasma was
virtually superimposable with one set up in plasma from a totally thyroid-
ectomised patient, which was presumed to be calcitonin free. It may be
partially attributable to incubation damage to the labelled calcitonin as
Baylin et al (1977) have reported that -human calcitonin is enzymatically
degraded in plasma. Clearly, it is desirable to minimise the effects of
this type of damage and the assay standards were consequently diluted in
assay diluent, a precaution also adopted by Heath and Sizemore (1977)
The effect of serum and plasma on the calcitonin standard curve observed
in this study was noticeably less pronounced than that reported in many
earlier studies (e.g. Heynen and Franchimont, 1974). Perhaps in these
studies sodium metabisulphite induced damage to the labelled calcitonin
125
may have reduced the affinity of 1-calcitonin for antiserum in the presence
of serum. However, the effect of serum and plasma is also a problem of
protein interaction and not simply one of damage to the labelled antigen
since, in principle at least, similar difficulties exist in the radioimmuno-
metric assay for calcitonin (Hesch et al, 1975),where it is the antibody
and not the antigen which is labelled.
The calcitonin radioimmunoassay was developed critically with a view to
optimising each of its components so as to ensure that its full analytical
125
potential was realised. The immunochemical integrity of the I-human
calcitonin preparation was improved by removing sodium metabisulphite
from the iodination procedure. This agent was shown to promote chemical
damage to the calcitonin molecule and thereby reduced its affinity for
296
specific antiserum. Assay incubation conditions were also adjusted in
the light of results presented (see Section 4-2) so that the final
assay characteristics achieved were considered acceptable (see Section
4.2.5, p.225).
The assay developed was capable of detecting as little as 20 ng/l human
calcitonin (minimum assay detection limit + SD = 26 + 6 ng/l). Nevertheless,
radioimmunoassay sensitivity still remains an obstacle limiting our under¬
standing of the physiological significance of calcitonin. It is likely that this
will continue to be the situation until superior anti-calcitonin sera become
available since the sensitivity potential of an immunoassay system is
ultimately limited largely by the quality of antiserum available. Attempts
to produce anti-calcitonin sera with improved characteristics in this study
were unsuccessful (see Section 4.2.2, p.201).
One aim of future assay development must be to improve sensitivity such
that it becomes possible to measure confidently circulating concentrations of
both PTH and calcitonin at the lower limit of the reference range and
beyond.
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5.3 THE RADIORECEPTOR ASSAY FOR CALCITONIN
Whereas the basis of specificity in the radioimmunoassay is immunological, it is
the biological activity of a peptide hormone which is monitored in the radioreceptor
assay since it is now recognised that hormone binding at a specific membrane
receptor is an important initial event in the target cell's response (Catt and
Dufau, 1976).
The kidney constitutes a recognised target organ for calcitonin (Ardaillou, 1975)
and the existence of specific renal receptors for calcitonin in rabbit kidney tissue
has been demonstrated in this study. It may be argued that since no evidence
has been presented to show that their association with calcitonin leads to
a biologically significant biochemical change the membrane sites under consideration
here should more correctly be termed hormone 'acceptor sites', a description
applicable to membrane structures which exhibit specific hormone binding activity
of undefined biological significance (Birnbaumer, 1974). However, the operational
use of the term 'receptor' was considered acceptable since the binding observed
displayed characteristics commonly associated with hormone-receptor interaction
(Ryan and Lee, 1976). The binding was hormone specific; salmon calcitonin and,
to a lesser extent, human calcitonin inhibited the binding of ^^1-salmon calcitonin
to the membrane preparations isolated (Figure 4-55, p. 243) whilst gastrin and
insulin failed to compete for binding sites (Table 4-34, p.242). Furthermore,
the calcitonin binding observed was target organ specific, only being associated
with membrane preparations derived from renal tissue (Table 4-35, p.245).
It is difficult to draw any firm conclusions about the sub-cellular distribution of
calcitonin binding activity in rabbit renal tissue. The receptor preparations
were isolated using a method based on that used by Shiu £££[(1973) for the
isolation of membrane fractions with prolactin binding activity from rabbit
mammary gland and it seems likely that this method may prove to be generally
applicable to the preparation of hormone sensitive membrane preparations.
It should be stressed, however, that the sub-ceLlular fractionation which this
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procedure achieves is relatively coarse when compared to that attained by a number
of other schemes which have been used to isolate receptor preparations (Neville,
1968; Fitzpatrick et al, 1969; Marxetal^, 1972b). In this study calcitonin
binding activity was found to be associated with both the 15K and 100K membrane
preparations (Figure 4-54, p.240), which are thought to represent mitochondrial
and post-mitochondrial fractions respectively (Shiu et aN 1973). Although in
their original work with rat kidney Marx et al (1972a) studied calcitonin receptor
activity only in a crude membrane preparation, the subsequent use of more
refined sub-cellular fractionation techniques led the same group to report that
the calcitonin binding activity was primarily associated with the plasma membrane
fraction (Marx et al, 1972b) and this was later confirmed by Sraer and Ardaillou
(1974). It is thought likely that the rabbit renal receptors studied here are also
associated with the plasma membrane, but further studies are required before
this can be confirmed.
In a number of respects the binding of calcitonin to rabbit renal receptors
proved to be similar to that which has been observed in earlier studies with
receptors isolated from rat kidney tissue. Binding of 125j -salmon calcitonin
was time and temperature dependent, equilibrium being achieved more rapidly
at room temperature than at 4° C (Figure 4-53, p. 239), although the same level
of binding was eventually reached at both temperatures. (Assay incubations
were carried out at 4° C since Sraer et al, 1974, showed that inactivation of
calcitonin by renal preparations was temperature dependent and increased over
the range 4° C to 37° C). The specific binding of -salmon calcitonin to the
rabbit renal receptor was pH-dependent (Figure 4-52, p. 236) and the finding that
the degree of binding increased when the incubation pH was decreased from 9 to 6,
but decreased again below pH 6, was in close agreement with results reported by
Sraer et^aj^(1974) for similar studies with the rat renal receptor. The importance
of the ionic environment of the receptor for optimal hormone binding activity was
stressed by Shiu and Friesen (1974). Increasing the concentration of divalent
calcium ions in the incubation medium clearly depressed the amount of calcitonin
binding to its receptor (Table 4-33, p. 237), although any physiological significance
of this effect remains to be elucidated.
Though the amount of labelled salmon calcitonin bound by receptor increased
linearly when the concentration of membrane protein present in the radio¬
receptor assay system was increased at fixed concentrations of labelled hormone,
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this relationship held good only over a limited range of membrane protein
concentration, and it was not possible to bind all the labelled hormone present
in the system (Figure 4-51, p. 235). This general feature of hormone-receptor
binding analysis (Ryan and Lee, 1976) has been partly attributed to incubation
damage to the labelled hormone and to the receptor itself. Failure to bind all
the available hormone may also be indicative of the presence in the labelled
preparation of a proportion of hormone molecules displaying reduced affinity
for receptor, and hence the radioreceptor may be used to compare the integrity
of hormone preparations. This has recently been exemplified by Becker et al
(1978) who have studied the biological significance of calcitonin heterogeneity
by radioreceptor analysis.
The failure of ^2Vhuman calcitonin to bind to rabbit renal receptors suggests
that the human calcitonin molecule is damaged during the chloramine-T iodination
procedure, since unlabelled human calcitonin is capable of binding to the
receptor site and competes with -salmon calcitonin for binding sites, albeit
much less effectively than unlabelled salmon calcitonin (Figure 4-55, p. 243).
This finding was directly analogous to those obtained by Marx et a£ (1972a and b)
and Sraer and Ardaillou (1974) with rat renal receptors, and Becker et £^(1978)
with receptors isolated from rat calvariae, all of whom obtained no receptor
binding with labelled human calcitonin and found unlabelled human calcitonin to
19 Sbe a less potent inhibitor of I-salmon calcitonin binding to receptor sites than
unlabelled salmon calcitonin.
Clearly, differences in the behaviour of salmon and human calcitonin are
manifestations of their respective chemical structures, and it was suggested
175
by Marx et.£l (1972b) and Ardaillou et a_L (1973) that the inability of I-human
calcitonin to bind to receptor was due to oxidation of the methionine residue
present in the molecule by chloramine-T during iodination, since the
sulphoxide derivative of human calcitonin is known to be inactive (Riniker et al, 1968)
This methionine, present at position 8 in the amino acid sequence of the human
molecule, is replaced by valine in the salmon calcitonin molecule. Evidence to
support this view comes from the work of Scarpace and Deftos (1977) who made
IOC
use of an electrolytic iodination method to prepare -human calcitonin which
retained biological activity in vitro and in vivo. However, in the present study,
the lactoperoxidase iodination method failed to produce a labelled human calcitonin
preparation which displayed receptor binding activity, although it is generally
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recognised as a very gentle oxidative iodination method which induces little loss
of hormone structural integrity (Miyachi and Chrambach, 1972; Shiu and Friesen,
1974).
Although differences in affinity for binding sites represent an important aspect of
biological activity it should be emphasised that these are not the only important
factors influencing the comparative biological effectiveness of the various calcitonins.
Keutmann e£al((1972) demonstrated that the half-life of salmon calcitonin in plasma
is longer than that of the mammalian calcitonins and hence the greater biological
effectiveness of salmon calcitonin compared to the human molecule in vivo is
probably attributable to at least two factors, increased affinity for receptor
binding and greater persistence in the circulation.
Calcitonin is known to produce a number of renal effects in man (Cochran et al, 1970;
Ardaillou, 1975) but to date calcitonin receptors remain to be demonstrated in human
kidney tissue. In the present study an attempt was made to isolate specific calcitonin
receptors from developing and adult human kidney tissue using the tissue
fractionation scheme which had been successfully used to prepare rabbit renal
calcitonin receptors. These efforts proved unsuccessful and no significant
specific binding of calcitonin was observed to any of the membrane preparations
isolated from human kidney tissue (Table 4-36, p.248). This lack of success did
not appear to be due to any technical failure of the isolation procedure since
a satisfactory rabbit renal preparation was obtained during the same experiment.
Neither could it be attributed to the use of an unsatisfactory labelled hormone
loc
preparation as a number of preparations of both I-salmon calcitonin and I-human
calcitonin were incubated with a membrane preparation from adult human kidney
without success (Table 4-37b, p.251). It is conceivable, of course, that either
the preparative system or the radioreceptor assay system used successfully to
study rabbit renal receptors were inherently unsuitable for application to the
study of human renal receptors, but it seems more probable that failure to obtain
human kidney material in a sufficiently fresh state may have contributed significantly
to the failure of this study to demonstrate human renaL calcitonin receptors, since
receptor sites are notoriously labile entities.
Although these studies have failed to demonstrate calcitonin binding activity in the
human kidney, the outcome of the investigations undertaken with receptors
successfully isolated from rabbit kidney tissue emphasises two important general
points. Firstly, that a high degree of integrity of hormone structure is required
for hormone receptor interaction and, secondly, that reactivity in an immunoassay
system does not necessarily reflect biological effectiveness as assessed by
radioreceptor binding. Radioimmunoassay and radioreceptor analysis should
be considered to be complementary methods in endocrinological investigations.
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5.4 PTH AND CALCITONIN IN PREGNANCY AND THE NEWBORN PERIOD
Data presented in this study (Figure 4-56, p.264) show that mean maternal plasma
concentrations of calcium, magnesium and phosphorus are remarkabLy stabLe
throughout pregnancy, suggesting that efficient homeostatic control mechanisms
normally operate to regulate maternal mineral metabolism despite the increasing
mineral demands of the developing fetus. Clearly, the neonate also normally
attains a degree of stability with regard to its extracelluLar calcium, magnesium
and phosphorus balance within a few days of birth.
It was the aim of this study to use the well characterised PTH and calcitonin
radioimmunoassays developed to attain a more complete understanding of the role
of these two calciotropic hormones in the regulation of mineral status in
pregnancy and the newborn period and in the aetiology of late neonatal hypocalcaemia.
As is almost invariably the case in physiological studies involving the measurement
of these hormones, two major analytical difficulties were encountered. Firstly,
the assays, though carefully characterised and optimised, were still associated
with variability of a degree not usually experienced with the analysis of most
hormones; this appears to be a function of the peculiar properties of these two
hormones. Secondly, a proportion of the specimens studied had low hormone
concentrations which were undetectable in the assay systems (Table 4-41, p. 266)
even though the assays developed were characterised by minimum detection limits
which appeared favourable compared to those of many existing radioassays.
Recognition of these analytical limitations allowed steps to be taken to counteract
their restrictive influence. No assumptions were made about the concentration of
hormone in the specimens which were undetectable or the distribution of values
in the population as a whole since non-parametric statistical methods were used
to analyse the analytical data. Additionally, even though the degree of assay
variation was considered acceptable in terms of the assay quality control policy
adopted, whenever possible statistical inferences were drawn from within-assay
data comparisons so as to minimise the influence of inter-assay variation. The
large size of the study also hopefully ensured that the results obtained might be
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considered truLy representative of the physiological situation which pertains
during pregnancy and the newborn period. It is thus possible to discuss the
analytical results with some degree of confidence.
That pregnancy might be associated with an increase in maternal parathyroid
activity was first proposed by Albright and Reifenstein (1948) and this idea has
found support from Cushard et a^(1972), Bouillon and DeMoor (1973) and
Reitz et a_l (1977), all of whom found that the concentration of PTH is
increased during pregnancy. In this study, although maternal plasma PTH
concentrations increased significantly from the 12th week of pregnancy, it
seems that the expectant mother may initially become relatively hypopara-
thyroid, since pregnant women were found to have significantly lower PTH
concentrations than non-pregnant women during the first half of their
pregnancies (Table 4-43, p.271). Despite the tendency for maternal PTH
concentrations to increase from the end of the first trimester, particularly
in mothers not given supplementary vitamin-D (see Section 4.4.4, p.269),
even at delivery maternal plasma PTH concentrations as a group were not
significantly different from those of non-pregnant women in the control group.
Interestingly, Cushard £££^(1972) also observed a decrease in maternal PTH
concentration from the 20th to 24th week of pregnancy. However, these
workers presented only sparse data from the first 20 weeks of the pregnancies
they studied and this may explain their lack of comment about this initial
reduction in plasma PTH. There is no evidence from the present study to
suggest that changes in maternal plasma PTH are primarily induced by
alterations in plasma calcium concentration per se since no correlation was
found between these two plasma constituents at any stage during pregnancy.
However, the finding that increased parathyroid activity in the second half of
pregnancy may represent a reversal of a tendency for hyposecretion during
the first trimester rather than a physiologicaL hyperparathyroidism merits
further investigation in future studies.
Garel and Barlet (1978), reviewing the findings of a number of investigations
carried out using experimental animals, have suggested that maternal
calcitonin tends to increase during gestation and
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Samaan et al (1975) have reported that pLasma concentrations of calcitonin
found in women at the end of pregnancy are higher than those at the start
of pregnancy or in the non-pregnant woman. In the present study no
significant difference was found between the calcitonin concentrations of
pregnant and non-pregnant women and there was barely a significant rise
in calcitonin concentration from the end of the first trimester to term
(p < 0.05). Maternal calcitonin concentrations measured did not correlate
with plasma concentrations of calcium, magnesium or phosphorus at any
stage during pregnancy, although a relationship between these minerals
and the hormone might have been anticipated were calcitonin playing
a functionally significant role in their regulation during this period. In
support of the suggestion of Lewis et M(1977) that maternal hypercalcitoninaemia
might serve to protect the mother's skeleton against excessive demineral-
isation, Garel and Barlet (1978) reported that ewes carrying triplets had the
highest concentrations of circulating calcitonin of all the pregnant ewes
they examined and they proposed that this was indicative of the high rate of
placental calcium transfer in these animals (Field and Shuttle, 1967).
However, there is no collaborative evidence to support this view from the
present study of human pregnancy; maternal plasma calcitonin values in
multiple and singleton pregnancies were not found to differ significantly.
This study, therefore, provides no evidence to support the view that
calcitonin may be of greater physiological significance in the expectant
mother than in the non-pregnant woman.
Since PTH does not appear to cross the placental barrier (Northrop et al, 1977)
measurement of the hormone in cord blood provides an indication of fetal
parathyroid activity at delivery. In this study PTH concentrations in
umbilical venous plasma were low (74% of specimens undetectable) and
significantly less than corresponding maternal values, onLy 36% of which
were undetectable (p < 0.001). This finding of low PTH concentrations
in neonates at delivery is in agreement with those of David and Anast (1974),
who found PTH detectable in just 17% of cord sera, and Root et al (1974),
who found measurable PTH in only 39% of cord sera. These findings indicate
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that there is little parathyroid activity at birth even though the infant is
relatively hypocalcaemic, and suggest that the activity of the parathyroid
glands may be suppressed in utero by high fetal calcium concentrations.
By day six only 46% of the infants studied still had undetectable plasma PTH
concentrations and their PTH concentrations at this time were significantly
higher than at delivery (p < 0.001). It is evident that over the first week
of life the activity of the neonatal parathyroids increases and at day six
plasma concentrations of PTH were found to correlate negatively with both
plasma calcium and magnesium (p < 0.01), suggesting that the familiar
reciprocal relationship between the hormone and these two minerals was
firmly established.
In contrast to the situation for PTH, analysis of 174 paired specimens obtained
at delivery showed that calcitonin concentration in umbilical venous plasma
was significantly higher (p < 0.001) than in the corresponding maternal
specimens (Table 4-42b, p. 268), thereby confirming the similar observation
made by Samaan et £^(1975) who compared the two values in 32 newborn
infants and their mothers. However, whereas these workers reported that
serum calcitonin fell after only 24 hours of post-natal life, in the present
study infant calcitonin concentration at the sixth day of life was not significantly
different from that at delivery. That circulating calcitonin concentrations
are high in the umbiLical vein at delivery is in accordance with the observation
of WoLfe et al%1975), who demonstrated that neonatal thyroid tissue is rich
in calcitonin, and suggests that the hormone may be of importance in fetal
life, although the suggestion by Garel and Barlet (1978) that it may act to
promote mineralisation of the developing fetal skeleton remains speculative
until direct studies of calcitonin action in the fetus are carried out. Although
a continuous hypercaLcaemic stimulus is no longer present after delivery,
it appears that high neonatal concentrations of calcitonin may persist at least
as long as six days after delivery and this may indicate that the hormone
is of functional importance in early life. It is of particular interest that
infant plasma calcitonin and phosphorus concentrations are related at the
sixth day, when they are negatively correlated (Table 4-44, p.273).
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Franchimont and Heynen (1976) observed a direct relationship between
serum inorganic phosphate and calcitonin in normal adults under basal
conditions and during phosphate infusion studies.
It has been suggested that calcitonin may be of physiological importance in
mammalian systems as a mediator in a reflex mechanism serving to protect
the animal against post-prandial hypercalcaemia (Gray and Munson, 1969;
Swaminathan et al, 1973). Such a reflex, involving stimulation of calcitonin
secretion by gastro-intestinaL hormones, might be of particular importance
in the newborn period when the young animal passes from a state in which it
receives a continuous supply of nutrients through the placenta to one in
which it is discontinuously fed. Gastrin, a known secretagogue of calcitonin
(Roos et a]_, 1975) is known to be released in response to the first infant
feed and has been shown to be generaILy raised in the newborn period.
(Von Berger et ad, 1976), and Hesch et a£(1973) have provided evidence
supporting the concept that gastro-intestinal stimulation of calcitonin secretion
may be of importance in early human life to protect against nutritive hyper¬
calcaemia.
Sixth-day plasma PTH concentrations in infants born to vitamin-D supplemented
mothers and breast fed infants were significantly lower than those in the
corresponding control groups (p < 0.001 and p < 0.01 respectively).
Plasma PTH and calcium concentrations are inversely related at this time
(Table 4-44, p.273) and the effect of maternal vitamin-D supplementation
and breast feeding on infant PTH is therefore that which might be predicted
since it has previously been shown that both these influences lead to higher
sixth-day plasma calcium concentrations in newborn infants (Cockburn et al,
1979). Neither of these two factors were found to affect infant calcitonin
concentrations.
For both PTH and calcitonin, significant correlations (p < 0.001) were
observed between plasma concentrations determined for the mother at
delivery and the infant at delivery and at the end of the first week of life
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(see Section 4.4.4, p.272), providing further indication that mineral homeo¬
stasis in the mother influences that of the newborn infant. However, there
is LittLe evidence from this study to suggest that this influence mainly operates
through a mechanism involving significant maternal hyperparathyroidism
during pregnancy, as has been proposed by Purvis et a]_(1973), since there is
little tendency for mothers to become markedly hyperparathyroid during
pregnancy, although expectant mothers not given supplementary vitamin-D
during pregnancy do tend to have higher PTH values at delivery than
supplemented mothers (p < 0.001). Nonetheless, the case history of Baby F
(see Section 4.4.4, p.277), born to a mother with primary hyperparathyroidism,
demonstrates that excessive maternal parathyroid hyperactivity can result
in neonatal hypocalcaemia. Indeed, this baby displayed the most severe
hypocalcaemic convulsions seen in this study.
It has long been recognised that newborn infants display a tendency to become
hypocalcaemic in the first 48 hours of life, this physiological trend generally
being spontaneously corrected over the next few days of life (David and Anast,
1974). Nevertheless, at the sixth day as many as 30(12.8%) of the 234
infants investigated were hypocalcaemic (plasma calcium < 1.85 mmol/1).
It is significant that the 30 hypocaLcaemic infants were predominantly
artificially fed (Table 4-45, p.275), differing significantly from the population
of infants as a whole in this respect (p < 0.001). This is in agreement with
an earlier report that breast feeding protects against hypocalcaemia in the
newborn period (Cockburn et al, 1979). Hypersecretion of calcitonin has been
suggested as one factor which may contribute to early neonatal hypocalcaemia
Samaan et al, 1975; Dirksen and Anast, 1976; Hillman et al_, 1977) and it
seems there may be little parathyroid activity to oppose any hypocalcaemic
action of calcitonin in the immediate post-natal period. Since high levels
of plasma calcitonin persist at least until the sixth day of life, it is conceivable
that this hormone may be partially responsible for late neonatal hypocalcaemia,
but the lack of correlation between plasma calcitonin and calcium (Table 4-44,
p. 273) argues against this. Heath and Sizemore (1977) reported that the
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serum concentration of immunoreactive calcitonin in normal adults was
greater in males than females. No such sex difference in calcitonin
concentration was observed in the neonatal period in the present study,
however, and thus hypersecretion of calcitonin does not appear to explain
the greater predisposition of male infants to become hypocaLcaemic in the
newborn period (Cockburn et al, 1979) or the increased incidence of
symptomatic late neonatal hypocalcaemia in boys (Pincus et al, 1958;-
Roberts et al, 1973). Plasma PTH and calcium are significantly negatively
correlated in the six-day old infant (p < 0.01) and there is little to suggest
that hyposecretion of PTH is a causative factor in late neonatal hypocalcaemia,
although it appears important in the pathogenesis of the early form of the
condition (Tsang et al_, 1973b; David and Anast, 1974; Rootetal, 1974).
It is pertinent to consider why infants with hypocalcaemia fail to correct this
imbalance when their PTH secretion generally appears to be appropriate to
their calcaemia. Linarelli e£al (1972; 1974) have suggested that end-organ
unresponsiveness to the action of PTH may be responsible for this failure
to correct hypocalcaemia and hyperphosphatemia, but a contrary point of
view has been expressed by Brown et a£(1978) who have demonstrated that the
neonatal kidney is able to respond to PTH by increasing both CAMP production
and phosphate excretion in a manner which is unrelated to gestational or
post-natal age.
Infants with symptomatic late onset neonatal hypocalcaemia were compared
with asymptomatic hypocalcaemic infants in an attempt to identify factors
of pathogenetic importance in this condition. However, although on the
basis of their clinical presentation the former group constituted a distinct
sub-group of hypocalcaemic infants, they were not found to differ significantly
from the asymptomatic group in terms of their plasma concentration of
magnesium, calcitonin, PTH or indeed calcium (see Section 4.4.4, p.274).
The symptomatic expression of neonatal hypocalcaemia may well depend
on neurological factors which remain undefined but it is of particular
interest that the symptomatic group of infants proved to be atypical of the
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group of hypocaLcaemic infants as a whole when the distribution of their
mothers by Treatment group was considered (Table 4-45, p. 275 and
Table 4-46, p.276). All the clinically disturbed infants were born to
mothers who had received no supplementary vitamin-D, suggesting that
maternal vitamin-D deficiency during pregnancy may predispose the infants
to the condition of late onset neonatal hypocalcaemia.
Kooh et £l (1976) reported that six infants with protracted neonatal hypocalcaemia
responded immediately to treatment with 1, 25-dihydroxyvitamin D3. It seems
possible that the therapeutic efficacy of this compound could be due to the
relief of relative 1, 25-dihydroxyvitamin D3 deficiency in these infants, caused
by impaired renal production of this metabolite from its precursor,
25-hydroxyvitamin D3, since this has been proposed as its mode of action in
hypoparathyroidism and pseudohypoparathyroidism (Kooh et al, 1975).
Although the nature of the underlying defect corrected by 1,25-dihydroxyvitamin D3
remains to be demonstrated, the findings of the present study may be consistent
with deficient renal 1 -hydroxylation of 25-hydroxyvitamin D in the neonatal
period. The increased tendency for artificially fed infants to be hypocalcaemic
may be explicable in terms of inhibition of the activity of the 1 -hydroxylase
by the high phosphate content of artificial feeds, an effect which might
exacerbate the clinical significance of any innate vitamin-D deficiency state.
It has been demonstrated that neonataL and maternal serum concentrations of
25-hydroxyvitamin D are directly related (Hillman and Haddad, 1974) and
that sixth day plasma concentrations of this metabolite tend to be significantly
lower in the infants of vitamin-D unsupplemented mothers than in those born
to mothers given vitamin-D (400 IU/day) from the 12th week of their pregnancy
(Cockburn et aj_, 1979). It follows that in infants with relatively poor vitamin-D
status born to mothers unsupplemented with vitamin-D during pregnancy,
inefficient renal hydroxylation of 25-hydroxyvitamin D may be a crucial
factor contributing to the pathogenesis of late neonatal hypocalcaemia.
However, if such a metabolic defect does underly the condition of late
neonatal hypocalcaemia it is not clear why secretion of PTH is not markedly
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increased in an attempt to stimulate renaL 1-hydroxylation of 25-hydroxy-
vitamin D, since high concentrations of hormone are usually seen in
association with end-organ unresponsiveness. It is conceivable that the
functional capacity for such positive regulation of the activity of the enzyme
may be limited in the newborn infant, and there is evidence from this and
other studies that this may be the case as parathyroid activity has been
shown to be limited during the first few days of life.
It is thus evident that ante-natal factors significantly influence neonatal
mineral metabolism. Suppression of parathyroid activity and, perhaps,
stimulation of C-cell activity in the fetus by the calcium-rich intrauterine
environment may contribute to the aetiology of early neonatal hypocalcaemia,
and maternal vitamin-D deficiency appears to predispose infants to the late
onset form of the condition, possibly because they are unable to efficiently
metabolise vitamin-D.
Further comprehension of the pathogenesis of neonatal hypocalcaemia will
require additional investigation of the complex inter-relationship of PTH,
calcitonin and the vitamin-D metabolites in both pregnancy and the newborn
period together with detaiLed studies of neonatal kidney function. However,
despite our current imperfect understanding of the biochemical mechanisms
underlying its existence, it seems apparent that the incidence and clinical
significance of neonatal hypocalcaemia may be reduced by ensuring that
expectant mothers receive an adequate intake of vitamin-D throughout
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